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ABSTRACT 
 
TCR gene therapy allows redirection of the antigen specificity of T cells by the 
introduction of novel TCR α and β chains by retroviral transduction.  These 
TCR gene modified T cells can be adoptively transferred to target defined 
tumour antigens.   The majority of TCR gene therapy studies has focused on 
the adoptive transfer of CD8+ T cells but there is increasing recognition of a 
central role for CD4+ T cells in effective immunotherapy protocols.  The use of 
CD4+ T cells has been limited by the lack of well defined class II restricted 
TCR and also because the majority of tumours don’t express class II MHC.  
As a result research has focused on introducing class I restricted TCR into 
CD4+ T cells.  Initial work has demonstrated that class I restricted CD4+ T 
cells often have reduced functional avidity compared to the parental CD8+ T 
cell.  In particular, CD4+ T cells transduced with CD8 dependent TCRs are 
often of much lower functional avidity when introduced in the absence of a 
CD8 co-receptor.  In order to improve the functional avidity of class I restricted 
CD4+ T cells, murine CD4+ T cells were co-transduced with F5 TCR (specific 
for influenza peptide, NP, in the context of H2-Kb) and additional CD3 
molecules.  The amount of CD3 within in a cell is rate limiting for the 
expression of introduced TCR and thus when cells are transduced with 
additional CD3 it removes this rate limiting step and thus enhances the 
surface expression of the TCR.  TCR surface expression is one of the key 
determinants of T cell functional avidity.  CD4+ T cells co-transduced with F5-
TCR and CD3 had increased surface expression of F5-TCR and increased 
pentamer binding.  This translated in vitro into increased functional avidity 
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compared to CD4+ T cells transduced with F5-TCR only.  When adoptively 
transferred in vivo into irradiated tumour bearing syngeneic recipients, F5-
TCR + CD3 CD4+ T cells had greater expansion and persistence and 
trafficked to the tumour site at higher and faster rates than F5-TCR only CD4+ 
T cells.  In addition, F5-CD3 CD4+ T cells demonstrated superior control of 
tumour growth.  Unexpectedly mice that received adoptive transfer of F5-TCR 
+ CD3 CD4+ T cells developed marked lethal toxicity. Further experiments to 
try to determine the nature of this toxicity suggest a multifactorial cause 
including mispairing of the introduced TCR α and β chains with the 
endogenous TCR and development of autoreactive T cells in the presence of 
additional CD3 mediated either by upregulation of the introduced TCR or the 
endogenous TCR.   
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CHAPTER ONE – INTRODUCTION 
 
1.1 INTRODUCTION 
 
Adoptive Immunotherapy involves the active transfer of naturally occurring or 
gene modified T cells to target tumour or viral antigens within a recipient.  
Autologous tumour infiltrating lymphocytes (TILs) can be isolated from 
individual patients and expanded ex vivo prior to adoptive transfer.  Another 
strategy to produce tumour specific T cells for adoptive transfer is to use 
retroviral transduction to introduce a tumour antigen specific TCR into 
polyclonal T cells thus redirecting their specificity.  This was first 
demonstrated by Clay et al who transduced human T cells with a TCR that 
was specific for a melanoma antigen in the context of HLA-A2  (1).  TCR gene 
transfer generates functional T cells that have the same specificity as the 
parental clone.  TCR transduced T cells secrete cytokines and proliferate in 
response to specific antigen and can lyse antigen positive targets in vitro   (2)  
(3).  In vivo mouse models have also demonstrated that tumour specific TCR 
gene modified T cells can provide tumour protection  (4)  (5)  (6).   
 
The first clinical trial of TCR gene modified T cells in humans was used to 
treat patients with metastatic melanoma.  Autologous T cells were transduced 
with a TCR specific for the melanoma antigen, MART-1 presented by HLA-A2.  
Transduced T cells were adoptively transferred to patients following non-
myeloablative conditioning chemotherapy. Objective responses were seen in 
2/15 patients (13%). Both responding patients had long-term disease control.   
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(7).  A follow up trial used a TCR that targeted the same MART-1 epitope but 
with higher pMHC binding affinity and this led to anti tumour responses in 6/20 
(30%) of patients treated  (8).  TCR transduced T cells that target the cancer 
testis antigen, NYESO1, have also been used to treat patients with metastatic 
melanoma or advanced synovial cell carcinoma where response rates of 45% 
and 67% respectively were observed  (9).   
 
Superior responses (up to 72%) are still seen following adoptive transfer of 
TILs compared to TCR transduced T cells, particularly in patients with 
metastatic melanoma   (10).  However, TCR transduced T cells have many 
advantages over TIL.  This technique can be used to generate tumour specific 
T cells expressing TCR that are absent from the normal T cell repertoire due 
to central tolerance mechanisms and can also be used to generate high 
avidity tumour specific T cells.  For the majority of malignancies it is not 
possible to isolate TIL in sufficient number.  TCR transduction can be used to 
generate large numbers of tumour specific T cells by transduction of a 
patients autologous lymphocytes and thus can vastly increase the number of 
types of tumours that could potentially be treated by adoptive transfer of TCR 
transduced T cells.  Initial studies of TCR gene therapy have focused on the 
adoptive transfer of CD8+ cytotoxic T cells but there is increasing use of 
CD4+ T cells in adoptive transfer protocols and increasing recognition of an 
important role for tumour specific CD4+ T cells in tumour eradication.  
However development of TCR transduced CD4+ T cells has not happened at 
the same pace as that of TCR transduced CD8+ T cells.  One of the main 
reasons for this is that there is a lack of well-defined MHC class II restricted 
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tumour epitopes and thus fewer tumour specific class II restricted TCRs have 
been isolated for use in gene transfer experiments. The transfer of Class I 
restricted TCR can be used to generate class I restricted CD4+ T cells and 
has been shown to produce functional antigen specific CD4+ T cells.  
However the majority of class I restricted TCRs are CD8 co-receptor 
dependent and thus CD4+ T cells expressing class I restricted TCR tend to be 
of lower avidity than CD8+ T cells expressing the identical TCR.  In addition, 
the full range of CD4+ T cell functions may be absent in the absence of a 
functional co-receptor interaction.   
 
This project has focused on a strategy to try to improve the functional avidity 
of a class I restricted TCR transduced CD4+ T cell.   Functional avidity is 
dependent on both the affinity of the TCR and also the density of TCR 
expression.  The amount of transduced TCR that is expressed on a T cell 
surface is limited by the amount of CD3 within the T cell.  The transduced 
TCR and the endogenous TCR must compete for binding to the endogenous 
CD3 molecules and thus it has been hypothesized that by transducing T cells 
with TCR plus additional CD3, an excess of CD3 can be provided and the 
competition for binding to CD3 reduced.  This should result in higher surface 
expression of the transduced TCR thus leading to enhanced functional avidity 
of the class I restricted CD4+ T cell.  This strategy of co-transfer of TCR and 
CD3 has already been explored in CD8+ T cells and has been shown to 
increase the in vitro functional avidity of T cells co-transduced with TCR and 
CD3 and this leads to superior tumour protection following adoptive transfer in 
vivo   (5). 
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1.2  THE IMMUNE RESPONSE TO TUMOURS 
 
1.2.1  Immune surveillance of cancer 
 
The immune system has a key role in controlling the development and growth 
of tumours in vivo.  However, tumours still develop despite the presence of an 
intact immune response.  In a process termed cancer immune surveillance, 
the immune system detects transformed cells that have escaped from the 
cells’ intrinsic tumour suppressor mechanisms and acts to eradicate malignant 
cells.  This process is dynamic, and the behaviour of the tumour is shaped by 
the immune response directed against it and vice versa. 
 
There is strong supporting evidence in both murine and human models for the 
presence of cancer immune surveillance.  Mice that have a homozygous 
deletion of RAG2 (and thus lack T, B and NK cells) have an increased 
incidence of naturally occurring and chemically induced tumours than wild 
type mice   (11).   An increased frequency of tumours is also demonstrated in 
mice lacking other immune mediators such as IFN-γ, IFN-γ receptor or 
perforin  (12)  (13)  (14).  In addition, humans with either congenital or 
acquired immunodeficiency have an increased frequency of malignancy, 
especially virally driven tumours   (15). 
 
To assess whether the immune system could shape the immunogenicity of 
tumours, chemically induced sarcomas derived from immunocompetent wild 
	   19	  
type mice and from immunodeficient RAG -/- mice were used in tumour 
transplantation experiments.  When injected into RAG-/- recipients, tumours 
generated in both RAG-/- mice or wild type mice grew progressively and with 
similar kinetics.  Similarly, tumours generated from wild type mice grew 
progressively when injected into immunocompetent mice.  However 40% of 
tumours derived from carcinogen treated RAG-/- mice were rejected after 
transplantation into immunocompetent wild type mice even following injection 
of a very high tumour cell burden.  This would suggest that tumours generated 
within mice that were immunodeficient were much more immunogenic than 
those derived from immunocompetent hosts. An intact immune system acts to 
edit and shape growing tumours, which as a result become less immunogenic 
and can evade and outgrow the immune response   (11). 
 
Schreiber et al proposed the theory of cancer immune editing which 
demonstrates how the immune response affects malignant cells in vivo   (16).  
This theory divides cancer immune editing into 3 phases, elimination, 
equilibrium and escape.  In the elimination phase, the immune system actively 
surveys to detect and destroy malignant cells as they arise.  Numerous 
effector cells and pathways are important for suppression of tumour 
development.  However with time this progresses to a state of dynamic 
equilibrium where the immune system acts to contain the tumour growth but 
does not fully eliminate the malignant cells. During the equilibrium phase 
tumour cells start to acquire gene mutations or changes in gene expression 
as a result of selection pressure exerted by the immune response, which 
leads to resistance to recognition and/or elimination. This then progresses to 
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the escape phase when the immune system fails to control these surviving 
tumour cell variants, which have reduced immunogenicity, resulting in 
uncontrolled proliferation.  
 
Tumour cells have developed multiple methods to escape and evade 
recognition by the immune system.   In simple terms, tumour cells can evade 
immune destruction either as a result of lack of recognition, resistance to 
cytotoxic mechanisms or by the induction of tolerance.  Mutations may lead to 
loss of tumour antigens and development of antigen loss variants that are not 
recognized by T cells  (17).  In addition, tumour cells can acquire defects in 
antigen presenting and processing pathways including loss or down regulation 
of Class I MHC, β2microglobulin, TAP, tapasin and proteasome components   
(18)  (19)  (20)  (21).  Other described mechanisms initiated within tumour 
cells to evade immune mediated killing are up regulation of anti-apoptotic 
molecules such as FLIP or Bcl-xl   (22)  (23).  Tumour cells may resist killing 
via death receptors through the expression of mutated forms of TRAIL or FAS 
ligand  (24)  (25).   Absence or abnormal function of components of the IFN-γ 
receptor signaling pathway leads to tumour cells becoming unresponsive to 
the effects of IFN-γ.   
 
The tumour microenvironment itself is often suppressive with secretion of 
immune regulating factors that can prevent T cell infiltration or promote T cell 
exhaustion.  Tumour cells promote the formation of an immunosuppressive 
environment by production of immunosuppressive cytokines such as TGF-β 
or IL-10   (26).  Overproduction of Indoleamine 2,3 dioxygenase by tumour 
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cells or by dendritic cells (DCs) in the tumour microenvironment can lead to 
suppression or anergy of tumour reactive T cells and activation of T regulatory 
cells  (27). DCs in tumour draining lymph nodes are often incompletely 
activated which may favour the induction of tolerance rather than of priming   
(28). 
 
1.2.2 Processing and presentation of tumour antigens.  
 
T cells recognize peptide in a complex with MHC molecules.  CD8+ T cells 
recognize peptide presented by Class I MHC and CD4+ T cells recognize 
peptide presented by class II MHC.  Class I MHC is composed of a 
polymorphic heavy chain bound to β2-microglobulin whilst Class II MHC is  
composed of polymorphic α and β chains.  Class I MHC is expressed on all 
nucleated cells allowing CD8+ T cells to detect infected or malignant cells.  
The expression of Class II MHC is restricted mainly to B cells, macrophages 
and DCs, which act as professional antigen presenting cells (APCs).  Class II 
MHC expression can also be induced by IFN-γ on non-professional APCs 
such as fibroblasts and endothelial cells  (29) or on tumour cells.  Non-
professional APCs however express variable levels of co-stimulatory 
molecules and thus have an inconsistent ability to process and present 
antigen. The transcription of MHC class II genes is controlled by the MHC 
class II trans activator (CIITA) that ensures tissue specific expression of class 
II MHC   (30)  (31). 
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Both the class I and class II MHC molecules fold to form a peptide-binding 
groove on their distal surface.  Along the length of the groove are pockets into 
which key anchor residues of the peptide bind. The interactions between the 
anchor residues of the peptide and the pocket of the groove determine the 
specificity of peptide binding.  Additional stability is provided by hydrogen 
bonds between conserved non-polymorphic amino acids within the MHC 
molecules.  Within the class I MHC, the conserved hydrogen bonds are at 
either end of the peptide binding groove which limits the binding of peptides to 
those that are 8-9 amino acids in length only   (32).  In contrast, the peptide-
binding groove of class II MHC molecules is “open” so theoretically peptides 
of any length can be bound.  The polymorphic nature of the class I and class 
II MHC proteins generates a vast number of different peptide binding grooves   
(33)   (34).   
 
Peptides that bind to class I MHC and stimulate CD8+ T cell responses are 
predominantly derived from endogenous intracellular antigens whilst peptides 
that bind to class II MHC and stimulate CD4+ T cell responses are 
predominantly derived from exogenous antigens.  However, exogenous 
antigens can also be presented by class I MHC in a process called cross 
presentation.  In addition, autophagy allows endogenous antigens from the 
cytosol to enter the phagosomal network where they are be presented by 
class II MHC  (35).  
 
In order to become competent effector cells, T cells must be primed with 
specific antigen presented by professional APCs, which express in addition to 
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MHC class I or II, high levels of co-stimulatory molecules and relevant 
adhesion molecules.  The most efficient APC is the DC, which are also the 
main cross presenting APC  (36).  Lymphoid organ resident CD8+ DCs are 
the most efficient at cross presentation particularly in steady state but in 
inflammatory conditions other DC subsets and macrophages also develop the 
ability to cross present  (37).  
 
DCs have a unique ability to acquire and present peripheral tissue antigens. 
They survey the peripheral tissues for the presence of infected or malignant 
cells.  Following uptake of exogenous antigen they then migrate to draining 
lymph nodes, which are enriched in naïve T, cells which will scan DCs 
continuously looking for their cognate antigen-MHC  (38).   DCs express very 
high levels of class II MHC together with high levels of co-stimulatory 
molecules and are very efficient at endocytosis of antigen.  Their dendritic 
morphology also allows them to make close contacts with many T cells at the 
same time.  Immature DCs are phagocytic but are relatively inefficient at 
processing antigen.  Stimulation with TLRs or cytokines leads to DC 
maturation resulting in the up regulation of class II MHC and co-stimulatory 
molecules.  They also acquire the ability to migrate to lymphoid organs and 
remodel their endosomal compartments for antigen processing.  Productive T 
cell activation requires a signal via the TCR-peptide-MHC interaction and also 
a second co-stimulatory signal.  The best-characterized second interaction is 
CD28 which binds to its ligands, CD80 and CD86 on the APC  (39).  TCR 
binding to peptide-MHC in the absence of the second co-stimulatory signal 
leads to apoptosis or anergy of the T cell  (40). 
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1.2.3 Processing of class I MHC binding peptides 
 
Processing of peptides for binding to class I MHC is performed within the 
cytoplasm by the proteasome-ubiquitin system   (41)   (42). This is the main 
process by which cytoplasmic or nuclear proteins are degraded within a cell.  
Proteins are initially conjugated with ubiquitin, which then targets them to the 
proteasome for degradation   (43)  (44)  (45).  In addition to protein 
degradation, ubiquitiniylation of proteins can control a wide range of cellular 
functions including protein activation, intracellular trafficking of proteins, 
regulation of signaling pathways and of DNA repair mechanisms  (46)   (47). 
 
The oligopeptides produced by the proteasome are broken down into amino 
acids where they can be reutilized for protein synthesis   (41).  However, 
some short peptides escape further breakdown and are transported into the 
lumen of the ER via the specialized peptide transporter, transporter 
associated with antigen processing (TAP) (48).  Within the ER, 
aminopeptidases trim peptides to 8-9 residues in length to produce peptides 
that can bind to class I MHC  (49)  (50)  (51).  
 
Prior to peptide binding, the class I molecules are stabilized by chaperone 
proteins within the ER such as Tapasin, calreticulin and ERp57 forming a 
peptide loading complex   (52)  (53).  Tapasin also interacts with TAP and 
therefore helps to couple the translocation of peptides into the ER via TAP to 
peptide loading onto class I MHC   (54).  Tapasin also acts as a peptide editor 
by promoting the binding of high affinity peptides to class I MHC  (55).  
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Following peptide binding, the chaperone proteins are released and the fully 
assembled peptide-MHC-I complex is exported to the cell surface  (56) 
(Figure 1). 
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Figure 1 – Class I MHC antigen processing and presentation -  Class I MHC molecules present 
peptides derived from endogenous cytoplasmic or nuclear antigens.  Proteins are initially 
conjugated with ubiquitin and then targeted for processing by the proteasome.  Short peptides 
generated by the proteasome are translocated into the ER by TAP where they are then loaded 
onto class I MHC.  Prior to peptide loading, class I MHC molecules are stabilized by chaperone 
proteins such as Erp57, Calreticulin and Tapasin.  Tapasin also binds to TAP and thus couples the 
translocation of peptides by TAP to loading onto class I MHC.  Tapasin also acts as a peptide 
editor.  Following peptide binding, the chaperone proteins are released and peptide-MHC class I 
are exported to the cell surface.  
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1.2.4 Cross Presentation 
 
Cross Presentation is the process where exogenous antigens are taken up by 
professional APCs and presented by class I MHC.  It is an important pathway 
for the presentation of tumour antigens by professional APCs.  It was first 
described by Bevan et al in 1976 who demonstrated that minor 
histocompatibility antigens from transplanted allogeneic cells (e.g. exogenous 
antigens) could prime naïve CD8 T cells in a class I restricted manner  (57).  
The presentation of exogenous antigen leading to CD8+ T cell activation is 
referred to as ‘cross priming’ whereas ‘cross tolerance’ refers to the induction 
of CD8 T cell deletion or anergy via presentation of exogenous antigen.   
 
One of the major pathways of cross presentation is the cytosolic pathway, 
which is dependent on both the proteasome and TAP  (58)  (59).  Exogenous 
antigens are taken up by phagocytosis and then transported from the 
phagosome into the cytoplasm for processing by the proteasome. There are a 
number of potential routes by which the proteins within the phagosome reach 
the cytoplasm:  direct translocation into the cytosol; fusion of the ER and 
phagasome resulting in the protein being retro-trans located out of the ER by 
TAP. Once within the cytosol, exogenous antigen is processed by the 
proteasome and then follows the same route as endogenous antigens to be 
loaded onto class I molecules within the ER.  The phagosome itself may act 
as a self-contained processing area containing TAP, class I MHC, Tapasin 
and other chaperone molecules.  The fusion of the ER with the phagosome 
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allows donation of several essential processing structures to the phagosome   
(60)  (61).  
 
A pathway for cross presentation also exists that is independent of both the 
proteasome and TAP and is referred to as the vacuolar pathway  (62). In the 
vacuolar pathway, exogenous antigen is degraded by cathepsin S following 
fusion of phagosomes with endolysosomes in a process called phagosome 
maturation  (63)  (64).  Class I MHC molecules are loaded with peptide within 
the phagasome after trafficking into the phagosome either by internalization 
from the plasma membrane or by fusion of the ER with the phagosome.  Both 
cytosolic and vacuolar cross presentation may occur within the same APC   
(62). 
 
1.2.5 Processing of class II MHC binding peptides. 
 
Peptides that bind to class II MHC are predominantly exogenous antigens 
acquired by professional APCs and degraded by the endosomal pathway. The 
α and β chains of class II MHC form heterodimers within the ER and then 
associate with the invariant chain (Ii).  Ii acts as a chaperone to stabilize the 
heterodimer and also acts to accelerate the egress of class II molecules from 
the ER  (65).  Ii contains 2 di-leucine sorting motifs that direct the complex of 
MHC class II-Ii  to a late endosomal compartment, called the MHC class II 
compartment (MIIC)  (66).  Within the MIIC, the Ii is digested by proteases 
until the residual class II associated peptide, CLIP, remains within the peptide-
binding groove.  CLIP acts as a surrogate peptide that prevents the premature 
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binding of peptides to class II MHC whilst it remains within the ER.  Within the 
MIIC, a non-polymorphic class II related molecule HLA-DM (H2-DM in mice) 
acts to facilitate and accelerate the exchange of the CLIP fragments for 
specific peptide.  Following peptide loading, the MHC class II- peptide 
complex is transported to the plasma membrane to present peptide (Figure 2).   
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Figure 2 – Class II MHC antigen processing and presentation – Class II MHC binds peptides 
derived from exogenous antigens that are processed by the endosomal pathway..  The α and β 
chains of class II MHC form a heterodimer within the ER and then associate with the invariant 
chain (Ii) which acts as a chaperone protein to stabilize class II MHC.  Ii contains 2 dileucine 
sorting motifs which targets the class II MHC to the late endosomal compartment, MIIC.  Within 
the MIIC, the Ii is digested by proteases, leaving a residual class II associated protein, CLIP,  
within the peptide binding groove.  Within the MIIC, HLA-DM acts to facilitate the exchange of 
CLIP for specific peptide,  Following loading with peptide, class II-MHC-peptide is exported to the 
cell surface. 
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1.2.6 T cell trafficking 
 
Prior to encounter of cognate antigen, naïve T cells migrate actively and in 
what appears to be a random fashion  (67).  Naïve T cells recirculate 
continuously between the lymphoid organs and the blood, increasing the 
probability of encountering cognate antigen.  Binding to cognate antigen leads 
to a prolonged and functional interaction between the T cell and the APC 
resulting in arrest of T cell migration within the lymph node and proliferation of 
antigen specific T cells  (68).  Recently activated T cells exit the lymph node 
and then rapidly localize to areas of inflammation in order to combat 
pathogens or tumours.  Targeted migration or homing of T cells is regulated 
by their differentiation state with the activation of T cells leading to altered 
expression of adhesion molecules and chemokine receptors.  Importantly T 
cells will express different selectins and selectin ligands, chemokine receptors 
and integrins depending on the activation state of the cell.   
 
Naïve T cells tend to migrate in a linear fashion from blood to lymph node to 
lymphatics and back into the bloodstream via the thoracic duct.  The process 
by which T cells exit the blood stream and enter the lymph node via the high 
endothelial venules is a highly coordinated process.  CD62L (L-selectin) is 
expressed by all naïve CD8+ T cells.  It is the interaction between CD62L and 
it’s ligand that initiates the transmigration process of T cells out of the blood 
stream into the lymph node.  To overcome the shear forces of the blood, 
naïve T cells must tether to the endothelium resulting in rolling of the T cells 
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along the high endothelial venules (HEV).  HEV are a specialized post 
capillary vascular endothelium within lymph node paracortical regions.  This 
rolling and tethering effect is mediated by the high avidity low affinity short 
lived interaction between CD62L on T cells   and peripheral node addressins 
(PNAd) which are highly expressed in HEV  (69)  (70).    
    
Following the tethering of the T cells, CCR7 on the T cell can be stimulated by 
the homeostatic chemokines CCL21 and CCL19 which are immobilized on the 
surface of the HEV  (71).  Signalling via CCR7 leads to a conformational 
change in and activation of LFA-1   (72)  (73).  Activated LFA-1 binds ICAM-1 
leading to T cell arrest within the HEV and transmigration of the T cell into the 
T cell area of the lymph node, the paracortex.  
 
Migration of T cells through the lymph node is controlled by sphingosine-1-
phosphate (S1P) which binds S1PR1 expressed by T cells  (74).  SP1R1 is a 
G protein coupled receptor that activates signaling pathways within the T cells 
which control cell polarity and migration  (75)  (76).  T cells are directed 
across a naturally occurring gradient of increasing S1P concentration which 
directs the exit of T cells from the lymph node to the efferent lymphatics  (77)  
(78).  If T cells migrate through a reactive node, the pro-inflammatory cytokine 
environment leads to down regulation of S1PR1 by the T cell leading to an 
increase in dwell time of activated T cells within the lymph node  (79).  Type I 
interferons induce expression of CD69 which inhibits the surface expression 
of S1PR1  (80).   If T cells encounter their cognate antigen, TCR stimulation 
results in reduced S1PR1 transcription leading to retention of antigen specific 
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T cells within the lymph node  (81)  (82).   Following activation or when 
inflammation is reduced, the expression of S1PR1 is regained through 
renewed transcription and via downregulation of CD69  (83) allowing exit of T 
cells from the lymph node.   
 
Expression of chemokines, CCL21 and CCL19 within the T cell zone 
enhances T cell motility, facilitating scanning of APCs for cognate antigen.  
(84).  Release of inflammatory cytokines and chemokines alters the lymph 
node architecture and thus modification of the homing ability of T cells.  This 
also results in recruitment of additional T cell subsets and innate immune cells 
to the lymph node.  Inflammation also increases microvascular blood flow to 
the lymph node thus increases the rate of T cell entry into the lymph node  
(85).   Within the lymph node, there is competiton for binding to antigen and 
as a result low affinity T cells exit the lymph node at earlier time points.  
Higher affinity T cells remain in contact with cognate antigen for longer and 
thus can clonally expand.   
 
The trafficking patterns of T cells change with their transition from naïve to 
effector or memory T cells secondary to a shift in surface expression of 
proteins that regulate cellular trafficking.  Naïve T cells constitutively traffic 
through lymphoid tissue whilst effector or memory T cells acquire the ability to 
enter non lymphoid sites where cognate antigen is located.  Following 
activation, effector T cells down regulate CD62L and CCR7 which prevents 
these cells from gaining access to the lymph node via the HEV.  In addition 
they upregulate the expression of homing molecules that will direct them to 
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non lymphoid tissues.  Unique selectin and chemokine and integrin 
expression by the T cell will influence tissue specific homing of T cells 
following initial activation within the lymph node.  Each tissue presents an 
organ specific molecular signature allowing entry of specific T cells expressing 
the relevant ligand  (86).  Different homing molecules are required for homing 
of T cells to the gut, skin or secondary lymphoid organs. Location of T cell 
priming may influence the homing characteristics e.g. T cells activated within 
lymph nodes draining the skin upregulate E-selectin and P-selectin ligands 
and CCR4 and CCR10  (87) whilst T cells that are found in the gut express 
α4β7 and CCR9  (88).   The multistep homing paradigm provides a model 
whereby unique combinations of selectin, chemokine receptors and integrins 
provide an organ specific area code and each tissue displays a specific and 
unique molecular signature which the T cell must recognize in order to gain 
entry to that tissue  (86).   This “imprinting” of T cells significantly influences 
their trafficking pattern but is not always a permanent state.  T cells that have 
been imprinted within the gut or the skin can be reprogrammed following 
interaction with an APC from an alternative anatomical location.  As memory T 
cells develop, the expression of CD62L and CCR7 can be upregulated.  
Effector memory T cells maintain a low expression level of CD62L and CCR7 
whilst central memory T cells have high expression levels.  Both effector 
memory and central memory T cells are found within the blood, spleen and 
peripheral tissues, central memory T cells are enriched within lymph nodes 
thus enabling memory T cells to maintain effective immunity within both the 
periphery and lymphoid organs.   
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1.3 THE TCR-CD3 COMPLEX AND CO-RECEPTOR FUNCTION 
 
1.3.1 TCR structure 
 
The αβTCR is a heterodimer composed of disulfide linked α and β chains, 
which share features with those of the Fab fragment of an antibody molecule.  
Both the TCR α and β chains are composed of a variable and a constant 
immunoglobulin like domain.  The variable region is encoded by the 
rearranged V, D and J gene segments and the constant region is encoded by 
the constant gene segment   (89).  The complementarity-determining regions 
(CDR) of the variable domains are the area of the TCR that contacts peptide-
MHC.  The hypervariable CDR3α and CDR3β bind over the centre of the 
bound peptide whilst the germ line encoded CDR1 and 2 regions bind to the 
MHC molecule.   CDR1α and CDR1β also make some contribution to peptide 
recognition by binding over the amino terminal and carboxy terminal peptide 
sequences respectively. Most αβTCRs bind diagonally across the peptide-
MHC complex.  TCRVβ is positioned over the α1 helix of the MHC and the 
TCRVα over the other MHC helix (α2 in MHC class I or β1 in MHC class II)   
(90)  (91).  
 
1.3.2 The immune synapse 
 
T lymphocytes traffic constantly through the body, but following recognition of 
cognate antigen, their migration is arrested and a stable contact is formed 
between the T cell and APC.  One of the initial steps following antigen 
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recognition is antigen induced upregulation of LFA-1 on the T cell which binds 
to ICAM-1 on the APC.  This acts to slow T cell migration and initiate 
formation of the immune synapse.  The immune synapse is a specialized 
structure that forms during the recognition of pMHC by TCR.  It is composed 
of a bullseye structure containing a central aggregation of TCR-pMHC 
complexes termed the central supramolecular activation cluster (cSMAC) 
surrounded by a ring of adhesion molecules such as LFA-1, the peripheral 
supramolecular activation cluster (pSMAC)  (92)  (93).  This structure forms 
within minutes of the initial TCR-pMHC contact and allows a stable synapse to 
form between the TCR and APC. TCR-pMHC microclusters form initially in the 
periphery and then translocate centrally into the cSMAC via an actin 
cytoskeletal dependent process.  The peripheral TCR microclusters are the 
site of initiation of active T cell signaling and the formation of the cSMAC is 
not essential to initiate signaling  (94)  (95).  The main function of the cSMAC 
may be to terminate signaling  (96), facilitating the ubiquitination and 
internalization and degradation of the TCR  (97).  In addition to playing an 
important role in T cell priming, the immune synapse  also provides a sealed 
point of contact to allow targeted delivery of cytolytic granules by effector T 
cells  (98).   
 
1.3.3 T cell co-receptor structure and function 
 
Mature T cells that recognize antigen presented by class I MHC express CD8 
whilst those that are class II restricted express CD4.   Both CD8 and CD4 act 
as universal co-receptors, which can potentially bind to any polymorphic class 
I or II molecule respectively.   CD8 and CD4 are structurally quite distinct.  
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CD4 is a single polypeptide composed of 4 extracellular immunoglobulin like 
domains (D1-D4).   The crystal structures of the D1 and D2 domains of 
human CD4 and murine peptide-MHC II (I-Ak) demonstrate that the N 
terminus of D1 (of CD4) binds to the 2 membrane proximal domains of MHC 
class II (α2 and β2)   (99).  The ternary crystal structure of TCR, peptide-MHC 
and CD4   (100) suggests that the TCR-MHC-CD4 complex forms an inverted 
V shaped structure where both TCR and CD4 are tilted inwards towards the 
MHC molecule, rather than pointing up vertically from the cell membrane.  
The MHC molecule is at the apex where the TCR and CD4 both bind MHC 
although TCR and CD4 do not come into direct contact.  This suggests that 
there is a wide separation (70Å) between the membrane proximal TCR and 
the D4 domain of CD4 which may be the place where the CD3 complex sits.  
The movement of TCR or CD4 following MHC binding may produce a 
conformational change in CD3.   
   
CD8 exists either as a CD8αα homodimer or a CD8αβ heterodimer.  CD8β 
requires association with CD8α in order to be stably expressed on the T cell 
surface.  Both CD8α and CD8β chains are membrane-anchored 
glycoproteins, which have an immunoglobulin like variable domain and a long 
stalk.   CD8αβ binds to the α2 and α3 areas of the class I MHC, to an area 
distant from the TCR-peptide MHC interaction  (101)  (102).  CD8αβ and 
CD8αα are not interchangeable and both may have distinct functions.  Co-
ordinate binding of CD8αβ and TCR to MHC results in a much stronger signal 
than that produced by CD8αα   (103)  (104).  In addition, CD8αα does not 
support the positive selection of class I restricted thymocytes during thymic 
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selection   (105).  In fact there is increasing evidence that CD8αα delivers an 
inhibitory signal.  CD8αα is often expressed in conjunction with high affinity 
TCRs  (106)  (107) and the co-expression of CD8αα has been shown to 
decrease the functional avidity to TCR leading to reduced activation 
suggesting that it may act as a co-repressor   (108)  (109).  
 
The exact role that CD4 and CD8αβ play in T cell activation is still being 
resolved but they are known to enhance TCR sensitivity for peptide.    Binding 
of CD4 to class II MHC has been shown to increase cytokine production by 
CD4 T cells  (110) and led to a marked reduction in the number of peptide-
MHC required for T cell triggering   (111).  Preventing the binding of CD8 by 
mutating the α3 domain of MHC class I led to a reduction in specific tetramer 
binding and reduced T cell activation and reduced killing of target cells  (112)  
(113).  Garcia et al showed that the affinity of the TCR for the peptide-MHC 
was enhanced by CD8 due to a reduced dissociation off rate in the presence 
of CD8   (114).  It has been suggested that CD8 acts to stabilize the 
interaction between peptide-MHC by increasing the half-life of binding or that 
CD8 binding to MHC promotes a more favorable docking conformation for 
TCR binding to peptide-MHC, or both.  CD8α associates with the src kinase, 
Lck via a conserved binding motif in the cytoplasmic domain of CD8α  (115) 
and acts to bring Lck into the vicinity of the TCR/CD3 complex. In addition, 
CD8β has been shown to promote lipid raft association   (116).  Lipid rafts are 
ordered micro domains that are rich in cholesterol and sphingolipids.  These 
rafts are stabilized by the presence of short saturated fatty acids such as 
palmitic or myristic acid.  The cytoplasmic tail of CD8β is palmitoylated which 
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allows it to efficiently partition into lipid rafts where it can associate with 
signaling molecules such as Lck and LAT which are also enriched in lipid rafts  
(117)  (104).  CD8β enrichment in lipid rafts may enhance the active 
recruitment of TCR/CD3 complexes to the lipid rafts.  Furthermore, deletion of 
the cytoplasmic tail of CD8β reduced the association of CD8 with TCR/CD3 
and led to a marked reduction of TCR binding to peptide-MHC   (116)   (118).   
 
CD4 does not act to stabilize the interaction of TCR with MHC:  blockade of 
CD4 binding has no effect on TCR-MHC affinity nor does it destabilize TCR-
peptide-MHC binding  (119).   CD4, like CD8α, associates with Lck via its 
cytoplasmic tail.  CD4 is palmitoylated and is enriched in lipid rafts   (120) and 
it is via these two actions that CD4 is thought to mediate co-receptor function. 
 
CD8 or CD4 co-receptor binding to MHC is not an absolute requirement for T 
cell activation.  High affinity TCR-peptide MHC interactions, such as in an 
alloreactive response, can be CD8 independent whilst weaker affinity 
interactions may be more dependent on co-receptor function to trigger a 
functional T cell response  (121)  (122).   
 
The interaction between CD8 and MHC-I is of much lower affinity than that 
between TCR and peptide-MHC-I.  The absolute requirement for CD8 binding 
to MHC-I may vary depending on TCR-pMHC-I affinity.  Experiments using 
mutated pMHCI tetramers with altered CD8 binding properties demonstrated 
that binding of CD8 can profoundly affect TCR-pMHCI avidity.  Class I MHC 
molecules with compromised CD8 binding were used to demonstrate that T 
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cell activation could not occur in the presence of weaker agonist antigens 
without CD8 co-receptor activation whilst T cell activation by strong agonists 
is only partially impaired by the loss of CD8 engagement  (123).  Using 
combinatorial peptide libraries and APCs that expressed HLA-A201 molecules 
which had differing CD8 binding affinities it was demonstrated that there was 
a direct positive association between the affinity of CD8 binding to MHC-I and 
the number of ligands it took to induce T cell activation  (124).   Increasing the 
affinity of the interaction between CD8 and MHC-I can lead to non specific T 
cell activation even in the absence of a functional TCR-pMHC interaction.  
Wooldridge et al generated a chimeric A2/Kb MHC molecule that increased 
the affinity of the pMHCI-CD8 interaction by >10 fold.  This led to loss of 
tetramer binding specificity with tetramers binding to the T cell surface even in 
the absence of TCR expression.  This non specific binding could be prevented 
by pretreatment with an anti-CD8 antibody which suggested that the loss of 
specificity for binding to pMHC-tetramer was mediated by CD8 and was 
occurring in a TCR independent manner.  It appeared that the chimeric A2/Kb 
molecule was crosslinking the CD8 molecules leading to activation of the T 
cell in an antibody like manner  (125).      
 
Thus in situations of low antigen potency, CD8 plays a much greater role in 
increasing T cell antigen sensitivity whilst for stronger agonists, the 
contribution made by CD8 is much less.  By extension of this theory it would 
be predicted that the CD8 co-receptor may act to increase the crossreactivity 
of T cells by increasing the range of agonist ligands to which T cells make 
functional responses.  Binding of CD8 to MHC-I may provide a mechanism 
	   41	  
whereby T cells can maintain their antigen specificity whilst achieving the 
desired level of sensitivity by the additional binding of CD8.  CD8 may thus be 
essential to regulate the balance between an optimal level of cross reactivity 
and a broad antigen specificity of CD8+ T cells.   CD8 function and the need 
for CD8 co-receptor interaction in both thymic education and in peripheral T 
cell activation may be dynamically increased or decreased in vivo.  
Mechanisms include the transcriptional inhibition of CD8 expression in double 
positive thymocytes  (126), alternative expression of CD8αα isoforms, 
alterations in glycosylation pattern and selective internalization of CD8 
following T cell activation  (126)  (127)  (128)  (129). 
 
1.3.4 The TCR-CD3 Complex 
 
CD3 forms a multimeric complex with the TCR and is responsible for the 
transmission of downstream signals from the TCR. It is essential for the stable 
expression of TCR on the cell surface.  CD3 molecules are not expressed on 
the cell surface in the absence of TCR and have no ligand binding function in 
the absence of TCR  (130).  Signals transmitted via the TCR/CD3 complex 
are the primary checkpoint controlling T cell activation and the quality of the 
intracellular signal delivered, which determines the ultimate function and fate 
of the cell.  The CD3 complex comprises 4 different chains: zeta(ζ), epsilon(ε), 
delta(δ) and gamma(γ).  All chains contain a immunoreceptor tyrosine based 
activation motif (ITAM) (YxxL/Ix6–12YxxL/I) within their cytoplasmic domains  
(131) – each ζ chain contains 3 ITAMS, whilst the other three chains have one 
ITAM motif per chain. 
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CD3-TCR assembly takes place within the endoplasmic reticulum (ER) and is 
an ordered and well-controlled process.  Incomplete or incorrectly assembled 
complexes are unable to leave the ER.  The determinants for the correct 
assembly of the TCR-CD3 complex are contained primarily within the 
transmembrane and juxtamembrane domains of the individual chains.  One of 
the initial steps is the pairing of CD3ε with CD3γ or CD3δ resulting in 
formation of CD3γε and CD3δε heterodimers whilst CD3ζ forms a CD3ζζ 
homodimer. CD3γε preferentially associates with the TCRα chain and CD3δε 
preferentially pairs with the TCRβ chain.  The association between TCR and 
CD3 dimers is driven by charged residues within the transmembrane regions 
of the TCR and CD3 chains.  Each of the CD3 chains has a single acidic 
residue within their transmembrane domain, which binds to a basic residue 
within the transmembrane region of the TCRα and TCRβ chains   (132)   
(133).  The formation of a complete eight chain complex is dependent on the 
correct placement of these ionizable residues. Alanine substitution of any of 
these residues prevents the formation of a complete and correctly assembled 
TCR-CD3 complex.  Conversely, correct assembly can still take place even if 
the transmembrane domains of the TCR are substituted entirely by 
polyleucine sequences as long as the basic residues remain in the correct 
position   (134).  Extracellular and intracellular domains are also not required 
for correct assembly as just the transmembrane and juxtamembrane 
sequences are sufficient to drive complex assembly.  These basic and acidic 
residues contain signals for degradation should the individual subunits remain 
unassembled   (135)  (132).  All of the CD3 chains contain one or more ER 
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retention motifs. It has been proposed that following the final assembly step of 
binding of the CD3ζζ homodimer, the ER retention motifs are masked. This 
then allows export of the fully assembled TCR-CD3 complex to the cell 
surface  (136)  (137)  (138).  If one or more components are absent then the 
incomplete complex is retained within the ER and degraded.  The final 
composition of the CD3 complex is one TCR αβ, one CD3γε heterodimer, one 
CD3δε heterodimer and one CD3ζζ homodimer  (132) (Figure 3).   
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Figure 3 – Assembly of TCR and CD3 complex.  The TCR-CD3 complex is a multichain 
complex and complete assembly with all chains is required prior to cell surface expression.  
TCR-CD3 assembly takes place within the ER and takes place in an ordered sequence.  
Following pairing of the TCR α and β chains to form a αβTCR heterodimer, CD3ε then pairs 
with either CD3γ or CD3δ to form CD3γε or CD3δε heterodimers.  CD3δε preferentially pairs 
with the TCRα chain whilst CD3γε preferentially pairs with the TCRβ chain.  CD3ζ forms a 
CD3ζζ homodimer and one of the final steps is binding of the CD3ζζ homodimer prior to export 
to the cell surface.  Any incorrectly assembled complexes are retained in the ER and degraded. 
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Initial experiments to study signaling events initiated by the TCR-CD3 
complex were completed using chimeric molecules where the cytoplasmic 
domains of individual CD3 chains were fused to extracellular and 
transmembrane domains from other cell surface proteins   (139)  (140)  (141). 
These chimeric proteins were then expressed in T cells that had been 
selected on the basis of absence of TCR expression.  Antibody crosslinking of 
the extracellular domain of the chimeric molecule triggered all downstream 
TCR mediated signaling events leading to T cell activation.  However, 
mutation of the tyrosine residues within the ITAM motifs prevented activation 
of the cell following antibody crosslinking.  These findings demonstrated that 
tyrosine phosphorylation of the CD3 ITAMS was an essential early step for T 
cell activation.  This early ITAM phosphorylation is performed by src protein 
tyrosine kinases (PTK), Lck and Fyn.  These phosphorylated tyrosine 
residues within the ITAMs act as docking sites for the recruitment of signaling 
proteins to the TCR complex forming a scaffold for downstream signaling.  
The two phosphorylated ITAMS within CD3ζζ act as a binding site for the 
tandem SH2 domains of ZAP-70  (142).   ZAP-70 undergoes a conformational 
change following binding to CD3ζζ, which leads to its activation   (143).  
Activated ZAP-70 then recruits and activates linker for the activation of T cells 
(LAT) and SLP-76.   LAT and SLP-76 recruit and activate a key signaling 
molecule, Phospholipase C-γ (PLC-γ).  PLC-γ triggers three further 
downstream signaling pathways leading to activation of transcription factors, 
NFκB, NFAT and AP-1 triggering T cell activation and proliferation. 
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It is likely that the entire complement of ITAMS contained within the CD3 
complex is required for normal T cell development and effector function.  Holst 
et al generated mice that expressed differing ratios of wild type and mutant 
ITAMS within the CD3 complex.  They showed that mice with less than 7 
functional ITAMS within the TCR-CD3 complex developed lethal 
autoimmunity.  This was thought to be secondary to a lower signal strength, 
which led to a failure to delete self reactive T cells in the thymus.  There was a 
linear correlation between the level of T cell proliferation and the number of 
wild type ITAMS although cytokine responses were not affected by the 
number of ITAMS present  (144).  This gave rise to the concept of “scalable 
signaling” where a range of possible responses can be generated following 
TCR engagement.  The main function of having multiple ITAMS thus appears 
to be to control the strength of the TCR signal.  Differing ITAMs within the 
individual chains may serve distinct functions and individual ITAMS may be 
responsible for recruitment of discrete and different signaling molecules and 
this may influence downstream signaling pathway recruitment and the quality 
of the signal   (145). 
 
1.3.5 Models of TCR signaling 
 
It is still incompletely understood how the binding of TCR to peptide-MHC 
leads to the initial phosphorylation of ITAMs within CD3.  Phosphorylation of 
ITAMS must be tightly controlled to prevent inappropriate activation of the T 
cell.  It is thought that one control mechanism is the sequestration of the 
cytoplasmic tails of CD3ε and CD3ζ within the plasma membrane when the T 
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cell is in a resting state.  The cytoplasmic domains of CD3ε and CD3ζ have a 
net positive charge due to stretches of basic amino acids and these interact 
with the negatively charged lipid bilayer of the plasma membrane. The key 
tyrosine residues are therefore buried within the interior of the lipid membrane 
and when in this position cannot be phosphorylated by Lck.   TCR ligation 
results in release of the cytoplasmic tails exposing the ITAMs for 
phosphorylation   (146)  (147).   
 
It is not clear what drives the release of the cytoplasmic tails from the 
membrane following TCR ligation.  TCR aggregation has been proposed as a 
possible model of T cell activation.  TCR aggregation would lead to very close 
apposition of CD3 ITAMS and protein tyrosine kinases leading to 
transphosphorylation.  In addition, receptor multimerization may lead to local 
competition for binding to acidic residues within the lipid membrane and as a 
result some CD3ε and CD3ζ tails would be released from the membrane.  
Models based on conformational change of the TCR have also been 
proposed.  A mechanical force may be transmitted across the membrane 
following binding of TCR to peptide-MHC leading to a conformational change 
of the TCR that is transmitted to the CD3 complex  (148)  (149)  (150).  The 
kinetic segregation model  (151) proposes that upon contact with the APC, 
proteins are segregated within the lipid membrane.  This is partially due to 
size differences and steric restraints of differing proteins. TCR triggering 
induces a signaling event, which is amplified and maintained due to exclusion 
of large bulkier protein tyrosine phosphatases such as CD45. The tyrosine 
phosphorylation is thus promoted and maintained due to phosphatase 
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exclusion.  A similar model proposes that individual TCRs are retained in an 
inactive conformation within positively charged areas of the cell membrane 
due to constraint provided by the actin cytoskeleton  (152).  Coupling of TCR 
phosphorylation and signaling to the actin cytoskeleton redistributes the TCR 
to a more ordered area of the plasma membrane, which excludes larger 
molecules and phosphatases such as CD45.  Most of these models of TCR 
triggering are not mutually exclusive and it may be that elements of all of them 
are important.   
 
1.4 PRINICPLES OF TCR GENE THERAPY 
 
1.4.1 Overview of TCR gene therapy 
 
The production of TCR transduced T cells initiates with the isolation a T cell 
clone that expresses a TCR that is specific for a defined target antigen/MHC 
complex.  The T cell clone is normally obtained by culturing TILs or peripheral 
blood mononuclear cells (PBMCs) in the presence of APCs that have been 
pulsed with the target epitope presented by a defined HLA allele.  High affinity 
T cell clones can be isolated using MHC-peptide tetramer staining and/or their 
ability to recognize and lyse target cells that have been pulsed with low 
concentrations of cognate peptide/MHC.  Once a high affinity clone has been 
selected, the genes encoding the α and β chains of the TCR are cloned into a 
retroviral vector.  These vectors are then transfected into packaging cell lines 
which produce TCR retroviral vector particles which are used to transduce 
polyclonally activated T cells.  T cell activation is an essential step in the 
	   49	  
transduction process as retroviral vector genes can only integrate into the 
genome of actively proliferating cells.  TCR α and β chains are then generated 
by the transduced T cell and a novel TCR expressed on the cell surface, 
which can be detected by flow cytometry within 24 hours of transduction.  
These TCR transduced T cells can then be adoptively transferred to patients 
to target defined antigens (Figure 4). 
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Figure 4 – Generation of tumour specific TCR transduced T cells for adoptive 
immunotherapy.  The production of tumour specific TCR transduced T cells initiates with 
isolation of a T cell clone that expresses a TCR of defined specificity for peptide-MHC.  These T 
cell clones can be obtained by culturing TILs or PBMCs with APCs of a known MHC haplotype 
that have been pulsed with a specific peptide.  Once a high affinity clone has been selected the 
genes encoding the α and β chains of the TCR are isolated and then cloned into a retroviral 
vector.  The retroviral vectors are then transfected into packaging cell lines which produce 
active retroviral particles that are then used to transduce a patient’s autologous PBMCs.  T cells 
expressing the introduced TCR can then be adoptively transferred to patients to target tumour 
epitopes. 
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1.4.2 Retroviral vectors 
 
Retroviral vectors are excellent agents for gene delivery into somatic cells. 
During the retroviral life cycle, the retroviral genome is integrated into the host 
genome as a provirus. As a result, genes inserted into retroviral vectors will 
be stably expressed for the life span of the host cell even through cell 
divisions.  In our research, the retroviral genome is replaced by genes 
encoding the α and β chains of the TCR.  As a result, retroviral vectors lack 
the viral genes that are required for replication and thus are replication 
incompetent.    
 
The elements required for the production of complete retroviral particles can 
be provided in trans within packaging cells.  Packaging cell lines are stably 
transfected with defective helper viruses containing the retroviral genes gag, 
pol and env which encode viral core proteins, core enzymes and envelope 
glycoproteins however they do not contain the relevant packaging signal.  The 
sequences required for integration, gene expression and the packaging of 
genomic RNA are provided in cis with the retroviral vector.  The minimal 
structural features that are required in cis are both long terminal repeats 
(LTRs), the primer binding sites and the packaging signal  (153)  (154).  The 
retroviral vector is transfected into the packaging cell line, which package the 
retroviral particles and secrete them into the supernatant, which is harvested 
and used to transduce host cells such as T lymphocytes.  These replication 
defective virions can only carry out one more round of infection and 
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integration as they lack the viral genome and therefore can’t go onto produce 
further active retroviral particles.   
 
1.4.3 Strategies to improves TCR gene therapy 
 
Whilst adoptive transfer of TILs in patients with metastatic melanoma has 
resulted in excellent clinical responses, for the majority of malignancies it is 
not possible to isolate tumour reactive lymphocytes in sufficient number.  As 
the majority of tumour antigens are self antigens and thus widely expressed 
within self tissues, the majority of high avidity tumour specific T cells will have 
been deleted during thymic selection or will be regulated by peripheral 
tolerance mechanisms.  As a result tumour reactive T cells can’t be isolated or 
only very low avidity T cells can be found within the autologous repertoire.   
One of the advantages of TCR gene therapy is that it allows the generation of 
tumour specific T cells that are absent from the endogenous T cell repertoire.  
 
One method to isolate high avidity tumour specific TCRs for TCR gene 
therapy utilizes transgenic mice that express human HLA molecules.  These 
transgenic mice can be immunized with human tumour epitopes and the 
murine T cells that bind the tumour epitope with high avidity can be selected 
and the TCR genes isolated  (155)  (156).  These TCRs thus will recognize 
human derived tumour peptides presented by human HLA molecules.  
Alternatively, the allorestricted approach can be used to generate high avidity 
T cells in vitro.  Here, human PBMCs are stimulated with allogeneic APCs that 
have been pulsed with tumour peptides.  From these, the tumour specific T 
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cells can be isolated from the purely allospecific responders  (157).   Using 
both of these methods, tumour specific TCRs that would ordinarily be absent 
from the normal peripheral T cell repertoire can be isolated and used for 
retroviral transduction.   
 
Since the initial studies utilizing TCR gene modified T cells there have been a 
number of improvements all of which should lead to enhanced efficacy when 
translating this technique into clinical practice.  These include improvements 
in vector design to enhance TCR surface expression, increasing the affinity of 
the TCR, selecting different T cell populations for transfer and utilizing 
conditioning therapy to enhance persistence of TCR transduced T cells 
following adoptive transfer.   
 
1.4.4 Increasing TCR surface expression 
 
The avidity of a TCR expressing T cell is dependent on the individual affinity 
of TCR for peptide-MHC and also how much TCR is expressed on the cell 
surface.   When a new TCR is introduced into a T cell, both the introduced 
and endogenous TCR are expressed on the cell surface.  One of the 
challenges of TCR gene therapy has been how to increase the surface 
expression of the introduced TCR.  Increased surface expression of TCR 
correlates with increased sensitivity for the target peptide-MHC and increased 
anti tumour activity in vivo  (158)  (159)  (160).   
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The amount of introduced TCR that is expressed on the cell surface is 
dependent on both the introduced TCR and the endogenous TCR.  The 
transduction of a “strong” TCR results in a higher surface expression at the 
expense of a “weak” endogenous TCR.  It is thought that TCR strength is 
related to the intrinsic pairing properties of the alpha and beta chains with one 
another and their ability to associate with CD3 within the cell   (161).  A 
“strong” transduced TCR will more effectively compete with and bind to the 
available CD3 than a “weak” endogenous TCR.  Introducing a TCR of equal 
strength to the endogenous TCR will result in dual expression of the two 
TCRs on the cell surface.   
 
One of the rate limiting steps for expression of the transduced TCR is 
competition with the endogenous TCR for binding to CD3.  Ahmadi et al 
transduced TCR and additional CD3 molecules into murine CD8+ T cells.  Co-
transduction of TCR and CD3 led to enhanced surface expression of the 
introduced TCR and increased binding to specific pentamer.  This led to 
increased functional avidity in vitro compared to CD8+ T cells transduced with 
TCR alone.  Following adoptive transfer into tumour challenged irradiated 
mice, tumour specific TCR + CD3 CD8+ T cells provided superior tumour 
protection in vivo than TCR only CD8+ T cells.  They underwent greater 
expansion in vivo and trafficked to the tumour bed faster and in higher 
numbers and also had superior recall responses  (5). 
 
When a novel TCR is introduced, there is potential that the introduced TCR 
will mispair with the endogenous TCR chains.  The introduced TCR-α and -β 
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chains may form mixed heterodimers of unknown specificity with the 
transduced TCR-α chain forming a heterodimer with the endogenous TCR-β 
chain and the transduced TCR-β chain forming a heterodimer with the 
endogenous TCR-α chain.  This can result in the expression of 4 different 
TCR α-β heterodimers by an individual transduced T cell.  This results not 
only in a marked reduction of the introduced TCR on the cell surface but also 
has the potential to generate T cells which express auto reactive TCRs which 
have not undergone negative selection in the thymus (Figure 5).  
 
There are now a number of strategies to prevent mispairing which act to 
increase the surface expression of the introduced TCR.  TCR-α and -β chains 
are normally covalently linked by a single disulphide bond between their 
constant regions.  TCR-α and -β chains have been genetically engineered to 
express a second disulphide bond within the constant region, which enhances 
the preferential pairing of the introduced TCR-α and –β chain with each other.  
This has been shown to reduce mispairing and increase the functional avidity 
of transduced T cells  (162)  (163)  (164).  Human TCR-α and -β chains have 
also been altered so that the human constant region is replaced by the murine 
constant region.  This has also been shown to leads to enhance preferential 
pairing of the modified TCR-α and -β chains leading to increased surface 
expression of the TCR.  In addition, the murine constant region binds more 
efficiently to  human CD3 components and can thus compete for CD3 binding 
more efficiently than the endogenous TCR   (164).    
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Figure 5 – TCR mispairing.  When a novel TCR is introduced into a polyclonal T cell by TCR 
transduction it can potentially result in the expression of 2 novel TCR of unknown specificity on the 
T cell surface.  The α chain of the introduced TCR can pair with the β chain of the endogenous 
TCR and the α chain of the endogenous TCR can pair with the β chain of the introduced TCR.  
This potentially can lead to generation of auto reactive T cells and also results in reduced surface 
expression of the introduced TCR.  There are a number of strategies in use to reduce or prevent 
mispairing such as introduction of a novel disulphide bond, murinization of the TCR constant 
regions and using zinc finger nucleases to down regulate the expression of the endogenous TCR. 
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Careful in vitro experiments have demonstrated that combining the 
introduction of an additional disulphide bond and murinization of the TCR 
constant regions has an additive effect on reducing mispairing and increasing 
surface expression of the introduced TCR although neither completely 
eliminates mispairing   (162).   
 
An additional TCR modification explored the replacement of the TCR constant 
domains with the human CD3ζ molecule.  Similar to murinization of the 
constant region, such modified TCR chains are unable to mispair with the 
endogenous TCR chains and only pair with each other   (165)   (166). In 
addition, TCRαβ:CD3ζ does not compete with the endogenous TCRαβ for 
binding to endogenous CD3.  The intracellular assembly and surface 
expression of the TCR:ζ fusion is completely independent of CD3γ,δ or ε.   
When compared to transduction of unmodified TCRαβ chains, the modified 
TCR:ζ showed higher surface expression and could transduce downstream 
signaling from the TCR in response to antigen specific cells.  It was shown 
that the TCR:ζ mediated potent activation of NFAT but it was not clear if all 
the normal signaling functions of the TCR/CD3 complex were retained.  The 
TCR:ζ construct lacks the extracellular connecting peptide motif, the 
transmembrane domain and the intracellular domain of the TCR chains, which 
may be involved in calcium mobilization, the NF-κB pathway and control TCR 
down regulation  (167)  (168)  (169).  In addition the TCR:ζ construct lacks the 
ITAMs of the CD3 γ,δ and ε chains, which is likely to affect the T cell function.  
It was demonstrated that the TCR:ζ was able to form immunological synapses 
following antigen recognition that was independent of the endogenous TCR-
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CD3 complexes.  The TCR:ζ closely associated  with CD8α and class I MHC 
and co-localized with CD28 and CD45 in lipid rafts in a similar fashion to wild 
type TCRs  (170). 
 
Expression of the introduced TCR may also be increased by suppression of 
endogenous TCR expression. This has been achieved by the use of zinc 
finger nucleases to target and disrupt the endogenous TCR-α and -β chain 
genes.  Zinc finger nucleases contain zinc finger DNA binding domains and 
an endonuclease. They can be designed to target and disrupt specific DNA 
sequences.  Following DNA binding, the endonuclease element introduces a 
DNA double strand break, which is then repaired by non homologous end 
joining leading to the random insertion and deletion of nucleotides and thus 
targeted gene disruption.  This strategy has been used to prevent expression 
of the endogenous TCR-α and -β chain genes prior to introduction of a tumour 
specific TCR.  Human T cells were initially transduced with vectors encoding 
zinc finger nucleases and these ‘edited’ T cells, lacking CD3 in the absence of 
endogenous TCR, were then selected and transduced with a vector encoding 
the WT1-TCR. WT1-TCR transduced edited T cells had high surface level 
expression of introduced WT1-TCR.  This resulted in enhanced activity 
against relevant target cells and also reduced non specific alloreactivity due to 
prevention of mispairing.  In a humanized mouse model, infusion of WT1-TCR 
transduced T cells that had normal endogenous TCR expression resulted in 
lethal GVHD in all mice as a result of mispairing of the introduced TCR and 
endogenous TCR chains.  This was in contrast to the WT1-TCR edited T cells 
that did not produce GVHD in any mice following infusion. WT1-TCR edited T 
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cells also displayed tumour efficacy in vivo following challenge with a primary 
human leukaemia and could persist in vivo for at least 28 days post transfer    
(171).   
 
Improvements in vector design have led to an increase in transduction 
efficiency and thus higher TCR surface expression.  Codon optimization to 
replace rare codons within the TCR genes with those in more frequent use 
has been shown to increase the expression level of the optimized TCR 
compared to wild type.  This, combined with removal of mRNA instability 
motifs and cryptic splice sites, leads to enhanced stability and translation of 
mRNA and thus higher levels of TCR transgene expression   (160)  (172).  
Use of Internal ribosomal entry sequences (IRES) or 2A sequences also 
allows the delivery of both the TCR-α and TCR-β chains within the one vector.  
The IRES is a distinct nucleotide sequence that allows translation initiation to 
occur in the middle of an mRNA sequence which results in the production of 
multiple proteins from a single mRNA transcript.  The IRES is placed between 
the TCR-α and TCR-β chain with translation of the upstream alpha gene 
initiating at the 5’cap. Translation of the downstream TCR-β gene occurs in a 
cap independent manner following binding of the ribosome to the IRES  (173).  
Use of viral derived 2A sequences may be even more effective than IRES 
sequences at delivering expression of equimolar amounts of the TCR-α and 
TCR-β chains  (174)  (175).  The 2A sequence is placed between the TCR-α 
and TCR-β genes and allows multiple proteins to be generated from a large 
polyprotein that has been encoded by a single open reading frame.  As the 
polypeptide is synthesized, the last amino acid of the 2A sequence prevents 
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peptide bond formation but without arresting translation.  The upstream 
polypeptide is released with the 2A sequence fused to its C terminus but the 
ribosome remains on the mRNA and translates the downstream sequence.  
This leads to production of nearly stoichiometric amounts of both the TCR- α 
and TCR-β chains produced from a single open reading frame. Direct 
comparison of retroviral vectors with IRES or 2A sequences linking the TCR-α 
and TCR-β chains, has demonstrated a higher level of TCR gene expression 
when utilizing 2A sequences with resulting improved T cell function  (176). 
 
1.4.5 Increasing TCR affinity 
 
As a result of thymic selection, circulating peripheral T cells express TCRs 
that have low affinity for their cognate peptide-MHC, usually within the range 
of 1-100µM  (177)  (178).  The affinity of individual TCRs can be increased by 
making amino acid substitutions within the CDRs.  Using bacteriophage or 
yeast display technology, high affinity TCRs can then be selected   (179)  
(121)  (180).  This can lead to generation of tumour specific TCRs with affinity 
within the nanomolar or picomolar range.  With very big increases in affinity, 
some TCRs do appear to lose antigen specificity and may potentially become 
autoreactive  (121). TCR function may also start to decrease when affinity is 
increased above a certain level.  Upon binding to peptide-MHC, high affinity 
TCRs have much longer dissociation times.  This will lead to a reduction in the 
number of TCRs that can bind to that peptide-MHC which may decrease T 
cell activation.  A comparison of high affinity and wild type TCR showed that 
whilst the high affinity TCR triggered much faster effector responses, there 
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was a loss of response in the presence of low density antigens as affinity 
increased  (181). Rational design of affinity matured TCRs thus should focus 
on production of TCRs that only have modest improvements in affinity 
compared to the wild type TCR rather than aiming for ultra high affinity TCRs.   
 
1.4.6  Enhancing persistence of adoptively transferred TCR transduced 
T cells  
 
Using TCR transduced T cells to deliver effective anti tumour responses may 
be dependent on persistence of the transduced cells and the generation of 
recall responses.  Studies using adoptive transfer of TILs in melanoma 
patients have shown that increased persistence of TILs correlated with 
enhanced anti melanoma responses  (182).  Multiple rounds of in vitro 
stimulation of tumour specific T cells typically leads to a population of T cell 
that predominantly have an end stage effector phenotype.  This may 
adversely affect their ability to persist post transfer, leading to reduction in 
anti- tumour responses  (183)  (184).  The transfer of naïve or memory T cell 
populations may be more efficacious at providing tumour protection and there 
is growing evidence to support this. 
 
Central Memory CD8+ T cells maintain high levels of CD62L and CCR7 and 
can efficiently recirculate through secondary lymphoid organs where they 
encounter APCs.  Effector memory CD8+ T cells have down regulated the 
expression of CD62L and thus preferentially recirculate in peripheral tissues.  
Effector memory T cells have lower levels of expansion on antigen 
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rechallenge compared to central memory T cells  (184)  (185).   Klebanoff et 
al showed that adoptive transfer of  tumour specific central memory T cells led 
to more effective anti-tumour responses than the transfer of effector memory 
T cells  (184).  Following adoptive transfer into unconditioned primates, CD8+ 
CMV-specific effector T cells derived from central memory T cells had 
enhanced persistence in vivo compared to effector T cells derived from 
effector memory precursors.  These central memory derived effector T cells 
could migrate to secondary lymphoid organs and they had the ability to revert 
back to either a CD62L- or CD62L+ memory cell phenotype   (186). 
 
The most effective T cell population for adoptive immunotherapy may be 
naïve T cells.   Using a pmel-1 TCR transgenic mouse model (where T cells 
were specific for a melanoma antigen, gp100, also expressed by self tissues) 
the adoptive transfer of CD62L+ CD44low CD8+ naïve T cells into mice 
resulted in faster clearance of established melanoma compared to the transfer 
of central memory CD62L+ CD44high CD8+ T cells.  This superior tumour 
protection was associated with greater in vivo expansion and production of 
greater levels of IFN-γ and IL-2 post transfer   (187). 
 
Lymphodepeletion of patients with chemotherapy and/or irradiation is very 
effective at promoting the expansion of the adoptively transferred T cell 
population.  In patients with melanoma, the administration of conditioning 
therapy to induce lymphopaenia prior to adoptive transfer led to an increase in 
persistence of the transferred T cells   (182)  (188)  (10).  Similarly in mouse 
models, increased levels of lymphodepletion have been associated with 
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increased persistence of adoptively transferred T cells and superior tumour 
clearance  (189).   Lymphodepletion drives homeostatic proliferation of 
residual peripheral T cells that reconstitute the peripheral T cell pool  (190)  
(191).  The same lymphopaenia driven homeostatic proliferation also drives 
expansion of adoptively transferred T cells  (192).  The homeostatic cytokines, 
IL-7 and IL-15 and also interactions between TCR and self-peptide-MHC are 
thought to promote this proliferation   (178)  (193)  (194)  (195).  The amount 
of proliferation of the adoptively transferred T cells is limited by the amount of 
IL-7 and IL-15 and the amount of self-peptide-MHC that is available.  
Cytoreduction of the host haematopoetic system ensures that the adoptively 
transferred T cells do not have to compete for access to homeostatic 
cytokines, thus promoting their expansion.  T cells with a higher affinity for self 
peptide-MHC may also have an additional proliferative advantage, which may 
benefit tumour specific T cells as many tumour epitopes are over expressed 
self peptides.   
 
1.4.7 Potential limitations of TCR gene therapy 
 
Mispairing of TCR α and β chains not only reduces the surface expression of 
the transduced TCR but may lead to potential harmful effects.  Mispairing 
generates TCRs of unknown specificities that have not been subjected to 
negative selection in the thymus and are thus potentially autoreactive.  Bendle 
et al have shown that the adoptive transfer of transduced T cells can lead to 
graft versus host disease post transfer.  This was demonstrated to be 
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secondary to the formation of de novo TCR heterodimers targeting self 
tissues   (196).   
 
On target/off tumour effects of TCR transduced T cells can also produce 
harmful effects following adoptive transfer which has been demonstrated in a 
number of clinical trials. In patients with colonic cancer who received adoptive 
transfer of T cells transduced with a high affinity CEA-specific TCR, 3/3 
patients treated developed a transient severe colitis.  This was associated 
with a fall in levels of CEA which is overexpressed in many epithelial cancers 
but is also expressed at lower levels in normal tissues. 1/3 patients in this trial 
had a reduction in tumour burden  (197).    A clinical trial treating patients with 
metastatic malignancies with the adoptive transfer of T cells transduced with a 
high avidity anti-MAGE-A3 TCR led to severe and unexpected on target 
toxicities  (198).  MAGE-A3 is a cancer testes antigen, a group of tumour 
antigens expressed in a variety of common epithelial tumours including 
melanoma, breast and lung cancer but which have very restricted expression 
in germ line tissues such as the adult testes or in placenta and trophoblasts 
making them ideal targets for tumour immunotherapy.  In this trial, 5/9 patients 
had cancer regression but unexpectedly 3/9 patients developed severe 
neurological toxicity within 1-2 days post infusion, 2 of whom subsequently 
died.  MRI scans of their brain demonstrated necrotizing leucoencephalopathy 
with extensive white matter defects associated with brain infiltration by the 
transduced T cells.  This was thought to have arisen due to recognition of the 
MAGE-A12 protein by the anti-MAGE-A3 TCR which is also known to bind to 
epitopes of MAGE-A9 and A12 in addition to MAGE-A3.  MAGE-12 
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expression was detected in brain sections from both normal and patient 
samples although this had previously not been described in human brain 
samples.  Targeting of MAGE-A12 by the TCR transduced T cells was 
thought to trigger the inflammatory response leading to the neurological 
toxicity.  Patients who went on to develop neurological toxicity had received a 
higher total number of cells and higher number of CD3+/CD8+/Tetramer+ T 
cells and also a higher percentage of cells with a naïve phenotype. These 
studies highlight the need for careful selection of TCR, particularly when using 
high avidity engineered TCRs that are directed against antigens that are 
overexpressed in tumour but are also expressed at low levels in normal 
tissues.   
 
Engineering T cells to express suicide genes in addition to TCR allows 
transduced T cells to be removed should toxicities arise post transfer.  The 
suicide gene encodes a protein that acts to convert a non toxic prodrug into a 
toxic metabolite, thus the suicide gene can be switched on by the 
administration of the prodrug.  The Herpes simplex thymidine kinase (HSV-
TK) is the most extensively studied suicide switch and has been validated in 
clinical trials. HSV-TK phosphorylates the prodrug ganciclovir to form 
triphosphate ganciclovir which is incorporated into elongating DNA strands 
ultimately leading to the selective death of transduced cells. It has been used 
in patients post allogeneic haematopoetic stem cell transplant who received 
donor lymphocyte infusions (DLI) engineered with HSV-TK for the purposes of 
treating disease relapse.  The overall incidence of GVHD was 22% and the 
subsequent administration of ganciclovir controlled GVHD in all cases  (199)   
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(200).  The represents a very effective strategy for the control of GVHD post 
DLI, although the immunogenicity of HSV-TK leads to reduced persistence of 
the HSV-TK expressing cells   (201).  
 
An alternative suicide gene strategy is based on human apoptosis proteins 
and thus may be less immunogenic.  A fusion protein consisting of a late 
stage apoptosis molecule, caspase 9 fused to a FK506 binding protein 
analogue has been used to transduce T lymphocytes.   Apoptosis of the 
transduced cells is rapidly induced following administration of a chemical 
inducer of dimerization (CID) which results in aggregation and activation of 
caspase 9.  In a study following patients treated with a haploidentical stem cell 
transplantation, 5 patients received donor T lymphocytes that had been 
transduced with the inducible caspase 9 construct.  The DLI was administered 
to enhance immune reconstitution but carries a high risk of developing GVHD 
post transfer.   4/5 patients developed GVHD but the administration of a single 
dose of the non toxic CID drug led to elimination of >90% of the modified 
donor T cells within 30 minutes of administration and this led to eradication of 
GVHD in all patients without any later evidence of recurrence  (202). 
 
An additional safety concern of gene therapy is insertional mutagenesis 
secondary to insertion of the transgene into the host chromosome leading to 
disruption or aberrant activation of cellular genes.  19 X-linked severe 
combined immunodeficiency patients received haematopoetic stem cells 
transduced with retroviral vectors carrying the IL-2 receptor gamma (IL-2R-γ) 
chain and 5 patients have subsequently developed T cell leukaemia  (203)  
	   67	  
(204)  (205). In 4 of the 5 cases the leukaemia arose secondary to retroviral 
integration in the region of a T cell oncogene, LMO2, resulting in its 
deregulated expression.  There may also have been a potential role for the IL-
2R-γ chain acting as a cooperating oncogene although this is controversial   
(206)  (207)  (208).   
 
Both lentiviral and retroviral vectors integrate into the host genome in a semi 
random manner but tend to insert close to transcriptional units.  Retroviral 
vectors integrate close to transcription start sites or DNA regulatory areas.  
Insertion at these points have a higher probability of causing deregulated 
gene expression  (209)  (210).  Lentiviral vectors have a safer insertion profile, 
integrating within active transcription units   (211)   (212).  Analysis of vector 
insertion hot spots within transduced haematopoetic stem cells showed that 
retroviral vector insertion sites were enriched at proto-oncogenes or genes 
controlling cell division but this was not seen with lentiviral vectors   (213).   
Lentiviral vectors required a 10 fold higher rate of insertion events to induce 
cellular transformation compared to a retroviral vector with an LTR of 
comparable strength when used in a tumour prone mouse model   (214).   
 
Whilst the predominant mechanism of insertional mutagenesis produced by 
retroviral vectors is enhancer mediated host gene activation, an alternative 
mechanism has been demonstrated using lentiviral vectors.  Chimeric fusion 
transcripts may arise containing both vector sequences and cellular mRNA 
due to alternative splicing  (215)  (216).  Splicing from a donor site within the 
lentiviral vector to an adjacent gene can produce a novel coding fusion 
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transcript or splicing to an acceptor site within the vector can lead to a 
truncated cellular transcript leading to dysregulated protein turnover or 
translation. Lentiviral vectors in particular have the potential to carry multiple 
splice donor and acceptor sites as the unspliced viral genomic RNA is 
exported from the nucleus by the lentiviral protein, rev.  In a clinical trial for 
treatment of beta thalassaemia using a lentiviral vector carrying the human β-
globin gene, one of the transplanted patients developed a dominant myeloid 
clone that contained a integrated vector copy within the HMGA2 gene.  The 
vector integration led to fusion of the splice donor sequence of HMGA2 with a 
cryptic splice acceptor site within an insulator element that had been inserted 
within the lentiviral LTR.  This aberrant splicing led to premature termination of 
the HMGA2 transcript which had increased stability leading to abnormally high 
levels of the HMGA2 protein expression and this was thought to be the 
mechanism leading to clonal dominance in this patient  (217).  
 
Mature T cells appear to be less susceptible to cellular transformation arising 
from insertional mutagenesis than more primitive haematopoetic stem cells 
(HSC) which already have intrinsic self renewal activity.  In addition to 
deregulation of gene expression by retroviral integration, the development of 
malignancy may also be dependent on transducing a cell type with intrinsic 
self renewal potential.  The semi random integration of retroviral vectors in the 
genome of long term repopulating HSC may increase their self renewal 
potential or lead to malignant transformation.  To assess the contribution of 
cell intrinsic features, Kustikova et al sorted HSC into the most primitive HSC 
and more mature haematopoetic progenitor cells prior to transduction with 
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retroviral vectors and transplanted into myeloablated syngeneic recipients.  
The clonal repertoire within the transplanted mice was analyzed and it was 
seen that clonal dominance only developed within the recipients of the most 
primitive self renewing HSCs which had a high frequency of insertional 
upregulation of proto-oncogenes.  In contrast, insertional mutagenesis did not 
lead to clonal dominance following transplantation of more mature progenitor 
cells  (218).  T cells and more mature progenitor cells appear to be more 
resistant to the formation of expanding cell clones with oncogenic lesions.    
Newrzela et al compared transduced populations of mature T cells and HSC 
that had been transduced with identical high copy number retroviral vectors 
that encoded potent T cell oncogenes.  After transplantation into RAG 
deficient mice, the mice that received transplantation of transduced HSC 
developed T cell lymphoma/leukaemia which had a characteristic phenotype 
and developed after a reproducible latency period.  In contrast, none of the 
recipient mice that received mature T cells modified with the identical 
retroviral vector developed T cell lymphoma/leukemia despite the long term 
persistence of the gene modified T cells  (219).  Thus even in the context of 
multiple retroviral integrations with continuous high expression of a potent 
oncogene, on long term follow up the mature T cells remained 
untransformable.  Follow up of patients who had received HSV-TK transduced 
T cells showed that up to 20% of gene insertions led to altered gene 
expression in the adjacent genes but this did not lead to transformation in any 
patients  (220).  No patients who have received adoptive immunotherapy of 
transduced T cells have developed malignancy as a direct result of the gene 
modified cells.   
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1.4.8 Chimeric antigen receptors  
 
Another strategy to redirect T cell antigen specificity by gene transfer is to 
introduce chimeric antigen receptors (CAR).  CAR consist of an antigen 
binding domain composed of an antibody derived single chain variable 
fragment (scFV) fused to an intracellular signaling domain  (221).  The 
advantanges over TCR gene therapy is that CAR are non-HLA restricted and 
thus can be used in patients of any HLA type and also will not be affected by 
tumour down regulation of HLA molecules.  In addition there is no risk of 
mispairing that arises with TCR gene therapy.  The antigen targeted by the 
CAR must be expressed on the cell surface but they can be targeted to non 
protein surface molecules such as carbohydrates or glycoplipids in addition to 
protein antigens.   The first generation of CAR contained a CD3ζ signaling 
domain and T cells modified with these CAR were able to secrete cytokines 
and lyse target cells following binding to specific antigen  (222)  (223) 
however they have shown limited clinical benefit due to ineffective activation 
or impaired persistence  (224)  (225)  (226).  The second generation of CAR 
incorporated the signaling domains of CD28 in addition to CD3ζ which acts to 
enhance T cell proliferation upon ligation resulting in improved effector activity  
(227)  (228)  (229).  This bypasses the need for the presence of a co-
stimulatory ligand and thus prevents the induction of anergy or apoptosis in 
the absence of signal 2.  Third generation CAR contain 2 co-stimulatory 
signaling domains such as 41BB or OX40 in addition to CD28 and have 
enhanced anti-tumour activity in vivo and improved persistence thought to be 
due to upregulation of antiapoptotic proteins like Bcl-xl  (230). 
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1.5 THE ROLE OF CD4+ T CELLS IN ADOPTIVE IMMUNOTHERAPY 
 
1.5.1 CD4+ T cell subsets 
 
It is now well recognized that naïve CD4 T cells differentiate into a number of 
differing CD4+ T cell subsets each of which have a distinct immunological role 
and produce distinct cytokine profiles.  Each subset also expresses lineage 
defining transcription factors that regulate cytokine production and effector 
function.  There is increasing recognition that individual subsets of CD4+ T 
cells are not fixed lineages and show some degree of plasticity.  
 
The Th1 and Th2 subsets of CD4+ T cells were first described in 1986  (231).  
Th1 cells are characterized by the production of IFN-γ and Lymphotoxin-α and 
the expression of the transcription factor, T-bet.  Th1 cells are important 
mediators of immunity to intracellular pathogens and tumour cells via 
activation of macrophages and production of pro-inflammatory cytokines.  Th2 
cells are characterized by production of IL-4, IL-5 and IL-13.  Their main role 
is the induction of IgE production by B cells, eosinophil activation and the 
eradication of extracellular parasites.  GATA3 is the transcription factor 
expressed by Th2 cells  (232)  (233).   Deregulated Th1 and Th2 responses 
play a role in certain diseases with Th1 cells being involved in many organ 
specific autoimmune diseases and Th2 cells promoting the development of 
allergy and atopy.  In vitro, Th2 cells can be generated following T cell 
activation in the presence of IL-4 and IL-2  (234)  (235) whilst Th1 cells can be 
generated in vitro in the presence of IL-12 and IFN-γ  (236).  The effector 
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cytokines that are produced by Th1 and Th2 cells act in a positive feedback 
loop to further amplify production of other Th1 cells or Th2 cells.  They also 
act to repress the differentiation of the alternative subset explaining why 
development of Th1 and Th2 cells was believed to be mutually exclusive.   
The sequential activation of STAT1 by IFN-γ and STAT4 by IL-12 drives the 
optimal expression of T-bet (the central transcription factor for Th1 
programming) whilst the activation of STAT6 by IL-4 upregulates GATA3.  
The stability of these developmental programs is enforced in part through the 
production by mature effectors of autocrine cytokine feedback loops.  
 
The discovery of Th17 and T regulatory cells (Tregs) further expanded this 
Th1/Th2 paradigm. Th17 cells produce IL-17 and IL-23.  They are 
characterized by the expression of transcription factors ROR-γt and RORα.   
Th17 cells can be generated from naïve CD4+ T cells by activation in the 
presence of TFG-β and IL-6 and are expanded in the presence of IL-23  (237)  
(238)  (239).  They have a role in eradication of certain extracellular bacteria 
and fungi, may play a role in anti tumour immunity, and are involved in 
inflammatory responses and the activation of innate immunity.  Their role 
appears to overlap to some degree with that of Th1 cells.  They have been 
shown to play a causative role in some autoimmune diseases that previously 
had been attributed to Th1 cells.  Cytokines that induce Th1 and Th2 
differentiation have been shown to be potent inhibitors of Th17 differentiation  
(240).  IL-2 in particular has reciprocal effects on the production of Th17 cells 
and Tregs, acting to promote Treg differentiation whilst inhibiting Th17 
differentiation  (241)  (242).  
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CD4+ Tregs have an essential immunosuppressive function acting to maintain 
peripheral tolerance and modulate immune responses.  In vivo, Tregs exist in 
two forms.  The naturally occurring Tregs (nTregs) develop within the thymus   
(243) whilst inducible Tregs (iTregs) can be generated in the periphery from 
naïve CD4+ T cells following T cell activation in the presence of IL-2 and 
TGF-β  (244).  Tregs constitutively express high levels of the IL-2Rα chain 
(CD25) and they make up 5-10% of the peripheral CD4+ T cell population.  
Both T regulatory populations are characterized by the expression of the 
transcription factor, FOXP3  (245)  (246). FOXP3 acts as the ‘master 
regulator’ for development and function of Tregs  (245) . Mice deficient in 
FOXP3 develop lethal autoimmune lymphoproliferative disease associated 
with a defect of CD4+ CD25+ Tregs   (245).  
 
One of the newest subsets of CD4+ T cells recently characterized are the T 
follicular helper CD4+ T cells (Tfh).  Tfh cells are found within the germinal 
centres of lymphoid organs where they promote immunoglobulin class 
switching and somatic hypermutation in B cells.  They produce IL-21 and 
express the transcription factor, Bcl-6  (247).  Tfh are specialized in providing 
help for B cells within germinal centres.  Differentiation of this population is 
driven by Bcl-6 which promotes entry of Tfh into germinal centres. 
 
With the discovery of more populations of CD4+ T helper subsets, questions 
have arisen regarding the stability of these populations.  When Th1 and Th2 
cells were first described these were thought to represent stable and 
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committed lineages of cells. Each individual subset has been clearly 
characterized by the production of signature cytokines and for expression of 
lineage defining transcription factors.  It has, however, recently been shown 
that there is a degree of plasticity.  Whilst certain cytokines are uniquely 
produced by different subsets, other cytokines are expressed by a number of 
differing subsets.  In addition, individual cells within the same T helper subset 
may demonstrate different patterns of cytokine production (e.g. within the Th1 
subset, individual cells may be able to produce differing combinations of IFN-
γ, LTα, IL-2 and TNFα).  Only a very limited population will have the capacity 
to produce all of these cytokines simultaneously  (248).  There are now a 
number of examples of CD4+ T cell subsets that have flexible and plastic 
cytokine production.  Th17 cells have been shown to acquire the ability to 
produce IFN-γ in addition to IL-17  (249) or to become selective producers of 
IFN-γ  (250).  This is in response to both IL-12 and IL-23 which leads to the 
induction of STAT4 and T-bet, both key transcription factors in the 
development of the Th1 phenotype.  It has been postulated that Th1 cells may 
represent a terminally differentiated effector population with Th17 being the 
precursor lineage.  GATA3+ IL-4+ Th2 cells can also be reprogrammed to 
also express T-bet and IFN-γ in the context of LCMV infection.  These double 
positive populations were found to be crucial for virus eradication  (251).  Tfh 
appear to be the most fluid population of CD4+ T cells and have been shown 
to acquire attributes of Th1, Th2 or Th17 cells  (252).  With regards to Tregs, 
the loss of expression of FOXP3 is not infrequent.  Tregs have also been 
shown to secrete IL-17 or IFN-γ and occasionally develop a pro-inflammatory 
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phenotype  (253).  The ability to produce IFN-γ does not always lead to loss of 
suppressive function.   
 
Plasticity and the ability to switch phenotype in response to differing 
environmental and antigenic cues appears to be a key feature of CD4+ T 
cells.  The expression of one lineage defining transcription factor was initially 
thought to generate a fixed cell phenotype, and the expression of key 
transcription factors was considered likely to be mutually exclusive e.g. T-bet 
in Th1 cells and GATA3 in Th2 cells.  This is, however, overly simplistic, as it 
is now clear that these transcription factors are not expressed in such a 
restricted fashion.  Individual CD4+ T cell subsets are much more 
heterogeneous than originally thought and much more dynamic.  Moreover 
expression of more than one master regulator is a frequent event.  Thus 
rather than a simplistic model of distinct expression of a single master 
regulator in terminally differentiated cells, it may be more accurate to think of 
co-expression of master regulators.  These factors can be dynamically 
regulated by extrinsic and intrinsic factors and can fine tune T cell capabilities 
as the situation requires.   
 
Epigenetic modifications are an important further modifier of CD4+ T cell 
differentiation and detailed epigenetic profiling has lent support to the concept 
of plasticity of CD4+ T cell subsets.   Relaxation or condensation of the 
chromatin structure can lead to activation or repression of transcription 
respectively.  Within a particular CD4+ T cell e.g. a Th1 cell, the lineage 
defining cytokine genes will be in a permissive configuration whilst the lineage 
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defining cytokine genes of the alternative CD4+ subtypes will be held in a 
repressive configuration.  These findings suggested that the cell fate of 
differing CD4+ T cell subsets was fixed, with the signature cytokines of 
alternative cell fates being permanently switched off.  However within a 
specified CD4+ subset e.g. Th1 cells, the genes encoding the transcription 
factors important for alternative cell fates e.g. GATA3, are not found in 
repressive configurations as might be expected.  Instead the chromatin of 
such genes was found to be in both permissive and repressive configurations  
(252).  This bivalent chromatin configuration ensures that the genes encoding 
master regulator transcription factors are not permanently switched off, 
allowing the cells to switch phenotype  (254).  
 
The inherent flexibility of CD4+ T cells and the ability to change phenotype in 
response to environmental and antigenic stimuli has clear implications for 
adoptive immunotherapy utilizing CD4+ T cells.   
 
1.5.2 CD4+ T cells in tumour immunity 
 
Both animal models and data from patients have enhanced the understanding 
of the role of CD4+ T cells in tumour immunity.  CD4+ T cells can eradicate 
tumours in the absence of CD8+ T cells, and can provide ‘help’ for cytotoxic 
tumour specific CD8+ T cells.  Greenberg et al used a murine model of 
disseminated acute leukaemia where recipient mice had been depleted of all 
CD8+ and CD4+ T cells.  Adoptive transfer of leukaemia specific CD4+ T cells 
led to complete disease eradication of the MHC class II negative leukaemia 
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cells  (255) even in the absence of cytotoxic CD8+ T cells.  However, in the 
absence of CD4+ T cells, tumour control was lost or reduced.  In a murine 
model of melanoma, mice were vaccinated with irradiated melanoma cells 
and then two weeks later re-challenged with unirradiated melanoma cells.  
Wild type mice rejected the tumour whilst CD4 -/- recipients had progressive 
tumour growth.  Whilst CD8 knockout mice also had impaired ability to reject 
tumours, a significant proportion of CD8 -/- mice were still able to reject 
tumour   (256). 
 
Tumour specific CD4+ T cells have been isolated from patients with a wide 
variety of different tumour histologies.  In patients with breast cancer, a high 
number of CD4+ T cells within the draining lymph nodes have been shown to 
be predictive for improved disease free survival  (257) whilst in lung and 
hepatic carcinoma, the finding of high CD4/CD8 ratios correlated with 
improved disease free survival  (258).   In a phase II clinical trial using partially 
HLA matched allogeneic EBV specific cytotoxic T lymphocytes (CTLs) for 
treatment of EBV-positive post transplantation lymphoproliferative disorder 
(PTLD), it was shown that a higher percentage of CD4+ T cells within the 
infused CTLs was associated with a statistically significant improvement in 
overall response.  In patients receiving CTLS that had <1% CD4+ T cells the 
overall response rate was 25% compared to 92% for those receiving a CTL 
infusion comprising >5% CD4+ T cells  (259).  Clinical trials in metastatic 
melanoma patients have shown that those who received adoptively 
transferred tumour specific CD8+ T cells alone had inferior responses to 
those receiving both tumour specific CD8+ and CD4+ T cells  (260). For the 
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treatment of CMV reactivation post allogeneic bone marrow transplant, the 
adoptive transfer of CMV specific CD8+ T cells in isolation has been shown to 
require a 1000 fold higher dose of T cells than if given concurrently with CMV 
specific CD4+ T cells  (261).  Adoptive transfer of autologous tumour specific 
CD4+ T cells in a patient with metastatic melanoma (in the absence of 
lymphodepleting chemotherapy or IL-2) led to complete tumour regression 
with the patient remaining in complete remission 2 years post treatment.  The 
adoptively transferred cells expanded 5000 fold following transfer and 
persisted long term.  It was also noted that de novo CD8+ T cell clones 
reactive against melanoma antigens were generated   (262).  
 
1.5.3 Mechanism of action of tumour specific CD4+ T cells 
 
CD4+ T cells are likely to have a central role in tumour eradication.  They act 
to orchestrate the function of a wide variety of both innate and adaptive 
immune cells which have key roles in tumour eradication.  CD4+ T cells play a 
role in the activation of tumour specific CD8+ T cells, the activation of APCs, 
macrophages and NK cells, whilst CD4+ T cells themselves can be directly 
cytotoxic. 
 
The priming of naïve CD8+ CTLs requires the interaction of CD8+ and CD4+ 
T cells and the APC, with CD4+ T cells providing help via CD40L-CD40 
signaling to the APC.  Presentation of antigen within a non inflammatory 
environment e.g. in the tumour microenvironment, CD4+ T cell mediated help 
is provided via licensing of professional APCs.  A number of models of 
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priming of CD4+ T cell dependent CTL responses demonstrated that in CD4 
depleted or deficient mice, an activating CD40 antibody could efficiently 
restore antigen specific CD8+ T cell responses  (263)  (264)  (265). 
Conversely, blockade of CD40L was observed to abrogate priming which was 
restored by adding back an activating CD40 antibody.  The current model 
suggests that CD40L on CD4+ T cells binds to CD40 on professional APCs, 
which ‘licenses’ the APC, leading to upregulation of co-stimulatory molecules 
and cytokine secretion.   The licensed APC then goes on to activate the CD8+ 
T cell via cross presentation of tumour antigen on class I MHC.   A small 
proportion of CD8+ T cells may also express CD40 and it is possible that 
CD40L on CD4+ T cells can bind to CD40 on CD8+ T cells directly, but this 
model still requires presentation of antigen by an APC to the CD8+ T cell. 
 
Perez Diaz compared tumour protection provided by monoclonal populations 
of tumour specific CD4+ and CD8+ T cells derived from anti-HY TCR 
transgenic mice.  Tumour challenge experiments were carried out in Matahari 
TCR-transgenic mice where the CD8+ T cells are specific for HY-antigen, Uty 
presented by H2-Db or in Marilyn TCR transgenic mice where the CD4+ T 
cells were specific for Dby presented by Ab.  Mice were challenged with a 
C57BL/6 male bladder tumour which expressed both Uty and Dby antigens.  
The Matahari transgenic mice (CD8+) were not able to clear tumour whilst 
80% of the Marilyn transgenic mice (CD4+) were able to mediate tumour 
rejection.  Class II expression on the host tissues was essential for tumour 
rejection by CD4+ T cells suggesting that the CD4+ T cells were acting 
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indirectly following interaction with host APC and complete tumour clearance 
was dependent also on the presence of NK cells  (266).   
 
Corthay et al used a transgenic TCR system where T cells were specific for 
an idiotypic peptide from a variable region of an immunoglobulin light chain 
secreted by a myeloma cell line, MOPC315, presented by MHC II, I-Ed   (267).  
Administration of syngeneic myeloma cells resulted in tumour rejection in 
transgenic mice where there was a high frequency of tumour specific CD4+ T 
cells but in non-transgenic mice there was fatal tumour growth.  Tumour 
protection was dependent on recognition of the idiotype peptide and was 
CD4+ T cell mediated.  The presence of B cells, γδT cells or CD8+ T cells 
was not required.  The MOPC315  does not express or upregulate MHC II and 
could therefore not be directly recognized by the transgenic CD4+ T cells.  
CD4+ T cells in this system secreted IFN-γ which activated tumour infiltrating 
macrophages to kill the class II negative myeloma cells.  A later study by the 
same group has also suggested a role for the anti-angiogenic chemokines 
CXCL9 and CXCL10 produced by tumour infiltrating macrophages in 
response to IFN-γ, which may halt tumour progression  (268).   
 
Quezada et al dissected the mechanisms of tumour protection using  adoptive 
transfer of CD4+ TRP1+ (a melanoma differentiation antigen) transgenic T 
cells in a murine model of advanced melanoma  (269).  Transfer of only 
50,000 naïve tumour reactive CD4+ TRP1+ T cells into irradiated recipients 
led to marked expansion and differentiation in vivo resulting in initial tumour 
regression in large established tumours.  Approximately 60% of mice later 
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developed tumour recurrence.  The addition of a blocking anti-CTLA4 
antibody at the time of adoptive transfer of CD4+ T cells led to complete and 
persistent tumour eradication.  The use of anti CTLA-4 led to an increased 
expansion of effector CD4+ TRP1+ T cells and a reduction in the number of 
CD4+ TRP1+ FOXP3+ T cells and the endogenous Treg population.  
Adoptively transferred CD4+ T cells had a Th1 phenotype, producing large 
amounts of TNF-α, IFN-γ and IL2 and again this was enhanced in the 
presence of anti CTLA-4.   Tumor reactive CD4+ T cells expressed high levels 
of granzyme and showed in vivo cytotoxicity.  Tumour rejection was 
dependent on production of IFN-γ:  Neutralization of IFN-γ with a blocking 
antibody prevented tumour rejection.  However, complete tumour eradication 
was still demonstrated in IFN-γ -/- recipient mice, suggesting that the 
adoptively transferred CD4+ TRP1+ T cells were producing IFN-γ and not 
host immune cells.  IFN-γ receptor knock out mice also rejected established 
tumour, suggesting that the tumour cell itself was the direct target of the anti 
tumour effects of IFN-γ.  Using RAG -/- recipient mice and perforin -/- mice it 
was shown that tumour rejection was also independent of the endogenous 
CD4, CD8 and B cell populations and of endogenous perforin killing activity.  
Depletion in vivo of NK1.1 cells and CD8+ T cells also failed to prevent 
tumour rejection.  It was shown that adoptively transferred CD4+ TRP1+ cells 
were cytotoxic in vivo via direct recognition of class II MHC and this was 
mediated via degranulation of granzyme containing lytic granules.  The 
tumour rejection was dependent on the expression of class II MHC by the 
tumour cells which was upregulated in response to IFN-γ production by the 
adoptively transferred CD4+ TRP1+ T cells.   
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CD4+ T cells also play a key role in generating CD8+ T cell memory 
responses.  When CD8+ T cells encounter antigen they start to rapidly 
proliferate and during this time will also differentiate into distinct effector 
phenotypes and migrate to sites of infection or inflammation to eradicate 
pathogens. There is massive clonal expansion of antigen specific CD8+ T 
cells following antigen encounter but the vast majority of effector CD8+ T cells 
will die by apoptosis following clearance of pathogen leaving only about 10% 
of antigen specific CD8+ T cells to form the CD8+ T cell memory pool  (270)  
(271)  (272).  CD4+ T cell mediated help is required at time of priming in order 
to generate robust CD8+ T cell memory responses and also maintains the 
CD8+ memory T cell pool.  2 models of generation of CD8+ memory T cells 
have been proposed, programming and maintenance, however this remains 
controversial and is probably dependent on the type of antigenic stimulus 
being studied.  The programming model suggests that CD8+ memory T cells 
are programmed by CD4+ T cells during the first few days of initial activation. 
Subsequent to this, CD4+ T cell mediated help is not required for CD8+ T cell 
memory responses.  Shedlock et al showed that CD8+ memory T cells that 
had been generated in CD4+ T cell replete mice could make normal recall 
responses if transferred into CD4+ T cell deplete hosts.  However CD8+ 
memory T cells that had been generated in CD4+ T cell deficient hosts 
mounted defective memory responses even if transferred into CD4+ T cell 
replete hosts  (273).  The second model, maintenance, argues that CD4+ T 
cell mediated help is required during the entire phase of memory CD8+ T cell 
differentiation and is important not just for the generation of CD8+ memory T 
cells but also for maintenance of this population.  CD8+ memory T cells that 
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have been generated in a wild type host decrease in number following 
transfer into a CD4+ T cell deficient host and showed functional impairment  
(274). The transfer of “unhelped” CD8+ T cells into a CD4+ T cell replete 
mouse model could actually lead to restoration of the impaired memory 
response suggesting that in this system, CD4+ T cell mediated help was not 
essential at priming.   
 
Lack of CD4+ T cell mediated help at priming leads to upregulation of TNF-
related apoptosis inducing ligand (TRAIL) upon secondary antigen encounter 
leading to antigen induced cell death (AICD) and diminished secondary 
responses.  If CD4+ T cell mediated help is present it acts to alter the 
transcriptional program of the CD8+ T cells preventing the upregulation of 
TRAIL leading to successful secondary expansion  (275).  It is therefore 
possible that blockade of TRAIL could rescue the secondary expansion of 
“helpless” CD8 memory cells.   
 
The presence of IL-2 at the time of CD8+ T cell priming is important for 
generation of functional CD8+ memory T cell responses.  T cells primed in the 
absence of IL-2 have an impaired ability to expand upon antigen reencounter 
although IL-2 was not required for the primary CD8+ T cell response  (270).  
IL-2 may be produced by CD4+ T cells acting in a paracrine fashion or may 
be derived from the CD8+ T cells themselves, following recognition of 
peptide-MHC on a licensed APC  (276).  The source of IL-2 i.e. paracrine vs. 
autocrine may be dependent on the type of antigen and/or strength of the 
priming stimulus.  The magnitude or duration of IL-2 may also influence the 
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functional differentiation of CD8+ T cells.  Prolonged IL-2 signaling has been 
shown to promote the development of short lived effector cells.  
 
1.5.4 The role of class I restricted CD4+ T cells in tumour 
immunotherapy 
 
With increasing recognition of the need for antigen specific CD4+ T cells for 
use in adoptive immunotherapy protocols, methods have been developed to 
generate tumour-associated antigen specific CD4+ T cells.  Only a limited 
number of class II binding tumour epitopes have been defined and as a result 
the number of class II restricted tumour specific TCR for use in TCR gene 
transfer is very small.  The number of known tumour peptides presented by 
class I is much larger and there is a much wider array of class I restricted 
TCRs available for use in TCR gene transfer and tumour protection models. 
For translational purposes, it will prove difficult to match patients for both MHC 
class I and II alleles for the available target epitopes.  Redirecting CD4+ T 
cells to recognize class I restricted epitopes using TCR gene therapy may be 
more beneficial than introducing class II restricted TCRs and has greater 
translational potential. Class I restricted CD4+ T cells will be able to recognize 
directly presented tumour antigens and CD4+ and CD8+ T cells both 
expressing the same class I restricted TCR could be adoptively transferred 
together. By introducing a large number of tumour specific CD4+ T cells then 
the scope for engaging cognate help is vastly improved.   
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It has been shown by a number of groups that the introduction of a MHC class 
I restricted TCR into CD4+ T cells can generate functional class I restricted 
CD4+ helper T cells both in vitro and in vivo.  The functional antigen-specific 
response of CD4+ T cells expressing class I restricted TCRs to a large part 
depends on the TCR that is used.  TCRs differ in their dependence on the 
CD8 co-receptor.  In the case of CD8 dependent TCRs, the co-transduction of 
the CD8 co-receptor is often required for the CD4+ T cells to be fully 
functional. When a CD8 independent TCR is transduced then there is less or 
no need to co-transduce the CD8 co-receptor in order to produce functional 
CD4+ T cells.   
 
Kessels et al transduced CD4+ T cells with the OT1-TCR and compared them 
to CD4+ T cells co-transduced with OT1-TCR plus CD8αβ  (6).  OT1-
TCR/CD8αβ co-transduced CD4+ T cells produced IFN-γ in response to 
specific antigen whilst OT1-TCR CD4+ T cells that lacked CD8 did not 
produce cytokines in response to antigen. To explore further the contribution 
that the CD8 co-receptor made to the function of OT1-TCR CD4+ T cells, they 
generated mutants of the CD8α chain. The intracellular domain of CD8α was 
replaced with the intracellular domain of the CD4 co-receptor or the CD8α  
intracellular domain was deleted completely.  OT1-TCR CD4 cells transduced 
with either CD8αβ mutant co-receptor retained antigen specific IFN-γ and IL-2 
responses.  The intracellular domain of CD8α therefore did not appear to be 
essential for full function of the OT1-TCR expressing CD4+ T cells.  Following 
adoptive transfer into mice, OT1-TCR CD4+ CD8αβ+ T cells expanded in vivo 
in response to specific antigen.  They also provided help for OT1-TCR CD8+ 
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T cells when adoptively transferred into MHC class II deficient mice that had 
been infected with an OVA expressing influenza strain.  In mice that received 
no CD4+ T cell help, the endogenous CD8+ T cell response did not increase 
above background but there was a substantial CD8 response if OT1-TCR 
CD4+ T cells were co-transferred with the OT1-TCR CD8+ T cells.  They 
postulated that the role of the co-receptor in these cells was dependent on 
lipid raft association via the β chain of CD8.  They found that functions such 
as cytokine production, CD40L expression and the ability to license APCs in 
vitro and to proliferate in vivo could not be improved by the inclusion of the 
CD4 co-receptor intracellular signaling domain and in addition all could be 
provided in the absence of CD8α signaling domain.   
 
Morris et al produced class I restricted CD4+ T cells by transduction of the F5-
TCR which is specific for the influenza peptide, NP presented by H2-Db   (4).  
The in vitro and in vivo experiments used an EL4 lymphoma cell line which 
was stably transfected with NP peptide.  EL4-NP cells express H2-Db but 
don’t express class II MHC.  Following in vitro stimulation with peptide loaded 
syngeneic dendritic cells, 10pm of peptide could induce IFN-γ production by 
F5-TCR CD8+ T cells but a 10 fold higher concentration of peptide (100pm) 
was required to trigger IFN-γ secretion in F5 CD4+ T cells.  F5-TCR CD4+ T 
cells produced little IFN-γ in response to class II negative EL4-NP cells 
whereas purified F5-TCR CD8+ T cells mounted an efficient IFN-γ response.  
If trans co-stimulation was provided with addition of syngeneic dendritic cells 
then the IFN-γ response of CD4+ F5-TCR T cells could be rescued.  This was 
not due to cross presentation of NP by the dendritic cells as allogeneic 
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dendritic cells could also rescue the IFN-γ response to EL4-NP cells. Despite 
poor production of IFN-γ by F5-TCR CD4+ T cells, these cells could produce 
IL-2 and proliferate in response to stimulation with EL4-NP cells alone.  
 
F5-TCR CD4+ T cells provided help and tumour protection in vivo when 
administered with a previously established non protective dose of F5-TCR 
CD8+ T cells in mice bearing EL4-NP tumours.  The tumour protection 
conferred by the CD4+ T cells in this system was dependent on the co-
administration of CD8+ T cells as transfer of F5-TCR CD4+ T cells with an 
anti-CD8 blocking antibody resulted in progressive tumour growth.  However, 
F5-TCR CD4+ T cells were shown to persist up to 90 days post transfer and 
could expand upon tumour rechallenge. 
 
It is thought that when a class I restricted TCR is introduced in to a CD4+ T 
cell that it continues to behave as a CD4+ T cell and does not adopt a CD8+ 
phenotype.  Expression of the CD4 and CD8 co-receptors on thymocytes 
affects their differentiation during development but it is not known whether the 
effector function in the periphery is affected by the interaction of the CD4 or 
CD8 co-receptor and whether the TCR is class I or II restricted. Does the 
introduced TCR dictate the polarization of the cell, or is the functional 
polarization an imprinted property acquired during development or is it 
acquired in culture conditions or altered by the introduced TCR?  
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1.6 CONCLUSION 
 
TCR gene therapy allows the specificity of T cells to be redirected, producing 
tumour specific T cells that can be adoptively transferred in vivo to target and 
eradicate tumour cells.   This strategy has the future potential to produce 
tumour specific T cells for all cancer patients for use in adoptive 
immunotherapy and to generate tumour specific T cells with greatly enhanced 
function.  Initial clinical studies have shown the potential benefits of TCR gene 
therapy but refinements are ongoing to improve the overall efficacy of this 
technique and also to improve the safety profile of TCR gene modified T cells.  
The tumour protection provided by TCR gene modified T cells is still inferior to 
that provided following the adoptive transfer of TIL.  There are several 
reasons that could explain a functional impairment of TCR gene modified T 
cells compared to non-modified T cells. TCR chains must combine with CD3 
molecules to form a complex prior to expression on the T cell surface.  In the 
absence of CD3, TCRs don’t assemble properly and are degraded.  Gene 
modified T cells express endogenous and also introduced TCR chains and 
they must compete for a limited number of CD3 molecules. Competition may 
reduce cell surface expression of the introduced TCR, which may impair the 
avidity of antigen recognition.  The incorrect pairing of introduced and 
endogenous TCR α/β chains could also reduce the avidity of transduced T 
cells.  The introduction of an additional disulphide bond between the α and β	 
chains, or sequence modifications in the TCR constant regions can reduce 
the mis-pairing between the introduced and endogenous TCR chains and 
improve TCR expression in transduced T cells. 
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Finally, current TCR gene transfer protocols frequently produce functional 
CD8+ T cells, but not CD4+ T cells. The adoptive transfer of antigen-specific 
CD8+ T cells in the absence of antigen-specific CD4+ T cells is likely to impair 
tumour protection.  This project focuses on improving the efficacy of CD4+ T 
cells that have been modified to express a class I restricted TCR by co-
transducing TCR in conjunction with additional CD3 molecules.  With this 
strategy, the aim is to increase the surface expression of the transduced class 
I restricted TCR in CD4+ T cells and that by this mechanism, the in vitro and 
in vivo functional avidity of the class I restricted CD4+ T cell can be improved.  
By improving the in vivo function of these transduced CD4+ T cells, it has 
been hypothesized that this will translate to more effective anti-tumour 
responses following adoptive transfer. 
 
1.7 AIMS AND OBJECTIVES 
 
In this project I explored whether the co-transfer of CD3 genes can improve 
the function of MHC class I-restricted TCRs in CD4+ helper T cells. This 
strategy utilized murine tumour models to test whether TCR+CD3 gene 
transfer could enhance tumour protection by adoptively transferred CD4+ and 
CD8+ T cells without increasing on-target or off-target toxicity. The following 
working hypotheses were tested: 
 
1) Co-transfer of TCR+CD3 enhances the functional activity of MHC-class I-
restricted TCRs in CD4+ helper T cells. 
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2) Co-transfer of TCR+CD3 improves antigen-specific T cell function in vivo. 
3)  Adoptive transfer of TCR+CD3 modified T cells results in enhanced 
tumour protection in vivo. 
4)  Adoptive transfer of TCR+CD3 modified T cells does not result in on-target 
or off-target toxicity in vivo. 
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CHAPTER 2 - MATERIALS AND METHODS 
 
2.1 MICE 
 
Mice were obtained from an established breeding colony in our on site animal 
facility.   For in vitro work, C57BL/6 female mice were used as splenocyte 
donors.  For in vivo work, Thy 1.1+ C57BL/6 female mice aged 10-12 weeks 
were used as donors and Thy 1.2+ C57BL/6 female mice aged 10-12 weeks 
were used as recipients unless otherwise stated. For production of bone 
marrow chimeric mice, 10 week old female F1 (C57BL/6 x Balb/c) mice, 10 
week old female Thy 1.1+ Balb/c mice and 10 week old Thy 1.1+ C57BL/6 
female mice were utilized (described below in section 2.7.4).  Thy 1.1+ 
C57BL/6 Luciferase+ transgenic mice were a kind gift from Doctor R Zeiser 
(Freiburg University, Germany).  All work was carried out under a UK home 
office project license. 
 
2.2 IN VITRO CELL CULTURE 
 
2.2.1 Culture of Phoenix Ecotropic (Ph-Eco) packaging cell line  
 
All tissue culture procedures were performed in a class II tissue culture 
cabinet.  Ph-Eco adherent cells (Nolan Laboratory, Stanford, CA) were used 
as the packaging line for production of retroviral particles.  Ph-Eco cells were 
cultured in T75 tissue culture flasks (Helena Biosciences, UK) in IMDM 
complete medium (IMDM medium) (Lonza) containing 10% heat inactivated 
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Foetal Calf Serum (FCS) (Biowest,France), 1% Penicillin/Streptomycin 
(Invitrogen) and 2mM L-glutamine (Sigma-Aldrich). 
   
2.2.2 Culture of EL4 and EL4-NP tumour cell lines  
 
EL4 cells (Sigma) are murine lymphoma cells derived from C57BL/6 mice. 
EL4-NP tumour cell lines are EL4 cells that have been stably transfected with 
influenza A nucleoprotein (NP) and were a kind gift from Doctor B Stockinger 
(National Institute for Medical Research, London).  EL4 and EL4-NP cells 
express H2-Db  but do not express class II MHC.    EL4 and EL4-NP cells 
were cultured in suspension in T75 culture flasks in IMDM complete medium.  
EL4-NP Luciferase+ cells were produced by transfection of EL4-NP cells with 
a red shifted luciferase plasmid and were a kind gift from Doctor M Pule 
(University College London, London).   
 
2.3 PEPTIDES 
 
All peptides were obtained from Proimmune (Oxford, UK).  The influenza virus 
A-NP derived synthetic peptide pNP366 (ASNENMDAM) binds to H2-Db 
molecules.  The Wilms’ Tumour protein (WT1) derived peptide pWT126 
(RMFPNAPYL) was used as an H2-Db binding control.  Peptides were 
reconstituted in PBS to a stock concentration of 2mM and stored at -20°C.   
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2.4 GENERATION OF TCR TRANSDUCED CELLS 
 
2.4.1 Retroviral Vectors 
 
The retroviral vectors pMP71-F5α-2A-F5β (F5 TCR), pMP71-CD3-ζ-2A-ε-2A-
δ-2A-γ-IRES-GFP (CD3-GFP), pMP71-rWT1-IRES-GFP (GFP control) and 
pMP71-F5β (F5β chain) were used for transduction.  The F5-TCR vector 
encodes the α and β chains of the F5-TCR with the α and β chains of the F5-
TCR separated by a 2A sequence.  The F5 TCR recognizes the influenza A 
virus NP (NP366-379) peptide in the context of murine Db molecules.  The 
CD3-GFP vector contains all four chains of the CD3 complex linked by 2A 
sequences and followed by an IRES-GFP sequence so that transduction of 
CD3-GFP vector can be assessed by GFP expression.  The GFP-control 
vector has the WT1 gene inserted into the cloning site in reverse orientation 
so that only the GFP sequence is translated from this vector.   The  pMP71-
F5β-TCR vector contains only the β chain of the F5 TCR and production of 
this vector is described in Section 2.7.  pCL-Eco is a retroviral packaging 
vector, which is used to enhance retroviral titres produced by Ph-Eco cells. 
(Vector maps of F5-TCR, CD3-GFP and F5-TCRβ are shown in Figure 6 and 
7 and sequences in Appendix 2.) 
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5LTR F5α 2A F5β 3LTR 
5LTR CD3-ζ 2A CD3-ε 2A CD3-δ 2A CD3-γ IRES GFP 3LTR 
(A) (B) 
(C) (D) 
(E) 
Figure 6 – pMP71 F5-TCR and pMP71 CD3-IRES-GFP retroviral vectors.  (A) pMP71 F5-
TCR Vector Map and (B) Schematic outline of F5-TCR insert.  (C) pMP71 CD3-IRES-GFP 
Vector Map and (D) CD3 insert encoding zeta, epsilon, delta and gamma chains of CD3 
complex, separated by 2A sequences.  (E) Schematic outline of CD3-IRES-GFP insert. 
	   95	  
   
Figure 7 –pMP71-F5-TCRβ retroviral vector.  (A) pMP71-F5-TCRβ retroviral vector map 
(B) Schematic outline of F5-TCRβ insert. 
5LTR F5β 3LTR 
(A) 
(B) 
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2.4.2 Transfection of Ph-Eco cells  
 
24 hours prior to transfection, 1.5 x 106  Ph-Eco cells were plated in 8ml of 
IMDM complete medium in 10 cm tissue culture plates (Nunc, Denmark).   
Fugene (Roche) was used for transfection of Ph-Eco Cells.  10µl of Fugene 
was added to 300µl of Optimum buffer and incubated at room temperature for 
5 minutes.  A mixture of 2.6µg of retroviral vector DNA and 1.5µg of pCL-Eco 
was re-suspended in distilled water at a final volume of 50µl and then added 
to the Fugene/Optimum mix.   Following a 15 minute incubation at room 
temperature, the transfection mix was added drop wise to the plated Ph-Eco 
cells.  24 hours following transfection, the medium was removed from the Ph-
Eco cells and replaced with 5.5ml of RPMI complete medium (RPMI 1640 
(Lonza), 10% heat inactivated FCS (Sigma), 1% Penicillin/Streptomycin, 1% 
2mM L-glutamine and 0.5% 2-Mercaptoethanol (Sigma, UK).  After a further 
24 hours incubation, the  retroviral supernatant was harvested and centrifuged 
at 1500rpm for 5 minutes to remove any cellular debris.  The retroviral 
supernatant was then used directly for transduction of murine splenocytes 
 
2.4.3 CD4+ T cell purification and activation 
 
Splenocytes were obtained from C57BL/6 (H2-Db) female mice.  CD4+ 
splenocytes were obtained by positive selection using anti CD4 magnetic 
beads (Miltenyi) and an LS separation magnetic column (Miltenyi) as per 
manufacturer’s protocol. CD4+ T cells were activated with CD3/CD28 
Dynabeads (Invitrogen) and IL-2 (Roche) 30U/ml.  CD4+ T cells were re-
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suspended at 1 x 106 cells/ml in RPMI complete medium in 6 well tissue 
culture plate.   CD4+ T cells were activated for 24 hours prior to transduction.  
 
 
2.4.4 Retroviral Transduction 
 
Non treated 6 well tissue culture plates (Cellstar) were coated with 2.5 ml 
retronectin/well (Takara Bio, Japan) and incubated at room temperature for 2 
hours.  Following coating with retronectin, plates were blocked for 30 minutes 
at room temperature with filter sterilized 2% Bovine Serum Albumin 
(BSA)/PBS (2.5ml per well).   For transduction of F5 TCR alone, 4 x 106 
activated splenocytes were re-suspended in 1.5 ml F5 TCR viral supernatant 
and 1.5ml RPMI complete medium and added to one well of a retronectin 
coated plate.  For co-transduction of cells with F5 TCR and CD3-GFP, 4 x 106 
activated splenocytes were re-suspended in 1.5ml F5 TCR viral supernatant 
and 1.5 mls CD3-GFP viral supernatant. For co-transduction of cells with F5 
TCR and GFP-control, 4 x 106 activated splenocytes were re-suspended in 
1.5ml F5 TCR viral supernatant and 1.5 mls GFP-control viral supernatant. 
For mock transduction, 4 x 106 activated splenocytes were re-suspended in 3 
ml RPMI complete medium.  Cells were centrifuged at 2000rpm for 90 
minutes with no brake and then incubated at 37°C, 5% CO2.  On day 1 and 
day 3 post transduction, transduced splenocytes were re-suspended in 6ml 
fresh RPMI complete medium and fresh IL-2 (Chirion) was added at 100U/ml.  
CD3/CD28 activation beads were removed by applying transduced cells to a 
magnet on day 1 post transduction.   
	   98	  
2.5 FLOW CYTOMETRY 
 
FACS analysis to assess transduction efficiency was assessed from day 3 
post transduction onwards.  Samples were stained in FACS buffer (PBS and 
1% FCS) with the appropriate dilution of relevant monoclonal antibodies.  F5 
TCR expression was assessed by staining with anti murine Vβ-11-PE or NP-
Pentamer-PE (Pro-immune).  Expression of CD3-GFP or GFP control was 
assessed by GFP expression.   The following monoclonal antibodies were 
used for flow cytometric staining:  rat anti-mouse CD4-APC; rat anti-mouse 
CD4 APC-H7; rat anti-mouse CD8 APC; rat anti-mouse CD8-V450; rat anti-
mouse Vβ11-PE; rat anti-mouse IFN-γ APC; rat anti-mouse Thy 1.1 PeCy7;  
rat anti-mouse CD19 PerCP-Cy5; rat anti-mouse H2-Kb-PE; rat anti-mouse 
H2-Kd-FITC; rat anti-mouse CD11b APC (All BD Biosciences) and rat anti-
mouse IL-2-APC (eBiosciences).  Samples were acquired on an LSR2 Flow 
Cytometer (BD Biosciences) and analyzed using FACS DIVA software or 
Flowjo (Treestar, Oregon).  FACS sorting of transduced cells was carried out 
where indicated using a FACS Aria cell sorter.  Transduced Cells were 
stained as per standard protocols prior to sort and re-suspended in RPMI 
supplemented with 1% FCS, 1% Penicillin/Streptomycin, 1% L-Glutamine, 
0.1% Gentamicin, 5% Amphotericin, 2.5% HEPES buffer and 2mM EDTA.  
Post FACS sorting, cells were collected in medium as above but 
supplemented with 10% FCS.   
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2.6 IN VITRO FUNCTIONAL ASSAYS 
 
2.6.1 IFN-γ and IL-2 ELISA and proliferation measured by Thymidine 
incorporation assay 
 
On day 5 post transduction, transduced CD4+ T cells were re-stimulated with 
peptide loaded C57BL/6 splenocytes.  5-10 x 106 stimulator cells were re-
suspended in 1ml RPMI complete medium.  Relevant peptide or irrelevant 
peptide were added at the appropriate concentration to stimulator cells and 
cells were then incubated for 1-2 hours at 37°C, 5% CO2 and then irradiated 
with 40 Gy.   Stimulator cells were loaded with NP peptide starting at a 
concentration of 10µM with a 1 in 10 peptide titration down to 1pM NP 
peptide.  As a negative control C57BL/6 splenocytes were peptide loaded with 
10µM irrelevant peptide (WT126 peptide). 
 
Re-stimulation of transduced cells was carried out in 96 well round bottomed 
plates.  5 x 104 transduced cells were incubated with 5 x 104 peptide loaded 
stimulator cells in 200µl RPMI complete medium/well.   Each condition was 
performed in triplicate.  Cells were incubated for 24 hours at 37°C, 5% CO2.  
Supernatant was then harvested for use in ELISA to measure IL-2 and IFN-γ 
production.  ELISA assays were performed as per manufacturer’s protocol 
using BD ELISA kits.  For proliferation assays, cells were pulsed with 0.5µCi 
(1Ci = 37GBq) {3H} thymidine and then incubated for a further 24 hours.  The 
cells were then harvested using an automated 96 well harvester (Amersham 
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Pharmacia) and thymidine incorporation measured using a gamma counter 
(Wallace, UK).   
 
2.6.2 Proliferation Assay using cell proliferation dye eFluor® 670 
 
Cell proliferation dye eFluor 670® (eBioscience) was diluted in PBS to give a 
final concentration of 1µM.  Transduced F5-TCR and F5-TCR + CD3 T cells 
were washed twice in PBS then each population of cells were re-suspended 
in 1ml of e-Fluor 670® and incubated at 37°C for 3 minutes. Cells were 
quenched with 4ml of 8% FCS-PBS (ice cold) and then centrifuged at 
1500rpm for 5 minutes at 4°C.  Cells were then re-suspended in 10ml 2% 
FCS-PBS (ice cold) and centrifuged at 1500rpm for 5 minutes, 4°C.  This 
washing step was repeated twice.  Labelled transduced T cells were re-
suspended at 1 x 106/ml in RPMI complete medium.  0.1 x 106 T cells were 
co-cultured with 0.1 x 106 peptide loaded splenocytes in a total volume of 
200µl/well in a 96 well round bottomed plate.  Cells were incubated for 48 
hours at 37°C.  Prior to FACS analysis, cells were labeled with CD8-PerCP or 
CD4-PerCP and Vβ11-PE. 
 
2.6.3 Intracellular cytokine staining 
 
Peptide loading of stimulator cells was carried out as described above in 
section 2.6.1.  For intracellular cytokine staining, 3 x 105 transduced cells were 
incubated with 3 x 105 peptide loaded stimulator cells in 200µl RPMI complete 
medium/well of a 96 well round bottomed plate.  PMA (25-50ng/ml final 
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concentration) and Ionomycin (0.5-1µg/ml final concentration) were added to 
3 x 105 transduced cells in 200µl RPMI complete medium per well as a 
positive control.  Cells were incubated for 2 hours and then Brefeldin A 
(Sigma) at 10µg/ml final concentration was added to all wells.    Cells were 
then incubated at 37°C, 5% CO2 for a further 16 hours prior to fixation and 
permeabilization steps. 
 
Cells were stained with cell surface markers prior to fixation and 
permeabilization.  Fixation and permeabilization was carried out as per 
standard protocols using BD Cytofix/CytopermTM  kit.  Cells were then stained 
with either IFN-γ-APC or IL-2-APC diluted at the appropriate concentration in 
50µl BD Perm/WashTM.  Cells were incubated for 30 minutes at 4°C in the 
dark.  Cells were washed twice in 200µl in BD Perm/Wash and then re-
suspended in 200µl FACS buffer prior to FACS analysis. 
 
2.6.4 Stimulation with EL4 or EL4-NP tumour cells 
 
On day 5 post transduction, transduced CD4+ T cells were stimulated with 
EL4 tumour cells or EL4-NP tumour cells – either alone or with bone marrow 
derived dendritic cells.  Bone marrow derived dendritic cells (BMDCs) were 
prepared from C57BL/6 mice bone marrow cells.  Bone marrow cells were 
harvested and cultured at 1 x 106 cells/ml in RPMI complete medium plus GM-
CSF 10ng/ml. On day +5, LPS was added at 1µg/ml and dendritic cells were 
harvested and used for assay on day 6 post production.  BMDCs were 
peptide loaded with 10µM NP or 10µM WT peptide or were left unloaded.  
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Following peptide loading BMDCs and tumour cells were irradiated prior to set 
up of overnight stimulation.  Supernatant was collected 24 hours later for use 
in ELISA. 
 
2.6.5 Cytokine production measured by luminex technology 
 
Populations of F5-TCR CD4+, F5-TCR + CD3 CD4+, F5-TCR CD8+ and F5-
TCR + CD3 CD8+ transduced T cell populations were stimulated overnight 
with peptide loaded splenocytes as described in Section 2.6.1.  Supernatant 
was collected following 24 hours of stimulation and then used for multiple 
cytokine analysis using luminex technology as per the manufacturer’s protocol 
(Invitrogen). 
 
2.7 PRODUCTION OF PMP71-F5-TCRβ RETROVIRAL VECTOR 
 
The pMP71-F5-TCRβ vector was generated from the original pMP71-F5-TCR 
vector.  Primers were designed that amplified only the β chain region of the 
F5-TCR which had been engineered to introduce an additional Not1 restriction 
enzyme site at the 5’ end of F5-TCRβ, just prior to the start codon.  The F5-
TCR is ordinarily flanked by a Not1 and Sal 1 site but the Not1 site in the 
pMP71-F5-TCR vector is at the 5’ end of F5-TCRα.  The F5-TCRβ chain was 
amplified using PCR with the following PCR mix:  1µl pMP71-F5-TCR DNA 
(10ng/µl); 25µl Phusion® High Fidelity PCR Mix (NEB); 1µl forward primer 
(0.5µM); 1µl reverse primer (0.5µM); 22µl distilled water.  The reaction 
conditions were as follows: For 35 cycles: 98°C for 30 seconds; 98°C for 10 
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seconds; 72°C for 70 seconds followed by 72°C for 10 minutes.  The resulting 
PCR products were run on a 1% agarose gel (Figure 8A).  The PCR product 
was purified using a Qiagen PCR purification kit and then the product 
digested as follows for 1 hour at 37°C.  PCR product 30µl; NEB buffer 3 35µl, 
BSA 0.5µl; Not 1 1.5µl (NEB); Sal1 1.5µl, distilled water 11.5µl.  In order to 
obtain the pMP71 backbone the original pMP71-F5-TCR vector was digested 
for 1 hour at 37° as follows:  pMP71-F5-TCR DNA 10µl (1µg/µl); NEB Buffer 3 
5µl; Sal1 1.5µl (NEB); Not1 1.5µl (NEB), distilled water 32µl.  The digestion 
products were run on a 1% agarose gel (Figure 8B).  The pMP71 backbone 
was cut out from the agarose gel and then gel extraction carried out using a 
Qiagen gel extraction kit.  Figure 8C shows the pMP71 backbone and F5-
TCRβ insert just prior to ligation.  The pMP71 backbone and F5-TCRβ were 
ligated together at room temperature for 15 minutes as follows:  pMP71 
backbone 3µl; F5-TCRβ insert 2ul; distilled water 6µl; ligase buffer 1µl; quick 
ligase (NEB) 1µl.  Following ligation, max efficiency DH5α cells™ (Invitrogen) 
were transformed with the pMP71 vector as follows:  50µl of cells were 
defrosted and kept on ice for 5-10 minutes.  2µl of ligation mix was added to 
the cells and then incubated on ice for 30 minutes.  The cells were then heat 
shocked at 42°C for 45 seconds and then incubated on ice for 2 minutes.  
250µl of SOC buffer was added to the transformation mixture and then 
shaken at 37°C for 1 hour.  100µl of transformation mix was then spread thinly 
on agar plates and incubated overnight at 37°C.  The following morning, 
colonies were picked from the plate and then miniprep of the plasmid  
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(A) (B) 
(C) 
Figure 8 – Production of pMP71-F5-TCRβ vector.  Production of the pMP71-F5-TCRβ 
vector is outlined in Chapter 2 Section 2.7.  (A) PCR product of F5-TCRβ insert (950bp) (B) 
Digestion products of pMP71-F5TCR showing the pMP71 backbone (4592bp) and the 
original F5 insert (1813bp). (C) Pre ligation gel showing pMP71 backbone and F5-TCRβ 
insert prior to ligation (D) Hyper ladder 1 demonstrating approximate band size. 
(D) 
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produced using a Qiagen miniprep kit.  The miniprep DNA was then used to 
maxiprep the pMP71-F5-TCRβ vector using a Qiagen kit.  DNA was 
resuspended post maxiprep at 1µg/µl and was stored at -20°C.  The pMP71-
F5-TCRβ vector was sequenced prior to use in TCR transduction experiments 
(Appendix 1). 
 
2.8 ADOPTIVE TRANSFER OF F5 TCR AND F5 TCR-CD3 CD4+ T CELLS  
 
2.8.1 Tumour challenge experimental set up 
 
Splenocytes for transduction were obtained from C57BL/6 Thy1.1 mice.  
CD4+ T cells were transduced with F5 TCR or with F5 TCR and CD3-GFP as 
described in section 2.4.  On day 2 post transduction, C57BL/6 Thy 1.2 
recipient mice were irradiated with 5.5Gy.  4 hours post irradiation mice were 
injected with 1 x 106 EL4-NP cells subcutaneously in the right flank.  1 x 106  
EL4-NP cells were re-suspended in 100µl final volume of 50:50 mix of PBS 
and Matrigel prior to injection.  On day 3 post transduction, TCR transduced 
cells were injected intravenously via the tail vein at the appropriate cell dose 
as described in the results section.  For some experiments, TCR transduced 
CD4+ T cells were FACS sorted prior to injection into purified populations of 
F5 TCR CD4+ cells and F5 TCR-CD3 CD4+ T cells (typically purity was >92% 
prior to injection).   Mice were housed in pathogen free conditions in an IVC 
unit and received 5% Baytril (Bayer) for one week prior to irradiation and 2 
weeks post.   Tumour size was measured using calipers every other day and 
mice were sacrificed if tumour size exceeded 15mm in any diameter or 
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ulceration was observed at any size.   Spleen, bone marrow, lymph nodes 
and peripheral blood were harvested for analysis on day of sacrifice.  Single 
cell suspension of spleen, bone marrow and lymph nodes was prepared and 
red cell lysis carried out using ACK lysis buffer (Lonza) on spleen and bone 
marrow.  Cells were counted and then stained for FACS analysis, which was 
carried out as in section 6.1.5.  Cells were stained with Thy1.1-PE-Cy7, CD4-
APC-H7,Vβ11-PE, CD62L-APC and CD44 V450.  Where indicated, for certain 
experiments a lower radiation dose of 4 Gy was used.  
 
2.8.2 In vivo bioluminescence imaging of tumour 
 
In certain tumour protections experiments, EL4-NP-luciferase positive tumour 
cells were used so that tumour growth could be followed using caliper 
measurement and bioluminescence imaging.  Mice were injected 
subcutaneously with of 7.5 mg/kg D-luciferin firefly (Biosynth).  Mice were 
anaesthetized 10 minutes post injection and imaged with a Xenogen IVIS-100 
(Caliper Life Sciences). 
 
2.8.3 In vivo bioluminescence imaging of transduced T cells 
 
Splenocytes for transduction were obtained from C57BL/6 Thy1.1 luciferase+ 
mice.  CD4+ T cells were transduced with F5 TCR or with F5 TCR and CD3-
GFP as per methods section 2.4.  On day 2 post transduction, C57BL/6 mice 
were irradiated with 5.5 Gy.  4 hours post irradiation mice were injected with 1 
x 106 EL4-NP cells  subcutaneously in the right flank.  1 x 106  EL4-NP cells 
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were re-suspended in 100µl final volume of 50:50 mix of PBS and Matrigel 
prior to injection.  On day 3 post transduction (24 hours post irradiation), 1 x 
106 TCR transduced cells in 200µl PBS were injected intravenously via the tail 
vein.  Prior to injection, transduced cells had been CD8 depleted using anti-
CD8 beads and LD depletion column (Miltenyi) to ensure that purified CD4+ T 
cells were administered.  Mice were imaged on day 3, 5, 7 and 10 post 
injection.  Mice were injected intraperitonealy with 15mg/Kg D-Luciferin Firefly 
(Biosynth). Mice were anaesthetized 10 minutes post injection and imaged 
with a Xenogen IVIS-100 (Caliper Life Sciences).  
 
2.8.4 Production of chimeric mice 
 
10 week old F1(C57BL/6 x Balb/c) mice were irradiated with 5.5Gy and then 
irradiated 48 hours later with a further 5.5Gy.  T cell depleted donor bone 
marrow cells were obtained from Thy 1.1+ Balb/c mice or Thy 1.1+ C57BL/6 
mice.  Donor bone marrow was depleted of CD4+ and CD8+ T cells prior to 
injection using magnetic anti-CD4 and anti-CD8 beads (Miltenyi) and LD 
depletion column.  F1 recipient mice were injected with 5 x 106 T cell depleted 
Balb/c or C57BL/6 bone marrow cells intravenously.  Mice were housed in 
pathogen free conditions and checked for achievement of full donor 
chimerism at 12 weeks post original bone marrow transfer.  To check full 
donor chimerism, peripheral blood samples were stained for expression of 
CD19, CD4, CD8, CD11b, H2-Kb and H2-Kd. 
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2.8.5 Tumour challenge experiment using chimeric F1 mice 
 
{C57BL/6F1}  and {Balb/cF1}  bone marrow chimeric mice were used as 
recipients.  Splenocytes for transduction were obtained from F1 (C57BL/6 x 
Balb/c) mice.  CD4+ T cells were transduced with F5-TCR or with F5-TCR 
and CD3-GFP as per methods section 2.4.  On day 2 post transduction, 
recipient {C57BL/6F1}  and {Balb/cF1}  bone marrow chimeric mice were 
irradiated with 4 Gy.  4 hours post irradiation mice were injected with 1 x 106 
EL4-NP-luciferase cells subcutaneously in the right flank.  On day 3 post 
transduction (20 hours post irradiation), 1 x 106 F5-TCR transduced cells in 
200µl PBS were injected intravenously via the tail vein.  Prior to injection, 
transduced cells had been CD8 depleted using anti-CD8 beads and a LD 
depletion column (Miltenyi) to ensure that purified CD4+ T cells were 
administered.  Tumour size was monitored using calipers and by 
bioluminescence imaging as above.  Mice were sacrificed if tumour size 
exceeded 15mm in any diameter or if severity score exceeded 3.5 or if >20% 
loss of weight from baseline.  Spleen, bone marrow, lymph nodes and 
peripheral blood were harvested for analysis on day of takedown.  Single cell 
suspension of spleen, bone marrow and lymph nodes was prepared and red 
cell lysis carried out using ACK lysis buffer (Lonza) on spleen and bone 
marrow.  Cells were counted and then staining for FACS analysis was carried 
out as in section 2.1.5.  Cells were stained with Thy1.2-PE-Cy7, CD4-APC-H7 
and Vβ11-PE.  
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2.9 STATISTICAL ANALYSIS 
 
P values were calculated using the Mann Whitney test performed using Prism 
5.0 software (Graphpad).  Survival curves were constructed using the Kaplan 
Meier method using Prism 5.0 software.  The log rank test was used to 
analyze subgroups in overall survival analysis.   A p value of equal to or less 
than 0.05 was considered significant.  (In figures, * - p<0.05; **- p <0.01; *** - 
p<0.001). 
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CHAPTER 3 – IN VITRO FUNCTIONAL ANALYSIS OF F5-TCR AND CD3 
TRANSDUCED CD4+ T CELLS  
 
 
3.1 Introduction 
 
Our laboratory have previously explored the transduction of CD4+ T cells with 
the class I MHC restricted TCR, F5-TCR.  The F5-TCR is specific for the 
influenza peptide, NP, presented by the murine class I MHC molecules, H2-
Db.  CD4+ T cells that express the F5-TCR can recognize specific antigen in 
vitro but have a lower functional avidity than CD8+ T cells expressing the 
same F5-TCR  (4).  When stimulated with dendritic cells loaded with NP 
peptide, a 10 fold higher concentration of peptide was required to trigger IFN-
γ secretion by F5-TCR transduced CD4+ T cells than was required by F5-
TCR transduced CD8+ T cells.  In addition, F5-TCR transduced CD4+ T cells 
did not produce IFN-γ in response to stimulation with the EL4-NP tumour cell 
line but NP-specific proliferation and IL-2 secretion was observed.  The F5-
TCR is partially CD8 dependent, and therefore in CD4+ T cells in the absence 
of the CD8 co-receptor, the functional avidity is lower compared to CD8+ T 
cells.  
 
The functional avidity of a T cell is dependent on both the affinity of the 
individual TCR for the peptide-MHC complex, the density of TCR expression 
and the ‘fitness’ of the T cell.  Irrespective of the affinity of the TCR for 
peptide-MHC, T cells will not be activated until a threshold number of TCR 
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have been ligated.  This is not an absolute number and is dependent on other 
factors such as the interaction of CD8 or CD4 co-receptors.  An in vitro study 
performed with human T cells with an estimated level of TCR expression of 
30,000 TCR/cell estimated that the minimum number of TCR required for 
activation in the absence of co-stimulation was 8,000 and in the presence of 
co-stimulation was 1,000  (277).  A number of studies have demonstrated that 
the density of TCR expression correlates with the level of T cell activation.  
Using a transgenic model where T cells expressed different levels of an 
identical TCR, it has been shown that reducing TCR number from 50,000/cell 
to 10,000/cell led to a 3 fold reduction in the level of calcium mobilization and 
also delayed T cell responses such as proliferation and IFN-γ production  
(278).  The level of calcium mobilization seen correlated linearly with TCR 
expression.   
 
Following TCR gene transfer, the expression level of the introduced TCR is 
typically lower than that observed in the parental T cell clone. TCR expression 
is dependent on how well the introduced TCR competes with the endogenous 
TCR for binding to CD3.  If there is only one TCR present, then the majority of 
TCR complexes would be expected to bind efficiently to CD3 and be 
expressed on the cell surface.  However in TCR transduced T cells, the 
introduced, endogenous and also any mispaired TCR heterodimers will 
compete for binding to the endogenous supply of CD3.   
 
With the aim of increasing surface expression of the introduced (desired) 
TCR, co-transfer of additional CD3 molecules was assessed.  We have 
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previously examined the in vitro and the in vivo functional avidity of TCR and 
CD3 co-transduced CD8+ T cells in a murine model.  This study 
demonstrated that the amount of CD3 was rate limiting for the expression of 
the introduced TCR.  The co-transduction of CD3 and TCR led to a 16-20 fold 
higher level of TCR surface expression and tetramer binding compared to 
TCR expression in cells that had been transduced with only the TCR genes.  
This observed increase in surface expression of the F5-TCR led to an 
improvement in functional avidity.  This translated in vivo to faster eradication 
of tumours, secondary to more efficient trafficking to the tumour site of TCR + 
CD3 T cells and higher levels of T cell expansion post adoptive transfer.  In 
addition, TCR + CD3 CD8+ T cells had superior recall responses following 
rechallenge  (5). 
 
3.2 Aims and Hypothesis 
 
The aim of experiments reported in this chapter was to explore whether the 
functional avidity of a CD4+ T cell transduced with a class I restricted TCR 
could be improved by the co-transfer of additional CD3.  As described above, 
experiments using F5-TCR expressing CD4+ T cells have demonstrated a 
reduced functional avidity compared to CD8+ T cells expressing the same 
TCR.  These experiments explore initially whether additional CD3 can 
increase the surface expression of the F5 TCR in CD4+ T cells and then 
assess the functional profile of the transduced T cells following in vitro 
stimulation. 
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3.3 Co-transduction CD3 increases surface expression of the introduced 
F5-TCR in CD4+ T cells. 
 
Co-transduction was carried out on purified populations of C57BL/6 CD4+ 
splenocytes.  CD4+ splenocytes were purified by positive selection using anti-
CD4 magnetic beads and then were polyclonally activated using anti CD3-
CD28 beads.  Typical purity post CD4+ selection was 95% or greater.  
Transduction was carried out 24 hours post activation as described in detail in 
Chapter 2, section 2.4.4. 
 
CD4+ splenocytes were transduced with F5-TCR alone, co-transduced with 
F5-TCR and CD3-GFP or with F5-TCR and GFP control.  In cells transduced 
with F5-TCR plus CD3-GFP, GFP expression was used to identify cells 
expressing endogenous CD3 (GFP negative) from cells expressing additional 
exogenous CD3 (GFP positive).  Transduced T cells were stained with the 
anti-Vβ11 antibody, which binds to the F5-TCR Vβ region.   
 
On day 4 post transduction, viable transduced T cells were stained with 
antibodies to CD4 and Vβ11 and analyzed by FACS to determine the purity 
and levels of TCR and exogenous CD3 expression.   Figure 9A shows typical 
expression levels post transduction.  CD4+ mock transduced T cells had an 
endogenous Vβ11 expression of 5.76%.  Following transduction with F5-TCR 
only, 87.8% of CD4+ T cells were Vβ11 positive.  Following transduction with 
F5-TCR and GFP control, 77.3% of CD4+ T cells expressed both Vβ11 and 
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GFP. Finally, following transduction of F5-TCR and CD3-GFP, 91.7% of 
CD4+ T cells had double expression of Vβ11 and CD3-GFP (Figure 9A).   
 
The co-transduction of CD3-GFP led to an increase in surface expression of 
the F5-TCR.  The Vβ11 Mean Fluorescent Intensity (MFI) of mock transduced 
cells, F5-TCR CD4+ T cells and F5 TCR + GFP control CD4+ T cells were 
3058, 2200 and 2083 respectively (Figure 9B).  In CD4+ T cells co-
transduced with F5-TCR and CD3-GFP the Vβ11 expression MFI was 8300.  
Thus, co-transduction of additional CD3 molecules plus F5-TCR led to a four 
fold increase in Vβ11 expression than that of cells transduced with F5-TCR 
alone or F5-TCR plus GFP-control.  Vβ11 MFI was equivalent in mock 
transduced CD4+ T cells and in F5-TCR only transduced CD4+ T cells.  
There was no increase in MFI seen when cells were co-transduced with F5-
TCR plus GFP-control compared to cells transduced with F5-TCR only.   
 
In addition, the transduced CD4+ T cells were stained with NP-pentamer to 
determine if increased TCR surface expression enhanced pentamer binding. 
Transduced cells were stained for expression of CD4 and Vβ11 or for CD4 
and NP-pentamer.  55.4% of CD4+ cells transduced with F5-TCR were able 
to bind NP-pentamer (Figure 10).  Of the cells co-transduced with F5-TCR 
and CD3, 34.1% of cells were NP-Pentamer/CD3-GFP double positive.  There  
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Figure 9 – Co-transfer of CD3 increases TCR expression in F5-TCR transduced CD4+ T 
cells.   Cells were stained with antibodies to Vβ11 and CD4 prior to FACS analysis. (A) – Typical 
CD4+ purity of transduced T cells post transduction (Cells were gated on viable lymphocytes).  (B) 
Transduction of CD4+ T cells with Mock, F5-TCR, F5-TCR + GFP or F5-TCR +CD3 (Cells were 
gated on viable lymphocytes and then on CD4+ T cells).  C) Transduction with F5-TCR and CD3 
increases the MFI of Vβ11 compared to cells transduced with F5-TCR only or F5-TCR + GFP.  
Cells were gated on viable lymphocytes.  Mock Transduced (MFI 3058), F5 TCR (MFI 2200), F5 
TCR and GFP control vector (MFI 2083) and F5 TCR and CD3-GFP vector (MFI 8300) .   
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Figure 10 – Co-transfer of CD3 enhances NP-pentamer binding by F5-TCR transduced 
CD4+ T cells.  Transduced populations were stained for expression of (A) Vβ11 or (B) binding 
to specific NP-pentamer.  Cells had been pre-gated on CD4+ splenocytes and viable 
lymphocytes (C) Transduction with F5-TCR and CD3 increases the MFI of Vβ11 and of NP-
Pentamer compared to cells transduced with F5-TCR only.  Cells were gated on viable 
lymphocytes.  Mock Transduced – MFI Vβ11 = 6469, F5-TCR MFI Vβ11 = 4603, F5-TCR MFI 
Pentamer = 5730, F5-TCR + CD3 MFI Vβ11 = 1.93 x 104 and F5-TCR + CD3 MFI Pentamer = 
2.45 x 104. 
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was a 4.2  fold increase in pentamer binding in the cells co-transduced with 
F5-TCR and CD3-GFP compared to cells transduced with F5 TCR alone (MFI 
NP-Pentamer F5 TCR only = 5730;  MFI NP Pentamer F5 TCR-CD3 GFP = 
2.45 x 104).  
 
3.4 CD4+ T cells co-transduced with F5-TCR and CD3 display increased 
antigen-specific cytokine production and functional avidity in vitro.  
 
Previous experiments demonstrated enhanced TCR expression following co-
transfer of additional CD3.  To assess whether this translated to improved 
function, cytokine production in response to stimulation with specific peptide 
was measured.  IL-2 and IFN-γ production of F5-TCR only CD4+ T cells and 
F5-TCR + CD3 CD4+ cells were compared using ELISA and intracellular 
cytokine staining following stimulation with relevant or irrelevant peptide.  
Initial experiments were performed using peptide loaded C57BL/6 splenocytes 
as antigen presenting cells.  C576BL/6 splenocytes express both class I and 
class II MHC.  The CD4 co-receptor was not expected to bind the class I MHC  
presenting peptide to the F5-TCR so the results obtained were independent of 
the CD4 co-receptor. 
 
ELISA was performed on supernatants produced following overnight 
stimulation of TCR transduced CD4+ T cells with peptide loaded splenocytes 
in a peptide titration experiment to determine T cell avidity.  Initially, the 
transduced CD4+ T cells were FACS sorted into purified populations of F5-
TCR only CD4+ T cells and F5-TCR + CD3 CD4+ T cells.  FACS sorting was 
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performed on day 5 post transduction.  Figure 11A shows a representative 
FACS sorting profiles pre and post sort.  Both F5-TCR only CD4+ and F5-
TCR-CD3 CD4+ populations had >90% purity post FACS sort.  The 
transduced cells were stimulated with peptide loaded splenocytes as 
described (Chapter 2, section 2.6) on the day of the FACS sort.   
 
CD4+ T cells co-transduced with F5-TCR and CD3 produced higher levels of 
both IL-2 and IFN-γ following stimulation with NP peptide (Figure 11B and 
11C).   F5-TCR + CD3 CD4+ T cells were able to produce IL-2 in response to 
100nm of NP peptide and above whereas TCR only CD4+ T cells produced 
lower concentrations of IL-2 in response to the highest (saturating) peptide 
concentration, 10µm.  F5-TCR + CD3 CD4+ T cells produced IFN-γ in 
response to 1µm and above whilst no production of IFN-γ was seen following 
stimulation of F5-TCR only CD4+ T cells.  The CD4+ T cells co-transduced 
with F5-TCR and CD3 were functional in vitro and produced IL-2 and IFN-γ in 
response to peptide stimulation.  Furthermore, they produced more cytokines 
than F5-TCR only CD4+ T cells and were able to respond to lower 
concentrations of specific peptide.  These results suggest that the higher 
surface level of TCR following co-transduction of CD3 improves the functional 
avidity of F5-TCR transduced CD4+ T cells. 
 
IL-2 and IFN-γ production was also measured by intracellular cytokine 
staining of transduced T cells following overnight stimulation with peptide 
loaded splenocytes.  As in the ELISA, peptide titration was performed with NP 
peptide to determine differences in functional avidity between F5-TCR CD4+  
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Figure 11 – F5-TCR transduced CD4+ T cells expressing additional CD3 have increased 
antigen-specific cytokine production and functional avidity in vitro.  Transduced T cells 
were FACS sorted into purified populations of F5-TCR + CD3 CD4+ T cells and F5-TCR CD4+ 
T cells prior to overnight stimulation with peptide loaded C57BL/6 splenocytes.  (A) – 
Representative plot of FACS sort profile pre and post sort following gating on viable 
lymphocytes. (B) IL-2 production measured by ELISA (n=3 experiments, each experiment was 
performed in triplicate).  (C) IFN-γ production measured by ELISA (n= 2 experiments, each 
experiment was performed in triplicate). 
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T cells and F5-TCR + CD3 CD4+ T cells.  For FACS analysis, cells were 
initially gated on viable CD4+ cells and then gated on F5-TCR only cells or 
F5-TCR + CD3 cells.  IL-2 or IFN-γ production in each separate populations 
was then analyzed. Representative FACS analysis from one experiment is 
shown in Figure 12A and 13A.  Figures 12B and 13B summarizes data from 4 
individual experiments.  
 
A higher proportion of F5 TCR + CD3 CD4+ T cells secreted IL-2 and IFN-γ 
when compared to F5-TCR only CD4+ T cells in response to all peptide 
concentrations tested.  F5-TCR + CD3 CD4+ T cells produced IL-2 and IFN-γ 
following stimulation with ≥ 10nm of NP peptide.  F5-TCR only CD4+ T cells  
had demonstrable cytokine production when stimulated with saturating 
(10µm) peptide concentrations only.    Thus, co-transfer of additional CD3 
resulted in increased numbers of antigen responsive cells and increased 
functional avidity as measured by intracellular cytokine staining.  
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Figure 12 – Co-transfer of CD3 increases proportion of antigen specific IFN-γ secreting F5-TCR transduced 
CD4+ T cells and their functional avidity.  Purified populations of F5 TCR CD4+ T cells or F5-TCR + CD3 CD4+ 
T cells were stimulated overnight with peptide loaded splenocytes and then fixed and permeabilized prior to 
staining for intracellular IFN-γ.  IFN-γ production is shown following gating on viable (A) CD4+ F5-TCR + CD3 
positive T cells (30% of CD4+ T cells were F5-TCR + CD3 transduced) or (B) F5-TCR CD4+ T cells (22% of CD4+ 
T cells were F5-TCR positive). FACS plots show results from one representative experiment. (C) Summary plot 
comparing % of F5-TCR or F5-TCR CD3 CD4+ T cells producing IFN-γ (n=4 experiments) 
(A) 
(B) 
IFN-γ 
S
S
C
 
10µM 1µM 100nM 10nM 
1nM 100pm 10pm 1pm 
PMA/ionomycin 
irrelevant 
23.7% 12.8% 13.2% 11.4% 6.5% 
2.5% 0.6% 0.5% 0.4% 1.0% 
10µM 1µM 100nM 10nM 
1nM 100pm 10pm 1pm 
PMA/ionomycin 
irrelevant 
v v v v v
v v v v v
23% 3.3% 4.1% 3.0% 1.7% 
0.9% 0.4% 0.3% 0.3% 0.4% 
S
S
C
 
IFN-γ 
10
-6
10
-5
10
-4
10
-3
10
-2
10
--1 1 10
irre
lev
an
t
PM
A/i
on
o
0
10
20
30
F5 CD3
F5
pNP (µM)
%
 IF
N
-γ
+ 
ce
lls
(C) 
	   122	  
  
(A) 
(B) IL-2 
S
S
C
 
10µM 1µM 100nM 10nM 
1nM 100pm 10pm 1pm 
PMA/ionomycin 
irrelevant 
8 83.8% 27% 26% 28.5% 22.8% 
7.9% 0.7% 0.7% 0.5% 0.9% 
Figure 13 – Co-transfer of CD3 increases proportion of antigen specific IL-2  secreting F5-TCR transduced 
CD4+ T cells and their functional avidity.  Purified populations of F5 TCR CD4+ T cells or F5-TCR + CD3 CD4+ 
T cells were stimulated overnight with peptide loaded splenocytes and then fixed and permeabilized prior to 
staining for intracellular IL-2  IL-2 production is shown following gating on viable (A) CD4+ F5-TCR + CD3 positive 
T cells (30% of CD4+ T cells were F5-TCR + CD3 transduced) or (B) F5-TCR CD4+ T cells (22% of CD4+ T cells 
were F5-TCR positive. FACS plots show results from one representative experiment.   (C) Summary plot 
comparing % of F5-TCR or F5-TCR CD3 CD4+ T cells producing IL-2 (n=4 experiments) 
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3.5 Enhanced antigen-specific proliferation of F5-TCR transduced CD4+ 
T cells expressing additional CD3.   
 
Proliferation of F5-TCR + CD3 CD4+ T cells and F5-TCR only CD4+ T cells 
was assessed using {3H}-thymidine incorporation assays as described in 
Chapter 2, Section 2.6.  The peptide stimulation was carried out on FACS 
sorted CD4+ T cells as before on day 5 post transduction.  Briefly, cells were  
stimulated for 24 hours with peptide loaded C57BL/6 splenocytes and then 
pulsed with {3H}-thymidine and incubated for a further 24 hours.   
 
CD4+ T cells co-transduced with F5-TCR and CD3 had higher levels of 
antigen specific proliferation than CD4+ T cells transduced with F5-TCR only 
(Figure 14A, n=3 experiments).  F5-TCR + CD3 CD4+ T cells proliferated in 
response to stimulation with 1nm of NP peptide whilst proliferation responses 
of F5-TCR CD4+ T cells were only seen following stimulation with 1µm of NP 
peptide or above. 
 
Proliferation was also assessed by measurement of the dilution of the cell 
trace dye efluor 670®.  Transduced T cells were labeled with cell trace efluor 
670® on day 5 post transduction and stimulated for 48 hours with peptide 
loaded splenocytes.  Cells were then stained with surface antibodies against 
Vβ11 and CD4 and the proliferation of transduced populations was assessed 
by measuring the dilution of efluor 670® dye (Figure 14B and Figure 14C).   
At all concentrations of NP peptide down to 1nm, F5-TCR + CD3 CD4+ T 
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cells had higher levels of proliferation than F5-TCR only CD4+ T cells.  F5-
TCR only CD4+ T cells proliferated in response to stimulation with 10nm NP 
peptide whilst F5-TCR + CD3 CD4+ T cells could proliferate in response to 
stimulation with 1nm of NP peptide.  
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Figure 14 – F5-TCR CD3 CD4+ T cells have higher levels of proliferation in response to specific peptide than 
F5-TCR CD4+ T cells.  (A) Proliferation measured by 3H-thymidine incorporation following overnight stimulation with 
syngeneic splenocytes loaded with NP peptide.  Transduced T cells were FACS sorted into purified populations of 
F5-TCR or F5-TCR + CD3 CD4+ T cells prior to stimulation.  Plots summarize results from 3 independent 
experiments.   (B) Proliferation measured by dilution of cell trace dye efluor 670®.  Proliferation of transduced CD4+ 
T cells  was measured following 48 hour stimulation with peptide loaded syngeneic splenocytes. Transduced CD4+ T 
cells were pre labelled with efluor 670® cell trace dye prior to stimulation (Transduced T cells were not FACS sorted 
prior to stimulation).  Results from 3 independent experiments are summarized in figure (B) and (C) shows 
representative FACS plots from one experiment.  Viable cells were gated on CD4 positive cells and then on F5-TCR 
expressing  or F5-TCR + CD3 expressing populations to assess the expression level  of efluor 670. 
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3.6 Comparison of the in vitro function of F5-TCR CD4+, F5-TCR + CD3 
CD4+ and F5-TCR + CD8+ T cells.  Does additional CD3 improve the 
functional avidity of CD4+ T cells transduced with F5 to that of F5-TCR 
expressing CD8+ T cells? 
 
Previous experiments comparing CD4+ and CD8+ T cells transduced with the 
identical class I restricted F5-TCR have shown that F5-TCR CD4+ T cells 
have lower avidity than F5-TCR CD8+ T cells  (4).  This is a result of the 
absence of binding of the CD4 co-receptor in the TCR-peptide-MHC class I 
interaction.  The experiments described here explored whether the co-
transduction of F5-TCR plus additional CD3 improved the functional avidity of 
CD4+ T cells to that observed for CD8+ T cells expressing the F5-TCR i.e. 
could increased TCR expression overcome the need for cognate co-receptor 
expression. 
 
F5-TCR-+ CD3 CD4+ and F5-TCR only CD8+ T cells were generated by 
retroviral transduction as in previous experiments.  IL-2 and IFN-γ secretion 
by F5-TCR + CD3 CD4+ T cells was measured in response to stimulation with 
decreasing concentrations of specific peptide.  Supernatant for ELISA was 
obtained following 24 hours in vitro stimulation.  The transduced T cells in 
these experiments were not FACS sorted prior to stimulation and as a result 
the amount of cytokines produced was higher than that observed using FACS 
sorted populations.   The results shown are the mean of 2 experiments 
(Figure 15). 
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Figure 15 – In vitro antigen specific function of F5-TCR CD3 CD4+ T cells and F5-TCR CD8+ T 
cells. Transduced populations of F5-TCR + CD3 CD4+ T cells and F5-TCR CD8+ T cells were 
stimulated overnight with  peptide loaded C57BL/6 splenocytes. (Transduced T cells were not FACS 
sorted prior to stimulation).  After 24 hours of stimulation, supernatant was collected to measure IFN-γ 
and IL-2 production by ELISA. (A) IFN-γ production in F5-TCR CD8+ T cells and F5-TCR CD4+ T cells 
and ELISA measuring IL-2 production in (B) F5-TCR CD3 CD4+ T cells and F5-TCR CD8+ T cells.  (C) 
Proliferation of F5-TCR CD3 CD4+ T cells and F5-TCR CD8+ T cells measured by dilution of efluor660 
cell trace dye.  (All are the mean of 2 experiments, for the ELISA the stimulations were performed in 
triplicate). (D) FACS plots demonstrating CD4+ or CD8+ purity of transduced cells and the % 
transduced cells.  
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For all parameters assessed  (IFN-γ and IL-2 production and proliferation), 
CD8+ T cells expressing the F5-TCR had higher functional avidity than CD4+ 
T cells co-transduced with the F5-TCR and CD3.  F5-TCR CD8+ T cells 
generated greater amounts of IFN-γ following stimulation with saturating 
concentrations of specific antigen than CD4+ T cells expressing the F5-TCR 
plus CD3.  F5-TCR CD8+ T cells generated an IFN-γ response when 
stimulated with 10pm NP peptide whilst F5-TCR + CD3 CD4+ T cells required 
100pm NP peptide to trigger an IFN-γ response.  Similarly, F5-TCR CD8+ T 
cells produced more IL-2 than F5-TCR + CD3 CD4+ T cells.  F5-TCR CD8+ T 
cells produced IL-2 in response to stimulation with 100pm NP peptide and F5-
TCR + CD3 CD4+ T cells required 1nm of NP peptide to trigger IL-2 
responses.  Proliferation responses to specific antigen were seen following 
stimulation of F5-TCR CD8+ T cells with 10pm NP peptide compared to 
100pm for F5-TCR + CD3 CD4+ T cells.  These results suggest that whilst the 
functional avidity of F5-TCR CD4+ T cells is improved by the co-transduction 
of CD3, it did not reach equivalence to CD8+ T cells expressing the same 
TCR.  The differences in functional avidity observed may related to lack of a 
co-receptor interaction or may be a related to inherent differences in maximal 
responses observable by CD4+ or CD8+ T cells.  For both CD4+ and CD8+ T 
cells, higher concentrations of specific peptide was required to generate IL-2 
than was required to generate IFN-γ or to induce proliferation. 
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3.7 Class I restricted CD4 T cells recognize antigen presented directly by 
class I expressing tumour cells. 
 
The previous functional experiments had used splenocytes loaded with 
specific peptide for stimulation of the transduced T cells.  Within the 
splenocyte suspension, there were large numbers of professional APCs such 
as DCs and B cells able to process and present the NP peptide to transduced 
T cells. 
 
Previous work demonstrated that CD4+ T cells transduced with F5-TCR could 
produce IL-2 and proliferate in response to stimulation with EL4 tumour cells 
expressing NP peptide (EL4-NP cells) but they could not produce IFN-γ  (4).  
F5-TCR expressing CD8+ T cells proliferated in response to stimulation with 
EL4-NP cells and produced both IL-2 and IFN-γ in an antigen specific 
manner.  Experiments were designed to test whether F5-TCR + CD3 CD4+ T 
cells generate functional IFN-γ responses following stimulation with EL4-NP 
cells i.e. tumour cells expressing endogenously processed peptide.   
 
F5-TCR CD4+ T cells and F5-TCR + CD3 CD4+ T cells were stimulated with 
either EL4-NP cells or EL4 tumour cells that do not express NP peptide and 
act as a negative control.  Transduced T cells were stimulated for 24 hours 
with irradiated tumour cells and then supernatant was collected for use in 
ELISA as described in Chapter 2. 
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Both F5-TCR and F5-TCR + CD3 CD4+ T cells generated IL-2 and IFN-γ 
following stimulation with EL4-NP cells (Figure 16).  Neither cell population 
produced cytokines in response to stimulation with EL4 cells (antigen 
negative).  The increase in IL-2 and IFN-γ produced by F5-TCR + CD3 CD4+ 
T cells was non significant, possibly as saturating concentrations of peptide 
were used.  These results differ from previous published data with F5-TCR 
CD4+ T cells where IFN-γ responses following stimulation with EL4-NP cells 
were not observed.  The experiments described here utilized a second 
generation retroviral vector modified to optimize TCR expression.  In addition, 
transduction efficiency of F5-TCR using the pMP71 vector was significantly 
higher than that using the original F5 pMX vector and this may explain the 
difference in functional readout that is seen.   
 
In these experiments the class I restricted TCR transduced CD4+ T cells 
recognized antigen presented by non-professional antigen presenting cells 
such as tumour cells.  Trans-co-stimulation provided by professional APCs in 
co-culture was not required for functional antigen specific responses.  When 
control DCs (not expressing NP peptide) were added to the co-culture of 
transduced T cells and tumour cells the amount of cytokine produced 
increased.  However, the presence of DCs in co-culture was not required to 
induce functional T cell responses to tumour cells. 
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Figure 16 – F5-TCR-CD3 CD4+ T cells and F5-TCR CD4+ T cells can respond to NP 
peptide presented by class II negative EL4 NP tumour cells in vitro. Populations of F5-
TCR + CD3 CD4+ T cells and F5-TCR CD4+  T cells were stimulated overnight with irradiated 
EL4 cells (NP negative and NP positive) in a 1:1 ratio of stimulators:transduced T cells +/- 
addition of trans-co-stimulation with dendritic cells.  Transduced T cells were not FACS sorted 
prior to stimulation.  Following 24 hours of stimulation, supernatant was collected to measure 
IFN-γ and IL-2 production by ELISA  (A) IFN-γ production  (B) IL-2 production.  Results shown 
are the mean of 2 experiments with each stimulation being performed in triplicate).    
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3.8 Cytokine production profile of CD8+ and CD4+ T cells expressing the 
same class I restricted F5-TCR is similar but not identical.   
 
It is not well established whether the functional profile of a CD4+ T cell is 
altered when it is transduced with a class I restricted TCR.  Initial experiments 
assessing production of IFN-γ, IL-2 and proliferation demonstrated that CD4+ 
T cells expressing class I restricted TCR (+/- additional CD3) retain antigen 
specific function.  However, the lack of CD4 co-receptor function may alter the 
activation of the CD4+ T cell and thus a qualitatively and/or quantitatively 
altered signal may be transduced from the TCR.  Furthermore additional CD3 
molecules (with a class I restricted TCR) may change the signal quality and 
the functional profile of the CD4+ T cell. 
 
Experiments were performed with a luminex assay to determine the cytokine 
profile produced by different sorted populations of transduced T cells following 
stimulation with specific peptide.  In these experiments, cytokine production 
by CD8+ T cells transduced with either F5-TCR or F5-TCR plus CD3 were 
compared with CD4+ T cells transduced with F5-TCR or F5-TCR plus CD3. 
 
Supernatant was harvested following a 24 hour stimulation with syngeneic 
splenocytes (peptide loaded with 10µm of relevant or irrelevant peptide).  
Supernatant was assessed for presence of the following cytokines: GM-CSF, 
IFN-γ, IL-2, TNF-α, IL-10, IL-12, IL-17, IL-1β, IL-4, IL-5, IL-6 and TGF-β using 
a luminex assay.   
 
	   133	  
All four populations of transduced T cells produced measurable amounts of 
IFN-γ, TNF-α, and IL-2 in response to stimulation with relevant peptide.  
Transduced CD8+ T cells produced higher concentrations of all 3 cytokines, 
with a 5 fold increase in IFN-γ compared to transduced CD4+ T cells and a 2-
3 fold higher concentration of TNF-α and IL-2 (Figure 17).  
 
Antigen specific IL-4, IL-5 and GM-CSF production is shown in Figure 15.  
Both F5-TCR CD4+ T cells and F5-TCR + CD3 CD4+ T cells produced IL-4 
and IL-5 following stimulation with relevant peptide with higher concentrations 
of both being produced by F5-TCR CD3 CD4+ T cells.   F5-TCR CD8+ T cells 
or F5-TCR + CD3 CD8+ T cells did not produce significant amounts of IL-4 or 
IL-5.   F5-TCR + CD3 CD4+ T cells, F5-TCR CD8+ T cells and F5-TCR + 
CD3 CD8+ T cells all produced GM-CSF in response to relevant peptide with 
highest concentrations being produced by F5-TCR CD8+ T cells (Figure 18).     
 
There was no significant production of IL-6, IL-10, IL-12, IL-17, IL-1β or TGF-β 
in response to stimulation with specific peptide by any of the 4 transduced T 
cell populations (data not shown).   
 
These results suggest that class I restricted CD4+ T cells are poly functional 
and within these populations of transduced CD4+ T cells there are CD4+ T 
cells of a Th1 phenotype but also of a Th2 phenotype.  The introduction of 
additional CD3 plus class I restricted TCR does not appear to change the 
functional profile of either CD4+ or CD8+ T cells.  The cytokine profile 
produced by the transduced CD4+ T cells does not demonstrate the presence  
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Figure 17 – CD4+ T cells expressing class I restricted TCR are polyfunctional, displaying 
a predominantly Th1 phenotype.   Luminex assay was carried out using supernatants 
obtained following overnight culture of TCR transduced T cells in a 1:1 mix with syngeneic 
splenocytes peptide loaded with 10µm relevant or irrelevant peptide (100,000 TCR positive T 
cells: 100,000 peptide loaded splenocytes per condition). Transduced T cells were not FACS 
sorted prior to stimulation.  IFN-γ, TNF-α and IL-2 production by F5-TCR + CD3 CD8+, F5-TCR 
CD8+, F5-TCR + CD3 CD4+ and F5-TCR CD4+ T cells following overnight stimulation is shown.  
(Results shown are the result of 3 independent experiments with each sample per experiment 
being performed in triplicate.) 
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Figure 18 – CD4+ T cells expressing a class I restricted TCR also have have features of 
Th2 CD4+ T cells. Luminex assay was carried out using supernatant’s obtained following 
overnight culture of TCR transduced T cells in a 1:1 mix with syngeneic splenocytes peptide 
loaded with 10µm relevant or irrelevant peptide (100,000 TCR positive T cells: 100,000 peptide 
loaded splenocytes).  T cells were not FACS sorted prior to stimulation.  IL-4, IL-5 and  GM-
CSF and production by F5-TCR + CD3 CD8+, F5-TCR CD8+, F5-TCR + CD3 CD4+ and F5-
TCR CD4+ T cells following overnight stimulation are shown. (Results shown are the result of 
3 independent experiments with each sample per experiment being performed in triplicate.) 
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of a significant population of Th17 CD4+ T cells or of T regulatory CD4+ T 
cells.   
 
3.9 Discussion 
 
One strategy to try to improve the anti-tumour function of TCR transduced T 
cells is to improve the functional avidity of the tumour specific T cell for it’s 
tumour antigen. T cells with higher functional avidity can be generated by 
increasing the affinity of the individual TCR or by increasing the surface 
expression of the introduced TCR.  This is particularly important when 
transducing a CD4+ T cell with a class I restricted TCER.  Introduction of a 
class I restricted TCR into CD4+ T cells does not always generate fully 
polyfunctional CD4+ T cells.  This may manifest as a reduced avidity 
compared to that seen in the parental CD8+ T cell or may result in a CD4+ T 
cell that can’t respond to specific antigen or does not display the full range of 
antigen specific responses as that of a CD8+ T cell expressing the same 
TCR.  CD4+ T cells transduced with a class I TCR have been shown to be of 
lower functional avidity than CD8+ T cells expressing the same TCR, which 
will ultimately affect their efficacy when translating this strategy into clinical 
practice.  Providing a surplus of CD3 molecules by co-transferring additional 
CD3 plus the introduced TCR reduces potential competition for binding with 
CD3 that may exist between introduced and endogenous TCR and thus 
should enhance the surface expression of the introduced class I restricted 
TCR.  The amount of TCR expressed on the T cell surface is one of the key 
determinants of functional avidity of the T cell and thus this should lead to 
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enhanced avidity even in the absence of a functional CD8 co-receptor 
interaction with MHC-I. 
 
These experiments have shown that the co-transduction of F5-TCR and CD3 
enhances the surface expression of the introduced TCR as demonstrated by 
staining for the Vβ11 region of the F5 TCR.   In addition this increase in F5-
TCR surface expression leads to increased binding to specific NP pentamer.  
No increase in F5-TCR expression was seen following co-transduction of F5-
TCR and GFP control, demonstrating that this increase in expression was as 
a direct result of provision of additional CD3 molecules in parallel with the 
introduced F5-TCR.   
 
Following in vitro stimulation, CD4+ T cells expressing F5-TCR + CD3 had 
superior function than F5-TCR CD4+ T cells.  F5-TCR CD4+ T cells could 
only produce IFN-γ and IL-2 and undergo proliferation following stimulation 
with the highest saturating concentrations of cognate antigen whilst CD4+ T 
cells co-transduced with F5-TCR and CD3 could respond to at least a 2 log 
fold lower concentration of specific peptide.  At all concentrations of peptide 
stimulation, the antigen responses of F5-TCR + CD3 CD4+ T cells were of 
greater magnitude than that of F5-TCR CD4+ T cells.  However, when 
compared to CD8+ T cells, F5-TCR + CD3 CD4+ T cells were still of lower 
avidity than that of F5-TCR CD8+ T cells and responses were of smaller 
magnitude.  So it would appear that whilst improving the avidity of a class I 
restricted CD4+ T cell, the provision of additional CD3 molecules did not 
improve the avidity to the level of the CD8+ T cell expressing the F5 TCR. 
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The cytokine profile of class I restricted CD4+ T cells was not altered by the 
co-transfer of additional CD3.  Both populations of CD4+ T cells transduced 
with either F5-TCR only or F5-TCR + CD3 demonstrated production of 
identical cytokine profiles, with production of both Th1 type and Th2 type 
cytokines.   Similarly, CD8+ T cells produced the same cytokines whether 
expressing F5-TCR only or F5-TCR plus CD3.  Whilst increasing the 
functional avidity of the CD4+ T cell, the co-transduction of CD3 did not alter 
its in vitro function. Class I restricted CD4+ T cells produced both Th1 type 
cytokines and Th2 type cytokines.  There was no production of IL-17 or TGF-
β or IL-10 seen by the CD4+ T cells which would suggest that there were not 
significant numbers of Th17 cells or CD4+ T regulatory T cells generated 
following TCR transduction with this TCR or with co-transfer of additional 
CD3.  
 
Both F5-TCR CD4+ T cells or F5-TCR + CD3 CD4+ T cells responded in vitro 
to antigen presented directly by class I MHC by tumour cells, suggesting that 
following in vivo transfer, CD4+ T cells expressing class I restricted TCRs 
may target tumour cells directly in addition to responding to antigen cross 
presented by professional antigen presenting cells.   
 
Thus the co-transfer of additional CD3 can improved the functional avidity of 
CD4+ T cells transduced with a class I restricted TCR.  This produces CD4+ T 
cells that demonstrate antigen specific cytokine production and proliferation in 
vitro even in the absence of binding of CD8 to class I MHC.  However the 
functional avidity of the F5-TCR-CD3 CD4+ T cells did not increase to the 
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level of a CD8+ T cell transduced with F5-TCR without additional CD3.  The 
CD4+ T cells generated in this manner thus appear to be of intermediate 
avidity and it may be that class I restricted CD4+ T cells cannot achieve the 
same avidity as that of the parent CD8+ T cell in the absence of the CD8 co-
receptor.   
 
The function of a class I restricted CD4+ T cell can also be improved by the 
co-transduction of additional CD8 molecules which can result in enhanced 
functional avidity and recovery of antigen specificity in class I restricted CD4+ 
T cells.   There has been no head to head comparison comparing the effects 
of co-transduction of CD8 versus the co-transduction of CD3 into class I 
restricted CD4+ T cells.  
 
Xue et al transduced human CD4+ T cells with HLA-A2 restricted TCRs that 
were specific for human EBV and CMV epitopes.  Transduction of CD4+ T 
cells with the class I restricted TCRs generated CD4+ T cells with a 10 fold 
lower functional avidity than CD8+ T cells expressing the identical TCR.  This 
impaired avidity was entirely due to lack of CD8 co-receptor as the avidity of 
the CD4+ T cell could be corrected to that of the CD8+ T cell by co-transfer of 
TCR and CD8 into CD4+ T cells.   These high avidity CD4+ T cells maintained 
the identical cytokine production profile to that of transduced CD4+ T cells 
that lacked additional CD8 molecules. In a xenogenic NOD/SCID mouse 
model, human CD4+ T cells that co-expressed HLA-A2 virus specific T cells 
and additional CD8 could efficiently eradicate tumours expressing specific 
EBV or CMV antigens.  CD8+ T cells were however protective at a lower cell 
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dose than that of CD4+ T cells co-transduced with TCR and CD8, although 
both displayed the same functional avidity in vivo.  No off or on target toxicity 
was demonstrated following adoptive transfer of CD4+ T cells co-transduced 
with CMV or EBV TCR plus additional CD8 co-receptor  (279).  Thus the 
transduction of additional CD8 molecules into the CD4+ T cells can increase 
the functional avidity of the CD4 T cell irrespective of the original affinity of the 
transduced TCR.  This may represent a safer method of increasing the 
functional avidity of a class I restricted CD4+ T cell than the provision of 
additional CD3.  When additional CD8 co-receptor is transduced there is no 
risk of upregulation of the expression of the endogenous TCR. In addition, the 
functional avidity of the CD4+ T cell would not be increased above that which 
would be expected by a CD8+ T cell expressing the identical TCR.  The 
density of TCR expression and the provision of the CD8 co-receptor 
interaction are both key determinants of the functional avidity of a class I 
restricted CD4+ T cell.  Whilst both methodologies lead to enhanced antigen 
specific function, there is the risk that by enhancing the functional avidity to 
higher levels by co-transducing additional CD3, there is potential that cross 
reactivity to self antigen may be revealed. 
 
Class I restricted TCR have been described as CD8 dependent or CD8 
independent. The absence of the CD8 interaction with pMHC may inhibit T 
cell activation to differing extents for different agonist ligands  (280).  The 
effect of the CD8 co-receptor is likely to be more apparent for weak rather 
than for strong pMHC-TCR interactions  (281).  Holler et al have suggested 
that CD8 dependence is controlled by the affinity of the TCR for pMHC.  In T 
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cell hybridomas that lacked CD8, cells expressing TCR that had an affinity for 
pMHC above a threshold level were able to make robust antigen specific 
responses whilst those with TCR below a certain threshold were unable to 
respond  (121).  CD8 is shown to affect both the on rate  (282)  (123) and the 
off rate  (124) of the TCR-pMHC interaction.  It has been suggested that for 
high affinity TCR that the signaling function of CD8 is most important whilst for 
TCR with lower affinity both the signaling and the stabilization of the TCR-
pMHC provided by CD8 are important  (283).   
 
The efficient regulation of CD8 T cell activity may be provided via modification 
of the CD8 co-receptor function. Variations in the glycosylation state and the 
level of expression of CD8 following antigen binding in vivo can affect the 
binding of TCR to pMHC  (284)  (285).  Therefore inihibition of the 
extracellular binding of CD8 to pMHCI may regulate TCR antigen recognition 
independent from the signaling properties of the CD8 coreceptor.  The 
recognition of all syngeneic pMHC I epitopes can be improved by the 
additional activity of CD8.   
 
Affinity maturation has been used to try to increase the functional avidity of T 
cells.  An affinity matured TCR which had a 1000 fold increased TCR affinity 
was introduced into CD4+T cells where it retained antigen specificity but the 
identical TCR expressed within CD8+ T cells developed non specific cross 
reactivity due to additional interaction of the CD8 co-receptor.  Blockade of the 
CD8-MHC-I interaction with an anti-CD8 antibody prevented this cross 
reactivity.  TCR with only modest increases in affinity retained their antigen 
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specificity whether expressed within CD4 or CD8 T cells.   (286).    It is likely 
that CD8 plays a vital role in modulating the functional avidity of T cells and 
thus the presence or absence of CD8 in class I restricted TCR expressing 
CD4+ T cells may have a profound affect on function.  Increasing the surface 
expression of the class I restricted TCR by additional CD3 doesn’t appear to 
provide the same increase of avidity as that of provision of a functional co-
receptor interaction.  Future experiments could be carried out to directly 
compare CD4+ T cells transduced with class I restricted TCR plus CD3 with 
CD4+ T cells transduced with the identical TCR plus CD8.  It would also be 
interesting to explore whether the provision of additional CD3 can improve the 
function of a class I restricted TCR that does require the presence of a CD8 
co-receptor in order to produce functional antigen specific responses.  This 
could be used to explore responses in CD8 T cell where the CD8 co-receptor 
interaction was blocked and also in CD4+ T cells which lacked the CD8 co-
receptor.   
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CHAPTER 4 – IN VIVO FUNCTIONAL ANALYSIS OF TCR TRANSDUCED 
CD4+ T CELLS MODIFIED TO EXPRESS ADDITIONAL CD3 MOLECULES 
 
4.1 Introduction 
 
The data described in Chapter 3 demonstrated that CD4+ T cells co-
transduced with TCR and CD3 had enhanced functional avidity in vitro.  
Tumour challenge experiments were designed to assess whether class I TCR 
expressing CD4+ T cells could provide tumour protection in vivo following 
adoptive transfer and whether transduction of additional CD3 enhanced 
tumour protection.  CD4+ T cells play a central role in tumour protection and 
the importance of transferring antigen specific CD4+ T cells together with 
antigen specific CD8+ T cells to maximize in vivo help has been 
demonstrated in murine models and human clinical studies.  There are also a 
number of reports of tumour specific CD4+ T cells having the ability to 
eradicate tumours directly even in the absence of antigen specific CD8+ T 
cells   (255)  (262)  (266). 
 
The experiments described here explore the effects of tumour specific CD4+ 
T cells in isolation without tumour specific CD8+ T cells.  Previous tumour 
challenge experiments utilizing F5-TCR transduced CD8+ T cells have 
demonstrated that F5-TCR CD8+ T cells can efficiently reject NP expressing 
tumours in vivo in the absence of tumour specific CD4+ T cells  (4).  In these 
current experiments, recipient mice received sub lethal irradiation, which 
depleted endogenous CD8+ T cells thus limiting their role in tumour 
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regression.  The tumourcidal effects observed can be attributed to a direct 
effect of adoptively transferred tumour specific CD4+ T cells (including the 
provision of help to innate immune cells within the recipient mice).  
 
This murine tumour model used syngeneic Thy 1.2+ C57BL/6 mice as 
recipients and C57BL/6 Thy 1.1+ mice as donors unless otherwise stated.  In 
initial experiments, recipient mice received sub lethal irradiation (5.5 Gy) 
resulting in lymphodepletion of the host haematopoesis and promoting 
homeostatic proliferation of adoptively transferred T cells.  Recipient mice 
were irradiated on Day 0, and then 4 hours post irradiation received a 
subcutaneous tumour challenge with EL4-NP tumour cells.  On day 1 (24 
hours post irradiation), mice received intravenous injection of TCR transduced 
CD4+ T cells.  The EL4 tumour cell line is a lymphoma derived from a 
C57BL/6 background.  It only expresses class I MHC (H2-Db) and does not 
express class II MHC molecules.  The EL4-NP cell line has been stably 
transfected with the NP-peptide, which is recognized by the F5-TCR.  For the 
initial tumour challenge experiments, EL4-NP luciferase+ cells were used. 
Tumour growth was monitored by bioluminescence imaging and caliper 
measurement of the tumour area.  Figure 19 shows a schematic 
representation of the experimental set up for tumour challenge experiments. 
 
	   145	  
   
 
C57BL/6 
Thy 1.2  
Recipient 
 
Day 0 
Time 0 hours 
Irradiate 
 5.5Gy 
 
 Day 0 
Time +4 hours 
EL4-NP-luciferase  
1 x 10 6cells/mouse s/c 
!!
 
Day 1 
Inject  Thy 1.1  
TCR transduced 
T cells IV 
!!
Figure 19  – Schematic representation of experimental set up  for in vivo tumour 
protection experiments.  Specific doses of radiation, tumour cells and T cells are 
indicated in the relevant text. 
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4.2 Aims and Hypothesis 
 
It was hypothesized that the adoptive transfer of F5-TCR + CD3 CD4+ T cells 
would confer superior tumour protection than F5-TCR CD4+ T cells due to 
enhanced T cell expansion following recognition of NP expressing EL4 tumour 
cells.  In addition F5-TCR + CD3 CD4+ T cells were predicted to traffic more 
efficiently to the tumour site than F5-TCR CD4+ T cells. It was expected that  
the adoptive transfer of F5-TCR + CD3 CD4+ T cells would not lead to 
harmful off target effects post adoptive transfer.  As in vitro experiments 
confirmed increased antigen specific functional avidity, further in vivo 
experiments were carried out to determine whether CD4+ T cells expressing a 
class I restricted TCR responded to antigen presented by non professional 
APCs such as tumour cells. 
 
4.3 Adoptive Transfer of F5-TCR CD3 CD4+ T cells confers enhanced 
tumour protection in vivo. 
 
Initial tumour challenge experiments were performed to compare tumour 
protection provided following the adoptive transfer of F5-TCR CD4+ T cells 
and F5-TCR + CD3 CD4+ T cells.  On day 0, recipient mice were irradiated 
with 5.5 Gy and 4 hours later were injected subcutaneously with 1 x 106 EL4-
NP-luciferase+ cells.  On day 1, mice received adoptive transfer of 1 x 106 
TCR positive or mock transduced CD4+ T cells.  Cells were FACS sorted 
prior to adoptive transfer and Figure 3A shows purity of F5-TCR CD4+ and 
F5-TCR + CD3 CD4+ T cells prior to injection.  There were 3 different 
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treatment groups: Mock Transduced CD4+ T cells, F5-TCR CD4+ T cells and 
F5-TCR + CD3 CD4+ T cells, each with eight mice per group. 
 
Mice were monitored for tumour growth, weight and clinical severity score on 
alternate days.  Tumour size was measured with calipers and by 
bioluminescence imaging.  As per Home Office license, mice with specified 
high clinical severity score, progressive tumour growth exceeding 15mm in 
any diameter or with >20% baseline weight loss were culled.  Figure 20 
demonstrates the mean tumour growth measured by tumour area and 
bioluminescence imaging. 
 
All mice had measurable tumour burden by day 6 following tumour challenge.   
In mice receiving mock transduced CD4+ T cells, progressive tumour growth 
was observed in all mice.  Tumour growth progressed at a similar rate in mice  
receiving F5-TCR CD4+ T cells.  In both groups of mice, progressive tumour 
growth resulted in sacrifice between 13 and 18 days post T cell transfer.  
Measurements of tumour growth (by calipers and bioluminescence imaging) 
demonstrated protection in mice that receiving F5-TCR + CD3 CD4+ T cells.  
In this group, tumours grew steadily to day 12 post challenge and then tumour 
growth plateaued.  However, complete tumour regression was only observed 
in 1/8 mice in this group.  None of the mice within the F5-TCR + CD3 CD4+ 
group died of progressive tumour growth.  All mice in this group had to be 
killed before the end of the experiment due to weight loss of >20% from 
baseline or an increased clinical severity score.  This toxicity arose between 
days 12 and day 20 post tumour challenge. The weight loss and high severity   
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Figure 20 –Enhanced tumour protection following adoptive transfer of  F5-TCR + CD3 CD4+ T cells. 
C57BL/6 Thy 1.2 donor mice received sub lethal irradiation with 5.5 Gy on day 0 and 4 hours later received 
1 x 106 luciferase expressing EL4-NP tumour cells subcutaneously.  On Day 1, mice received 1 x 106 F5-
TCR, F5-TCR + CD3 or mock transduced CD4+ T cells intravenously. Results shown are from 1 experiment 
with 8 mice/group. (A) FACS plots of FACS sorted F5-TCR + CD3 CD4+ and F5-TCR only CD4+ T cells 
prior to adoptive transfer.    (B) Mean tumour area measured by calipers.  (C) Mean bioluminescent signal in 
photons/second recorded at site of tumour growth.  (D)  Bioluminescent signal at site of tumour growth 
between day 3-16 days post tumour challenges.  For measurement of bioluminescent signal, mice were 
always arranged in identical order on each day of measurement.  All mice within mock and F5-TCR group 
died of progressive tumour growth.  Within the  F5-TCR + CD3 group, no mice died of progressive tumour 
growth but all mice died of toxicity related to TCR transduced T cells.   
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score could not be attributed to tumour growth as all of the mice had low 
tumour burden (as determined by bioluminescence) and/or had started to 
regress.  None of the mice that received mock transduced CD4+ T cells or 
F5-TCR CD4+ T cells developed cachexia or severity scores above that 
expected from sub lethal irradiation or from progressive tumour growth. 
 
The finding of increased toxicity within the recipients of F5-TCR + CD3 CD4+ 
T cells was confirmed in a second independent experiment.  The experimental 
set up was similar to the previous experiment although luciferase negative 
tumour cells were used for challenge and the number of mice per group was 
5.  In this experiment, all mice receiving mock transduced CD4+ T cells had 
progressive tumour growth between day 11 and 12 post tumour challenge.  All 
mice that received F5-TCR CD4+ T cells had progressive tumour growth that 
occurred between day 11 and day 19 post tumour challenge.  All of the mice 
within the F5-TCR + CD3 CD4+ group had to be sacrificed as a result of 
severe cachexia or high severity scores that developed between day 10 and 
day 12 post tumour challenge.   
 
Figures 21A and 21B summarize the maximal weight loss and clinical severity 
scores of the mice from 2 separate experiments.  Mice that received F5-TCR 
+ CD3 CD4+ T cells developed significantly more weight loss from baseline 
and higher severity scores than mice that received mock transduced CD4+ T 
cells or F5-TCR CD4+ T cells.  As a result, no survival benefit was observed 
following the adoptive transfer of CD4+ T cells co-transduced with TCR and  
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(A) 
Figure 21  – Adoptive Transfer of F5-TCR + CD3 CD4 T cells leads to marked cachexia 
and increased severity scores despite tumour protection.  (A) Maximal weight loss of 
recipient mice following adoptive transfer (Results shown are from 2 independent 
experiments, n= 13 mice) (B) Maximal Severity Scores (C) Kaplan Meier Plots of Survival 
post tumour challenge in two independent tumour challenge experiments. 
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CD3 even though there was a reduction in tumour burden in this group 
(Figure 21C).   
 
Prior to onset of toxicity, adoptively transferred CD4+ T cells co-transduced 
with F5-TCR and CD3 appeared to provide superior tumour protection 
following adoptive transfer compared to CD4+ T cells expressing F5-TCR 
only.  However, no survival benefit was observed due to these marked 
toxicities.  
 
In this model, an anti-tumour effect was seen in the absence of tumour 
antigen specific F5-TCR CD8+ T cells.  Whether this due to direct cytotoxicity 
of the F5-TCR + CD3 CD4+ T cells or whether it is via recruitment of other 
effector cells to mediate tumour eradication is not clear and was not 
specifically investigated. 
 
Marked weight loss and increased severity scores were restricted to mice 
receiving CD4+ T cells co-transduced with F5-TCR and additional CD3.  No 
such toxicity was observed in mice who received mock transduced or F5-TCR 
CD4+ T cells.  However, all mice in the F5-TCR group died of tumour 
progression, which may have masked T cell mediated toxicities. 
 
It is possible that the increased TCR expression associated with co-transfer of 
CD3 increases T cell cross reactivity and targeting of normal tissues by TCR 
transduced T cells in a non antigen dependent manner.   Furthermore, the 
rate of F5 TCR α and β chain mispairing may be increased with greater TCR 
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expression levels leading to off target effects due to production of TCR with 
novel specificities.  Mispaired TCR will not have undergone negative selection 
in the thymus and may not be controlled by peripheral tolerance mechanisms.  
If mispairing was occurring at a clinically significant level, it may have been 
expected that toxicity would also have been apparent in the TCR only group 
but to a lesser degree.  It is also possible that transduction of additional CD3 
leads to an up regulation of the endogenous TCR.  Increased expression of 
endogenous TCR may itself lead to auto reactivity and the bypassing of 
normal tolerance mechanisms.  In subsequent experiments, the possible 
mechanisms of toxicity are explored in more detail. 
 
4.4 Adoptive Transfer of F5-TCR + CD3 CD4+ T cells results in enhanced 
tumour infiltration.  
 
In vitro, F5-TCR + CD3 CD4+ T cells were observed to undergo higher 
antigen-specific proliferation than F5-TCR only CD4+ T cells and responded 
to lower concentrations of peptide. Tumour protection was greater with F5-
TCR + CD3 CD4+ T cells.  It was therefore postulated that F5-TCR + CD3 
CD4+ T cells would undergo higher levels of antigen driven expansion in vivo 
and may also traffic to the tumour site at a faster rate.  
 
To assess T cell trafficking to the tumour site and expansion of transferred 
cells in vivo, bioluminescence imaging of luciferase positive TCR-transduced 
CD4+ T cells was utilized.  CD4+ T cells obtained from luciferase+ transgenic 
C57BL/6 mice were used for TCR transduction and adoptive transfer.  In vivo  
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tumour challenge with luciferase negative EL4-NP tumour cells was 
administered.  Recipient mice were sub lethally irradiated with 5.5 Gy 
irradiation on day 0 and 4 hours subsequent to this injected with 1 x 106 EL-
NP luciferase negative tumour cells.  On Day 1 post tumour challenge, mice 
were injected intravenously with 1 x 106 luciferase positive F5-TCR CD4+ T 
cells, 1 x 106 F5-TCR + CD3 CD4+ T cells or 1 x 106 mock transduced CD4+ 
T cells.  Infiltration of CD4+ T cells into the tumour site was visualized serially 
post tumour challenge using in vivo bioluminescence imaging.  F5-TCR + 
CD3 CD4+ T cells were first detectable in the tumour site at seven days post 
tumour challenge.  TCR only CD4+ T cells could be detected at the tumour 
site but not until nine days post tumour challenge. (Figure 22A). 
 
A control C57BL/6 mouse was injected subcutaneously with different doses of 
luciferase+ T cells, and the bioluminescent signal achieved from each T cell 
dose was measured (Figure 22D).  (These T cell titration measurements were 
performed in conjunction with Doctor Maryam Ahmadhi).  The bioluminescent 
signal from each mouse at each time point was converted into an approximate 
number of luciferase+ T cells. The mean bioluminescent signal in photon/sec 
and mean T cell number are shown in Figures 22B and 22C.  CD4+ T cells 
co-transduced with F5-TCR and CD3 were detectable in significantly greater 
numbers at the tumour site at both day 7 and day 9 post adoptive transfer 
compared to F5-TCR only CD4+ T cells (p≤0.01).  There was no significant 
increase in expansion of F5-TCR only CD4+ T cells when compared to mock 
transduced CD4+ T cells.  These experiments indicated that F5-TCR + CD3 
CD4+ T cells were able to expand more efficiently in vivo following adoptive  
	   154	  
 
 
 
F5-TCR F5-TCR + CD3 MOCK 
 D9 
D7 
D5 
D3 
(A) 
Figure 22 – Enhanced tumour infiltration by F5-TCR + CD3 CD4+ T cells. C57BL/6 Thy 1.2 
donor mice received sub lethal irradiation with 5.5 Gy on day 0 and 4 hours later received 1 x 106  
EL4-NP tumour cells subcutaneously.  On Day 1, mice received 1 x 106 F5-TCR, F5-TCR + CD3 
or mock transduced CD4+ luciferase+ T cells intravenously. Results shown are from one 
experiment with 5 mice per group.  (A) Bioluminescent signal demonstrating infiltration by 
adoptively transferred CD4+ T cells. (B) Mean bioluminescent signal in photons/second recorded 
at tumour site (C) Photons/second were converted into an approximate T cell number at tumour 
site.  Mean T cell number is shown.  (D) Bioluminescent signal seen following injections of defined 
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transfer and were able to traffic to the tumour site more effectively than F5-
TCR only CD4+ T cells. 
 
Infiltration of F5-TCR + CD3 CD4+ T cells in peripheral tissues such as the 
nose, tail and paws of the mice was also observed.  It is hypothesized that the 
TCR transduced T cells are binding to an antigen in the periphery which is 
distant from the site of the original injected tumour and is unlikely to represent 
metastatic tumour given the location.  Thus the TCR transduced T cells are 
recognizing a peripheral antigen that is not NP peptide which lends support to 
the hypothesis that F5-TCR + CD3 CD4+ T cells may be autoreactive or 
cross-reactive, assuming the cognate antigen is only expressed in the tumour 
tissue.  
 
4.5 In vivo expansion and persistence is enhanced following adoptive 
transfer of F5-TCR CD3 CD4+ T cells 
 
To assess the expansion and persistence of TCR-transduced CD4+ T cells 
post adoptive transfer, the transferred T cells were isolated and quantified 
from different organs.  Tissue samples were obtained from bone marrow, 
lymph node and spleen on the day of sacrifice.  The results shown were from 
4 independent experiments with a total of 22 mice per group.  Single cell 
suspensions from each organ were prepared as described in the section 2.7 
and stained with anti-murine Thy 1.1 and anti murine CD4 monoclonal 
antibodies prior to FACS analysis.  As recipient mice were Thy 1.2+, all of the 
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Thy 1.1+ CD4+ T cells detected were derived from the adoptively transferred 
cells. 
 
Following adoptive transfer, a higher proportion of Thy 1.1+ CD4+ T cells 
were detectable in mice that received F5-TCR + CD3 CD4+ T cells compared 
to mice given F5-TCR only CD4+ T cells.  A significantly higher percentage of 
adoptively transferred T cells were seen in the F5-TCR + CD3 group in all 
organs analyzed.  In mice that received TCR only CD4+ T cells, the mean 
percentage of Thy 1.1+ CD4+ T cells (the percentage of viable lymphocytes 
that were Thy 1.1+ CD4+) detectable within the bone marrow, spleen and 
lymph node was 2.2% (range 0.02-11.4%), 4.5% (range 0.04%-24%) and 
5.7% (range 0.01-19.6%) respectively.  In mice that received CD4+ T cells co-
transduced with F5-TCR and CD3 the mean percentage of Thy 1.1+ CD4+ T 
cells detected within bone marrow, spleen and lymph node was 28.9% (range 
1.1-75.9%)(p≤0.001), 18.8% (range 0.9-53.4%)(p≤0.001) and 26.5% (range 
0.6%-75.5%) (p≤0.001) respectively (Figure 23).  When the absolute number 
of CD4+ Thy 1.1 T cells were analyzed there was a significantly higher 
number of adoptively transferred cells detected in the bone marrow and 
spleen of mice that received F5-TCR + CD3 CD4+ T cells compared to F5-
TCR CD4+ T cells.  Within the spleen, there was no significant difference in 
absolute cell number of CD4+ Thy1.1+ T cells seen between the two groups.   
 
In this analysis, the survival time of mice post tumour challenge ranged from 
10 – 25 days.  With increasing time post irradiation, re-expansion of recipient 
haematopoesis will be greater thus reducing the detectable proportion of  
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Figure 23  . In vivo expansion and persistence of F5-TCR CD4+ T cells  is enhanced by the 
presence of additional CD3.  Analysis of bone marrow, spleen and lymph node samples to 
assess persistence/expansion of F5-TCR or F5-TCR +  CD3 TCR transduced CD4+ T cells 
following tumour challenge experiments.  Samples were taken on day 10-25 post tumour 
challenge.  Cells were gated on viable lymphocytes and representative FACS plots of Thy 1.1+ 
CD4 + T cells and  % of Thy 1.1+ CD4+ T cells  and absolute cell number in (A) bone marrow, (B) 
spleen and (C) lymph node are shown.  Plots show results from 4 independent experiments.   
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adoptively transferred T cells.  Differences of cell expansion seen between the 
F5-TCR only and F5-TCR + CD3 groups may be exaggerated, particularly if 
there is a bias to one group being analyzed at much earlier time points.  In 
order to reduce this bias, a comparison of mean percentage of Thy 1.1+ and 
CD4+ T cells was performed on samples taken on day 10-14 post tumour 
challenge (n=13/group) and samples taken on day 15-25 post tumour 
challenge (n=8/group).   In the analysis performed on day 10-14 there was a 
significantly higher percentage of Thy1.1+ CD4+ T cells in the bone marrow 
(p≤0.01), spleen (p≤0.01) and lymph node (p≤0.01) in mice that received F5-
TCR + CD3 CD4+ T cells compared to mice that received F5-TCR only CD4+ 
T cells (Figure 24).  This would suggest that F5-TCR + CD3 CD4+ T cells 
underwent a higher level of in vivo expansion initially following adoptive 
transfer compared to F5-TCR only CD4+ T cells.   
 
Analysis of later time points reflects more the ability of transferred T cells to 
persist in vivo rather than initial expansion. In the analysis performed on 
samples taken between day 15 and day 25 (n=8/group) there was still a 
significantly higher proportion of Thy 1.1+ CD4+ T cells present within the 
bone marrow (p≤0.05) and spleen (p≤0.01) of mice that received F5-TCR + 
CD3 CD4+ T cells.  However, persistence of adoptively transferred CD4+ T 
cells within the lymph nodes is not significantly different following transfer of 
F5-TCR + CD3 CD4+ or F5-TCR only CD4+ T cells.  This may suggest that 
F5-TCR + CD3 CD4+ T cells persist more readily within the bone marrow and 
spleen than in the lymph node or they may have undergone initial greater 
expansion within these organs.  This may also reflect more effective 
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persistence of F5-TCR CD4+ T cells within the lymph node than within other 
organs.  Figure 24 and 25 shows the analysis of the two different time points 
and also summarizes the minimum, maximum and means of the populations.   
 
Whilst these experiments assume that the superior expansion and 
persistence of F5-TCR + CD3 CD4+ T cells is secondary to recognition of  
cognate NP peptide, expansion may also be driven by recognition of a self 
antigen as a result of increased auto reactivity of the F5-TCR + CD3 CD4+ T 
cells.  It may also reflect expansion of CD4+ T cells that are expressing 
mispaired TCR which have unknown specificities. 
  
	   160	  
 
  
F5
-T
CR
 C
D3
 C
D4
+
F5
-T
CR
 C
D4
+
0
20
40
60
80
**
%
 T
hy
 1
.1
+ 
C
D
4+
F5
-T
CR
 C
D3
 C
D4
+
F5
-T
CR
 C
D4
+
0
20
40
60
**
%
 T
hy
 1
.1
+ 
C
D
4+
F5
-T
CR
 C
D3
 C
D4
+
F5
-T
CR
 C
D4
+
0
20
40
60
80
**
%
 T
hy
 1
.1
+ 
C
D
4+
F5
-T
CR
 C
D3
 C
D4
+
F5
-T
CR
 C
D4
+
0
20
40
60
80
*
%
 T
hy
 1
.1
+ 
C
D
4+
F5
-T
CR
 C
D3
 C
D4
+
F5
-T
CR
 C
D4
+
0
20
40
60
**
%
 T
hy
 1
.1
+ 
C
D
4+
F5
-T
CR
 C
D3
 C
D4
+
F5
-T
CR
 C
D4
+
0
20
40
60
80
ns
%
 T
hy
 1
.1
+ 
C
D
4+
DAY 10-14 DAY 15-25 
BONE MARROW 
SPLEEN 
LYMPH NODE 
Figure 24  – Persistence of F5-TCR only and F5-TCR + CD3 T cells at early and late time 
points post adoptive transfer into tumour bearing mice.  Percentage of Thy 1.1+ and 
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Figure 25 – Summary of Minimum, Maximum and Mean % Thy 1.1+ CD4+ T cells at 
Day 10-14 and Day 15-25. 
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4.6 CD4+ T cells expressing class I restricted TCR recognize class II 
negative tumour cells in vivo. 
 
CD4+ T cells expressing a class I restricted TCR recognize peptide presented 
by class I MHC molecules.  It has not been established whether class I 
restricted CD4+ T cells can respond to peptide-MHC-I on the surface of any 
nucleated cell or whether they can only respond to peptide-MHC-I presented 
by professional APCs.  The in vitro data described in chapter 3 supports the 
hypothesis that CD4+ T cells expressing the class I restricted TCR, F5-TCR 
can be stimulated by antigen that is directly presented by class I MHC on 
tumour cells (which lack class II MHC).  
 
To explore this further in vivo, a tumour challenge was carried out in a model 
system using bone marrow chimeric mice in which the haematopoetic cells of 
the recipient mice were of a different H2 haplotype to that which is recognized 
by the F5-TCR.  In this context, any antigen specific responses would be 
mediated by direct recognition of peptide-MHC-I presented by EL4-NP tumour 
cells and not by presentation of NP peptide by class I MHC on professional 
APCs.  The experimental model is shown schematically in Figure 26.  The F5-
TCR recognizes the NP peptide in the context of H2-Kb.  This model system 
used bone marrow cells derived from C57BL/6 mice (H2b) or bone marrow 
cells derived from Balb/c mice (H2d).  In bone marrow chimeric mice 
reconstituted with Balb/c (H2d) haematopoetic cells, F5-TCR CD4+ T cells can 
only respond to NP peptide presented by H2b on EL4-NP tumour cells and not 
by professional APCs which express H2d.   Therefore if tumour specific  
	   163	  
 
 
 
 
F1(C57BL/6 x Balb/c) mice 
reconstituted with Thy 1.1+ Balb/c 
bone marrow (H2d ) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F1(C57BL/6 x Balb/c) mice 
reconstituted with Thy 1.1+ Balb/c 
bone marrow (H2b ) 
 
Day 0 
Time 0 hours 
Irradiate 
 4 Gy 
 Day 0 
Time +4 hours 
Inject EL4-NP-luciferase 
1 x 10 6 cells/mouse s/c 
!!
Day 1 
Inject  F1(C57BL/6 x Balb/c) 
Thy 1.2+ TCR transduced 
T cells IV 
!!
Figure 26 – Schematic representation of experimental set up for bone 
marrow chimeric tumour challenge experiments.   
 
1 x 106 F5-TCR CD3 CD4+ Thy 1.2+ 
 
1 x 106 F5-TCR CD4+ Thy 1.2+ 
 
1 x 106 Mock CD4+ Thy 1.2+ 
 
1 x 106 F5-TCR CD3 CD4+ Thy 1.2+ 
 
1 x 106 F5-TCR CD4+ Thy 1.2+ 
 
1 x 106 Mock CD4+ Thy 1.2+ 
APC 
H2b 
APC 
H2d F5-TCR 
CD4+ 
 
 
 
EL4-NP  
H2b 
!
F5-TCR 
CD4+ 
 
 
 
EL4-NP  
H2b 
!
(A) [Balb/c!F1] chimeras 
 
(B) [C57BL/6!F1]chimeras 
 
	   164	  
responses were seen in the Balb/c chimeric mice it would support the 
hypothesis that class I restricted CD4+ T cells could respond directly to 
antigen presented by a non professional APC.   
 
To produce bone marrow chimeric mice, F1 (C57BL/6 x Balb/c) mice were 
irradiated and then given a bone marrow transplant with T cell depleted Thy 
1.1+ Balb/c bone marrow cells or Thy 1.1+ C57BL/6 bone marrow cells.  Mice 
were then housed in pathogen free conditions for 12 weeks to allow time for 
full haematopoetic reconstitution.  Prior to tumour challenge experiments, 
blood samples from the chimeric mice were obtained and analyzed to assess 
full donor chimerism by staining for CD19, CD4, CD8, CD11b, H2-Kb and H2-
Kd (Figure 27 and 28).   Splenocytes derived from Thy 1.2+ F1 (C57BL/6 x 
Balb/c) mice were used for transduction and adoptive transfer so that the 
adoptively transferred cells could be monitored ex vivo.   
 
For the tumour challenge experiments a lower irradiation dose was used as 
these mice had previously been irradiated with 2 x 5.5 Gy at the time of bone 
marrow transplant.  In addition Balb/c bone marrow cells are more 
radiosensitive than C57BL/6 bone marrow cells. Recipient mice were 
irradiated with 4 Gy on day 0 and then 4 hours post irradiation were injected 
subcutaneously with EL4-NP Luciferase+ tumour cells.  On day 1, recipient 
mice were injected IV with 1 x 106 F5-TCR + CD3 CD4+ T cells, F5-TCR 
CD4+ T cells or mock transduced CD4+ T cells.   Mice were monitored for 
tumour growth and with bioluminescent imaging.  Mice were monitored for 
weight loss and severity scoring.  
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Figure 27 – Analysis of engraftment of C57BL/6 F1 chimeric mice. Representative 
plots of blood samples taken from bone marrow chimeric mice on day -1 of tumour 
challenge experiments  (3 months post initial establishment of chimeras.)  F1(C57BL/6 x 
Balb/c mice) were lethally irradiated and then given a bone marrow transplant with CD4/8 
depleted C57BL/6 (H2b) bone marrow.   Plots show the extent of chimerism in C57BL/6 
mice and [C57BL/6! F1] chimeras  in the CD4+, CD8+, CD19+ and CD11+ populations.  
For FACS analysis cells were initially gated on viable lymphocytes then gated on CD4, 
CD8, CD19 or CD11+ cells as shown and expression of H2b versus H2d was analyzed in 
each population. 
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Figure 28 – Analysis of engraftment of Balb/c F1 chimeric mice. Representative 
plots of blood samples taken from bone marrow chimeric mice on day -1 of tumour 
challenge experiments  (3 months post initial establishment of chimeras.)  F1(C57BL/6 x 
Balb/c mice) were lethally irradiated and then given a bone marrow transplant with CD4/8 
depleted Balb/c (H2d) bone marrow.   Plots show the extent of chimerism in Balb/c mice 
and [Balb/c! F1] chimeras  in the CD4+, CD8+, CD19+ and CD11+ populations.  For 
FACS analysis cells were initially gated on viable lymphocytes then gated on CD4, CD8, 
CD19 or CD11+ cells as shown and expression of H2b versus H2d was analyzed in each 
population. 
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In the {C57BL/6F1} chimeras, adoptive transfer of F5-TCR + CD3 CD4+ T 
cells resulted in more efficient control of tumour growth than F5-TCR CD4+ T 
cells.  In the F5-TCR + CD3 CD4+ group, tumour growth peaked at day 16 
post tumour challenge and then tumour regression was seen in all mice.   No 
mice died of progressive tumour growth.  In the F5-TCR only CD4+ group, 
tumour burden was higher and peaked at day 19 post tumour challenge.  3/5 
mice died of progressive tumour growth.  No mice in either group died of 
toxicity which likely reflects the lower irradiation dose that was used in this 
experiment (Figure 29).   
 
In the model using {Balb/cF1} chimeric recipients, the transduced T cells 
were not able to respond NP peptide presented by H2d professional APCs 
and thus tumour eradication is dependent on direct presentation by the EL4-
NP tumour cells.  Following the adoptive transfer of F5-TCR + CD3 CD4+ T 
cells into {Balb/cF1} chimeras, minimal tumour growth was seen in 4/5 mice.  
Only 1/5 mice had a measurable tumour burden that peaked at 20mm2 on day 
20 post tumour challenge.  None of the mice that received F5-TCR + CD3 
CD4+ T cells had progressive tumour growth.  Following adoptive transfer of 
F5-TCR CD4+ T cells into {Balb/cF1} chimeras, the tumour burden was 
higher than that seen in the F5-TCR + CD3 CD4+ group although this was not 
a significant difference.  In the F5-TCR CD4+ group, 1/5 mice cleared the 
tumour completely and one mouse died of tumour progression (Figure 30).  
These results (and the in vitro data) would suggest that CD4+ T cells 
expressing a class I restricted TCR can recognize EL4-NP tumour cells 
directly even in the absence of interaction with professional APCs.   
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Figure 29 – CD4+ T cells expressing class I restricted TCR can respond to antigen 
presented by non professional antigen presenting cells.  F1 (C57BL/6 x Balb/c) recipient 
mice which had been reconstituted with Thy 1.1+ C57BL/6 bone marrow were irradiated on 
day 0 with 4 Gray and then 4 hours later injected subcutaneously with 1 x 106 EL4-NP 
luciferase + tumour cells.  Mice were injected IV with 1 x 106 F5-TCR CD3 CD4+, F5-TCR 
CD4+ or mock transduced CD4+ T cells on day 1.  (A) Mean Tumour Area measured by 
calipers.  (B) Mean bioluminescent signal in photons/second recorded at site of tumour growth 
(C) Bioluminescent signal at tumour site measured on day 6-18 post tumour challenge. 
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Figure 30 – CD4+ T cells expressing class I restricted TCR can respond to antigen 
presented by non professional antigen presenting cells.  F1(C57BL/6 x Balb/c) recipient 
mice which had been reconstituted with Thy 1.1+ Balb/c  bone marrow were irradiated on day 
0 with 4 Gy and then 4 hours later injected subcutaneously with 1 x 106 EL4-NP luciferase + 
tumour cells.  Mice were injected IV with 1 x 106 F5-TCR CD3 CD4+, F5-TCR CD4+ or Mock 
Transduced CD4+ T cells on day 1.  (A) Mean tumour area measured by calipers.  (B) Mean 
bioluminescent signal in photons/second recorded at site of tumour growth(C) 
Bioluminescence signal at tumour site measured on day 6-18 post tumour challenge.  
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In addition, these results also suggest that tumour eradication was more 
efficient in the {Balb/cF1} chimera model where antigen was presented 
solely by non-professional APC eg the EL4-NP tumour cell.  These results 
were however complicated by toxicity seen in {Balb/cF1} chimeras following 
adoptive transfer of transduced CD4+ T cells.  In the F5-TCR + CD3 CD4+ 
group, 4/5 mice were culled before the end of the experiment because of 
marked weight loss or high severity score on day 14,17 and 20 post tumour 
challenge.  In the F5-TCR only CD4+ group, 2/5 mice were culled before the 
end of the experiment because of toxicity on day 17 and day 20 post tumour 
challenge.  None of the {C57BL/6F1} chimera recipients died of toxicity.  
These differences may reflect the increased sensitivity of the {Balb/cF1} 
chimeras to the effects of the 4Gy irradiation compared to the {C57BL/6F1} 
chimeras or may reflect increased targeting of normal tissues by the 
adoptively transferred T cells in the {Balb/cF1} chimeras. 
 
When looking at the percentage of Thy 1.2+ CD4+ T cells within the bone 
marrow, spleen and lymph nodes the results have to be interpreted with care 
as there were only small numbers and the mice were culled at different time 
points post tumour challenge.  (day 14 n=1; day 17 n=2; day 19 n=1; day 20 
n=4; day 23 n=1; day 24 n=1; day 26 n=10).  No significant differences were 
observed between any of the groups or in any of the organs analyzed (Figure 
31).  The {Balb/cF1} chimeras receiving F5-TCR + CD3 CD4+ T cells had 
the highest percentage of adoptively transferred cells in all organs whilst the  
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Figure 31 – CD4+ T cells expressing class I restricted TCR can respond to antigen 
presented by non professional antigen presenting cells.  (A) Maximal weight loss (B) 
Maximal severity score (C) Kaplan Meier plot of Overall Survival.  (D) Mean percentage of Thy 
1.2+ CD4+ T cells in bone marrow, lymph node and spleen. 
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{C57BL/6F1} chimeras receiving F5-TCR CD4+ T cells had the lowest 
percentage of adoptively transferred populations at the time of analysis.  Thus 
F5-TCR or F5-TCR + CD3 CD4+ T cells that have been adoptively transferred 
into recipients where the APCs are of a different MHC background to that 
recognized by the F5-TCR can persist and expand to the same or higher 
levels than seen in recipients with APCs expressing the correct MHC type.  
Combined with the tumour growth curves this adds support to the fact the F5-
TCR expressing CD4+ T cells can respond to tumour that is presented by the 
tumour cells directly and don’t have an absolute requirement for the presence 
of a professional APC.  
 
 
 
4.7 Discussion 
 
 
There is now increasing evidence that CD4+ T cells can provide tumour 
protection in vivo by direct cytotoxicity to tumour cells or by provision of help 
to tumour specific CD8+ T cells and to innate immune cells.  The efficiacy of 
CD4+ T cells at reducing tumour burden has been effectively demonstrated 
using adoptive transfer of class II restricted transgenic CD4+ T cells.  The 
adoptive transfer of as few as 50,000 transgenic CD4+ T cells specific for 
TRP1+ (a melanoma differentiation antigen) could be used to eradicate 
advanced melanoma in a murine model  (269). These adoptively transferred 
CD4+ T cells had a Th1 phenotype, producing large amounts of TNF-α, IFN-γ 
and IL2 and expressed high levels of granzyme and demonstrated in vivo 
cytotoxicity.  Cytotoxicity of the adoptively transferred CD4+ TRP1+ cells was 
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mediated via direct recognition of class II MHC on the tumour cells and 
dependent on degranulation of granzyme containing lytic granules.  
Production of IFN-γ by the adoptively transferred CD4+ T cells led to 
upregulation of class II MHC on the tumour cell.  Tumour rejection was also 
independent of the endogenous CD4+, CD8+, B cell and NK cell populations 
and of endogenous perforin killing activity.  
 
In some models it has been suggested that CD4+ T cells may provide even 
more efficient tumour protection than CD8+ T cells.  Kerkar et al transduced 
murine CD8+ T cells with a class I restricted TCR specific for melanoma 
antigen, gp100 and transduced murine CD4+ T cells with a class II restricted 
TCR specific for TRP-1.  To test function, transduced T cells were adoptively 
transferred into a B16 murine melanoma model.  Interestingly the adoptive 
transfer of gp100-CD8+ T cells led to delayed tumour growth whilst the 
adoptive transfer of TRP-1 transduced CD4+ T cells led to marked anti-
tumour immunity.  This could not be explained by a increased expression 
level of the TCR within the CD4+ population as the adoptive transfer of a five 
fold higher number of CD8+ T cells did not lead to enhanced anti-tumour 
responses.  It was thought that these differences were either as a result of 
inherent anti-tumour immunity provided by the 2 differing populations of cells 
or due to some intrinsic difference in the individual TCR properties  (287).   
 
The main advantage of using CD4+ T cells transduced with a class I restricted 
TCR is that it obviates the need for provision of separate class II restricted 
epitopes which are less frequently expressed by cancer cells and also difficult 
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to define.  In addition CD8+ and CD4+ T cells could be transferred that both 
target the same tumour antigen or could be transduced with different class I 
restricted TCR to target to separate tumour epitopes.  It may be desirable too 
target different tumour antigens as this may promote determinant spreading 
and reduces the risk of development of antigen loss variants.  Whether class I 
restricted CD4+ T cells are as effective as cytotoxic CD8+ T cells expressing 
the same TCR or as effective as class II restricted CD4+ T cells at providing 
in vivo help or direct cytotoxicity has not yet been clearly delineated.   
 
The clinical and preclinical data using class I restricted CD4+ T cells is still 
quite limited and the exact mechanisms by which they mediate anti-tumour 
immunity are still being clarified.  There have been a number of papers now 
demonstrating that class I restricted CD4+ T cells can provide anti tumour 
protection in vivo, either alone or in conjunction with tumour specific CD8+ T 
cells.   Frankel et al  (288) used a TCR derived from a TIL specific for a 
melanoma epitope, tyronsinase 368-376.  Unusually, the TIL was unique in 
that it was reactive to HLA-A2 but it was expressed by a CD4+/CD8- T cell, 
thus functioning in vivo in a CD8 independent manner.  The TCR α and β 
chains from the TIL were cloned and used to transduce peripheral blood 
lymphocytes.  In vitro experiments using sorted CD4+ and CD8+ populations 
and antibody blockade of co-receptors demonstrated that this TCR was both 
CD4 and CD8 independent.  In a HLA-A2/Kb transgenic mouse model, 
transfer of this anti-tyronsinase TCR into mouse splenocytes led to CD4 and 
CD8 independent antigen reactivity against melanoma cells in vitro.  Adoptive 
transfer of TCR transduced T cells led to regression of established B16/A2-Kb 
	   175	  
melanoma in lymphodepleted mice.  Mice received either equal numbers of 
TCR transduced CD8+, CD4+ or a combination of CD8+ and CD4+ T cells.  
All groups demonstrated a statistically significant delay in tumour growth and 
a equal anti tumour response was seen in all 3 groups with no significant 
difference between the 3 groups.  Chabra et al transduced CD4+ T cells with 
a TCR specific for the HLA-A2 restricted melanoma antigen, MART-1  (289).  
These CD4+ T cells demonstrated a Th1 cytokine profile in response to 
specific antigen and also had granule mediated cytotoxicity upon recognition 
of peptide loaded targets or melanoma cell lines expressing MART-1.  CD4+ 
T cells were as efficient as CD8+ T cells transduced with the same TCR at 
direct cytotoxicity and were of the same functional avidity.  This TCR was fully 
CD8 independent when expressed in CD4+ T cells.   
 
In contrast, the F5-TCR is a CD8 dependent TCR and when expressed alone 
in CD4+ T cells can not provide tumour protection in the absence of CD4+ T 
cells.  Previous work in our lab using F5-TCR CD4+ T cells has demonstrated 
that the F5-TCR CD4+ T cells could provide help for F5-TCR CD8+ T cells to 
eradicate EL4-NP tumour cells in vivo.  A non tumour protective dose of F5-
TCR CD4+ T cells could lead to tumour eradication if adoptively transferred in 
conjunction with F5-TCR CD4+ T cells.  However the adoptive transfer of F5-
TCR CD4+ T cells without functional F5-CD8+ T cells led to progressive 
tumuor growth in all mice  (4).  These current experiments have gone on to 
explore whether class I restricted CD4+ T cells could eradicate tumours 
following adoptive transfer, even in the absence of tumour specific CD8+ T 
cells.  F5-TCR + CD3 CD4+ T cells did initially control the tumour growth 
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more efficiently than F5-TCR CD4+ T cells.  All mice that received adoptive 
transfer of F5-TCR CD4+ T cells died of progressive tumour growth, with 
tumour growth occurring at a similar rate to that seen when mock transduced 
CD4+ T cells were adoptively transferred.  In contrast, none of the mice that 
received F5-TCR + CD3 CD4+ T cells died of progressive tumour growth.  
However the full extent of tumour protection provided by these cells could not 
be fully realized due to the sudden onset of toxicities in all mice that received 
F5-TCR + CD3 CD4+ T cells.   
 
Following adoptive transfer in vivo into irradiated syngeneic mice who had 
received tumour challenge, F5-TCR + CD3 CD4+ T cells showed enhanced 
expansion in vivo compared to F5-TCR CD4+ T cells.  There was a significant 
difference in expansion within the bone marrow, spleen and lymph nodes of 
the recipient mice.  The increased surface expression of the transduced TCR 
leads to enhanced sensitivity to peptide and enhanced expansion in response 
to specific antigen in vivo.  In addition, when analyzing later time points post 
adoptive transfer, there was a significantly higher proportion of adoptively 
transferred cells seen in the bone marrow and spleen of mice receiving TCR + 
CD3 CD4+ T cells suggesting that in addition to having superior initial 
expansion in vivo, these CD4+ T cells also persisted for longer and at higher 
levels than F5-TCR CD4+ T cells.  Using in vivo imaging, it was clearly 
demonstrated that F5-TCR + CD3 CD4+ T cells trafficked to the tumour bed 
at a faster rate and in higher numbers than F5-TCR CD4+ T cells.  These 
superior in vivo effects were due to the enhanced sensitivity to peptide arising 
from higher levels of F5-TCR expression when CD3 and F5-TCR are co-
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transduced in CD4+ T cells.  As a result of the enhanced expansion, 
persistence and faster trafficking to the tumour site, F5-TCR + CD3 CD4+ T 
cells are able to more effectively reduce tumour burden compared to F5-TCR 
CD4+ T cells.  This superior anti-tumour effects is mediated even in the 
absence of antigen specific CD8+ T cells.   
 
The in vivo experiments using bone marrow chimeric mice support the 
hypothesis that class I restricted CD4+ T cells can respond to antigen 
presented by non professional APCs.  Whilst the results of the tumour 
protection are more difficult to interpret due to the toxicity seen, there is 
definite tumour protection seen following adoptive transfer of F5-TCR + CD3 
CD4+ T cells into recipient mice of a differing bone marrow haplotype.  In this 
experimental set up, the adoptively transferred cells can respond to antigen 
presented by the H2b expressing tumour cells despite lack of professional 
APCs expressing H2b  class I molecules. 
 
Whilst these experiments have shown that the in vivo function of class I 
restricted CD4+ T cells can be improved by the co-transduction of CD3.  
These CD4+ T cells can reduce the tumour burden compared to CD4+ T cells 
transduced with TCR alone.  The exact mechanism by which the CD4+ T cells 
reduce tumour burden in vivo has not been explored and it is not clear 
whether this is due to direct cytotoxicity of the adoptively transferred cells or of 
a helper function of the class I restricted CD4+ T cells.  Given that cytotoxic 
function can be provided by CD8+ T cells, it would be most effective if class I 
restricted CD4+ T cells were able to provide help in vivo and more 
	   178	  
experiments are required to explore this in detail.  Clearly however the 
additional tumour protection provided by the F5-TCR + CD3 CD4+ T cells is 
completely negated by the severe toxicity that is seen in the mice receiving 
the F5-TCR + CD3 CD4+ T cells.   In the next chapter, experiments were 
carried out to try to explore in further detail the exact mechanism of these 
toxicities.  
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CHAPTER 5 – INVESTIGATION OF IN VIVO TOXICITY OF F5-TCR + CD3 
CD4+ T CELLS 
 
 
5.1 Introduction 
 
Adoptive Transfer of F5-TCR + CD3 CD4+ T cells into sub lethally irradiated 
tumour challenged mice resulted in unexpectedly high levels of toxicity 
resulting in marked reduction in overall survival.  These effects were seen 
only in mice receiving CD4+ T cells expressing F5-TCR and additional CD3 
and not in mice receiving F5-TCR CD4+ T cells.  Thus the toxicity that is seen 
may arise secondary to the increased expression of either the introduced TCR 
or the endogenous TCR.  An alternative possibility is that the toxic effects are 
due to mispairing of the introduced and endogenous TCR leading to 
generation of TCR of unknown specificities. 
 
5.2 Aims and Hypothesis 
 
The aim of this chapter was to explore in more detail the mechanisms 
underlying the increased toxicity seen following the adoptive transfer of F5-
TCR + CD3 CD4+ T cells.  It was hypothesized that the higher expression 
level of the introduced TCR led to increased auto reactivity and targeting of 
normal tissues in the context of sub lethal irradiation.  Experiments were 
designed to try to determine whether the toxic effects were due solely to the 
increased expression level of the introduced TCR or whether there was any 
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evidence for of significant levels of TCR mispairing or also any signs of 
toxicity being related to upregulation of the endogenous TCR.   
 
5.3 Toxicity of F5-TCR CD3 CD4+ T cells is not related to dose of 
adoptively transferred population. 
 
The toxicity that was observed in the mice receiving F5-TCR + CD3 CD4+ T 
cells may be due to targeting of normal tissue by the adoptively transferred 
CD4+ T cells.  Alternatively, the marked in vivo expansion of F5-TCR + CD3 
CD4+ T cells may generate massive cytokine release leading to bystander 
damage of normal host tissues via the release of pro inflammatory cytokines.  
It may therefore be possible to limit the toxicity by reducing the dose of 
antigen specific T cells adoptively transferred.   
 
To explore this in more detail, a tumour challenge experiment was designed 
using 3 different doses of F5-TCR + CD3 CD4+ T cells:  1 x 106, 0.3 x 106  
and 0.03 x 106 F5-TCR + CD3 CD4+ T cells.  The irradiation dose, tumour cell 
dose and timing of tumour inoculation were the same as in previous 
experiments.   
 
Tumours grew progressively in all groups until day 6 post tumour challenge 
and then tumour growth plateaued in the 1 x 106 dose group.  In the 0.3 x 106 
dose group, tumour growth peaked at day 8 post transfer and then plateaued.  
In the 0.03 x 106 dose group tumour growth continued until day 18 post 
transfer and then plateaued.  Control of tumour was most effective in mice 
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that received 1 x 106 F5-TCR + CD3 CD4+ T cells and as would be expected 
the mice receiving the lowest dose of T cells had the fastest rate of tumour 
progression although none had fatal tumour progression.  The rate of tumour 
growth was still less than that seen in mice receiving mock-transduced CD4+ 
T cells or F5-TCR CD4+ T cells (Figure 32).   
 
Mice that received 1 x 106 F5-TCR + CD3 positive cells had very rapid onset 
of cachexia and increase in clinical severity score resulting in sacrifice of all 
mice between days 10-11 post tumour challenge.  Toxicity was also observed 
at the lower doses of 0.3 x 106 and 0.03 x 106 F5-TCR + CD3 CD4+ T cells 
with fatal cachexia developing by day 13-19 and day 19-23 post tumour 
challenge respectively.   Onset of toxicity thus was delayed with a reduction in 
cell number transferred but it was still observed in all mice in the lowest cell 
dose tested.  As expected, adoptive transfer of lower numbers of F5-TCR + 
CD3 CD4+ T cells led to less efficient control of tumour growth.   
 
5.4 Toxicity is independent of cognate antigen. 
 
Toxicity was observed in mice that received CD4+ T cells that had been co-
transduced with F5-TCR and additional CD3 but did not occur in recipients of 
CD4+ T cells transduced with the F5-TCR alone.  Initial experiments were 
performed in mice expressing the cognate peptide presented by class I MHC 
on EL4-NP tumour cells.  However, it was not clear if the observed toxicity 
was dependent on antigen specific expansion of the F5-TCR + CD3 CD4+ T 
cells.  In order to explore this, adoptive transfer experiments were carried out  
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Figure 32 – Toxicity is delayed by reduction in dose of adoptively transferred F5-TCR 
CD3 +  CD4+ T cells.  C57BL/6 mice were sub lethally irradiated and then given a tumour 
challenge with 1 x 106 EL4-NP tumour cells on Day 0.  On Day 1,  the following doses of F5-
TCR CD3 +  CD4+ T cells were administered:  1 x 106, 0.3 x 106 or 0.03 x 106. (A) Mean tumour 
area measured by calipers.  (B) Kaplan Meier survival curves post tumour challenge. (C) 
Bioluminescent signal at site of tumour growth between day 6 and day 10 post tumor challenge 
(D) % weight loss from baseline of individual recipient mice. (D) Severity score post tumour 
challenge in individual mice.  Results shown are based on 1 experiment with n=3 mice/group.  
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where one group of mice was not challenged with tumour.  Recipient mice 
were irradiated with 5.5 Gy irradiation on day 0 and one group were 
challenged with 1 x 106 EL4-NP tumour cells subcutaneously and one group 
received no tumour challenge.   Adoptive T cell transfer was carried out on 
day 1 with 1 x 106 F5-TCR + CD3 CD4+ T cells per group.  Mice were then 
monitored for weight loss and clinical severity scores as in previous 
experiments.   
 
The results shown are from 4 independent experiments (F5-TCR + CD3 
CD4+ no antigen n=15, F5-TCR + CD3 CD4+ n=12).  In the mice not 
challenged with tumour, 13 out of 15 mice had to be sacrificed secondary to 
marked cachexia and/or high severity scores.  This occurred between 10 and 
19 days post irradiation.  No significant difference in survival was observed 
between the groups regardless of exposure to antigen (tumour cells) (p=0.68).  
In the absence of antigen, the median survival was 17 days and in the 
presence of antigen, the median survival was 12 days (Figure 33A).  Plots of 
maximal weight loss demonstrated that the extent of weight loss was not 
significantly different with or without antigen although the mean severity score 
was higher in the presence of cognate antigen (Figure 33B and 33C).  Thus 
toxicity observed post adoptive transfer of F5-TCR + CD3 CD4+ T cells was 
not significantly different whether mice received challenge with tumour 
expressing cognate antigen or not.   
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Figure 33 – Toxicity arising following adoptive transfer of F5-TCR + CD3 CD4+ T 
cells is not dependent on presence of cognate antigen.  Mice were irradiated with 5.5 
Gy on day 0; one group were challenged with 1 x 106 EL4-NP tumour cells subcutaneously 
and one group did not receive tumour challenge.  Adoptive Transfer of 1 x 106 F5-TCR 
CD3 CD4+ T cells was carried out on day 1.  (A) Kaplan Meier survival curves post 
adoptive transfer  (B) Maximal weight loss (C) Maximal severity score (D) Comparison of 
% Thy 1.1 CD4+ T cells in F5-TCR CD3 (No antigen), F5-TCR CD3 (with antigen.  Data 
from experiments using F5-TCR only CD4+ T cells is shown for comparison.   Results 
shown are from 4 independent experiments, F5-TCR + CD3 CD4+ no antigen n= 15; F5-
TCR + CD3 CD4+ with antigen n=12). 
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In addition, samples from spleen, bone marrow and lymph node were 
analyzed on the day of sacrifice as in previous experiments to look at 
persistence or expansion of the adoptively transferred T cells.  From the F5-
TCR + CD3 no antigen group, spleen, bone marrow and lymph node samples 
were only available from 11, 6 and 7 mice respectively.  Within the spleen, the 
mean % of Thy 1.1+ CD4+ T cells was 16.1% (range 2-33%) in the no antigen 
group and 27.8% (range 11-47%) in the group that was antigen challenged 
(p=0.04).  In the bone marrow the mean % of Thy1.1+ CD4+ T cells was 
15.9% (range 1.5-52%) in the no antigen group and 46.1% (range 15-75.9%) 
in group that received antigen challenge (p=0.007).  Within the lymph node 
the mean % of Thy1.1+ CD4+ T cells was 9.8% (range 1.4-24.8%) in the no 
antigen group compared to 38.7% (range 24.9-51.7%) in the group that 
received antigen (p=0.0002)  (Figure 33D).   Thus the mean % of Thy 1.1+ 
CD4+ T cells was significantly lower in the absence of antigen following the 
adoptive transfer of F5-TCR CD3 CD4+ T cells compared to in the presence 
of cognate antigen.  This would suggest that the toxicity seen is not directly 
due to expansion of F5-TCR CD3 CD4+ T cells driven by recognition of NP 
peptide-MHC.  However it is possible that the α and β chains of the F5 TCR 
are mispairing and that the adoptively transferred T cells expressing 
mispaired TCRs expand following recognition of an unknown self antigen.  It 
would be expected that only a proportion of the adoptively transferred T cells 
will express a mispaired TCR, with the majority expressing the F5 TCR.  
Therefore in the presence of cognate NP peptide, expansion of the adoptively 
transferred F5-TCR expressing CD4+ T cells may be enhanced.   
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5.5 Toxicity occurs following adoptive transfer of CD4+ T cells that 
express additional CD3 in the absence of transduced TCR or mispaired 
TCR. 
 
To determine whether toxicity was related in part or in whole due to the up 
regulation of endogenous TCR, CD4+ T cells were transduced with additional 
CD3 only.  Toxicities observed in these mice would be subsequent to the up 
regulation of the endogenous TCR in transferred T cells or secondary to a 
toxic effect of the additional CD3 molecule itself.  The experimental set up 
was as in the previous experiment:  Recipient mice received sub lethal 
irradiation with 5.5 Gy on day 0 and then on day 1 underwent adoptive 
transfer of 1 x 106 CD3 only CD4+ T cells (n=12) or of 1 x 106 F5-TCR + CD3 
CD4+ T cells (n=13) or of 1 x 106 mock transduced CD4+ T cells (n=5).  No 
tumour challenge was administered in this experiment.  Mice were monitored 
by weights and clinical severity scores as in previous experiments.   Results 
shown are from 3 independent experiments.   
 
In the CD3 CD4+ T cells group, 6 of the 12 mice were sacrificed either 
secondary to weight loss or increases in clinical severity score. The remaining 
6 mice remained well with no toxicity observed until the end of the experiment.   
In the F5-TCR + CD3 CD4+ group, 11 out of 13 mice were sacrificed as a 
result of increased weight loss and/or high clinical severity scores.  All 5 mice 
in the mock group remained well throughout the experiment with no weight 
loss or increase in clinical severity score observed.  When compared to the 
survival of mice that received F5-TCR + CD3 CD4+ T cells (and no tumour 
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challenge), the survival of the CD3 only CD4+ group was superior.  The 
median survival of CD3 CD4+ group was 26 days compared to 15 days in the 
F5-TCR + CD3 CD4+ group (p=0.006) (Figure 34A).   
 
Comparison of maximal weight loss and maximal severity score between the 
groups did not demonstrate any significant increase in weight loss or clinical 
severity scores when comparing the CD3 CD4+ T cell group and F5-TCR + 
CD3 CD4+ T cell groups.  Compared to the mice that received mock 
transduced CD4+ T cells both the CD3 CD4+ T cell group and the F5-TCR + 
CD3 CD4+ T cell group lost significantly higher amounts of weight from 
baseline and had significantly higher clinical severity scores.  Whilst toxicity 
was less in the CD3 only group compared to the F5-TCR + CD3 group, half of 
the mice showed evidence of weight loss and high clinical severity scores and 
thus had a reduction in overall survival.  It is hypothesized that the reduced 
survival that is seen in the CD3 only group is mediated by upregulation of the 
endogenous TCR generating autoreactive T cells which target normal tissues 
leading to GVHD (Figure 34B and 34C).   
 
There was no significant difference in the mean percentage of Thy 1.1+ CD4+ 
T cells seen within the bone marrow or lymph node in the CD3 only group or 
the F5-TCR + CD3 group (Figure 34D).   Within the spleen, a significantly 
higher percentage of Thy 1.1+ CD4+ T cells was seen in the F5-TCR + CD3 
group compared the CD3 only group.  Not surprisingly, mice that received F5-
TCR + CD3 CD4+ T cells and tumour challenge had a significantly higher %  
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Figure 34 – Toxicity arises following adoptive transfer of CD4+ T cells transduced 
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of adoptively transferred cells present in all organs analyzed compared to 
mice receiving CD3 only CD4+ T cells in the absence of antigen.  
 
5.6 Reducing the irradiation dose prior to adoptive transfer of F5-TCR 
CD3 CD4+ T cells prevents toxicity 
 
Dose-dependent lymphodepletion is well documented for radiation therapy. 
Radiation-induced reduction of host haematopoesis increases the relative 
availability of homeostatic cytokines such as IL-7 and IL-15 for the adoptively 
transferred T cells, promoting their proliferation in vivo.  However, higher 
irradiation doses may cause additional tissue damage and inflammation in the 
recipient.   Damaged host tissues secrete pro-inflammatory cytokines such as 
TNF-α and IL-1 together with other danger signals leading to activation of host 
APCs.  Furthermore, radiation-induced damage to the gastrointestinal tract 
results in the systemic translocation of LPS through the bowel wall further 
activating APCs  (228)  (229).  Donor T cells which are recruited to the 
inflamed tissues are then activated by the APCs resulting in proliferation and 
differentiation.  Further production of inflammatory cytokines by activated 
donor T cells amplifies the harmful pro-inflammatory response leading to 
further tissue destruction.  There is a linear relationship between radiation 
dose, tissue damage, cytokine storm and acute GVHD related mortality  (230)  
(231)  (232).   It is therefore expected that high doses of irradiation may have 
exacerbated potential harmful T cell mediated toxicities arising post adoptive 
transfer of F5-TCR + CD3 T cells.  
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Experiments were performed to determine whether the toxicity mediated 
following adoptive transfer of F5-TCR + CD3 CD4+ T cells could be reduced 
or prevented by reducing the dose of conditioning irradiation.  In these 
experiments, recipient mice received 4Gy irradiation on day 0 and then 4 
hours post irradiation were injected with 1 x 106 EL4-NP luciferase positive 
cells subcutaneously.  On day 1, mice were injected intravenously with 1 x 106 
F5-TCR + CD3 CD4+, F5-TCR only CD4+ or Mock transduced CD4+ T cells.  
There were 5 mice per group.  In the previous experiments all mice received 
5.5 Gy. 
 
In the F5-TCR + CD3 group, there was more efficient control of tumour growth 
than in the mice that received F5-TCR only CD4+ T cells or mock-transduced 
CD4+ T cells.  The mean tumour area was lower at all time points measured 
in mice receiving F5-TCR + CD3 CD4+ T cells.  No mice in the F5-TCR + 
CD3 group had progressive tumour growth. The F5-TCR only group had the 
fastest rate of tumour growth and the highest tumour burden, which peaked at 
day 12 post injection and then regression was observed in 3/5 mice.  In the 
mock-transduced group the tumour growth peaked at day 15 post injection 
and then regressed in 3/5 mice (Figure 35).  
 
In addition to reduced homeostatic expansion potential for transferred T cells 
after lower doses of radiation, there will be greater numbers of residual host T 
cells which may play a role in tumour rejection.  Host T cells will be able to 
respond to NP peptide expressed by the EL-4 NP lymphoma cells and this will  
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Figure 35 – Reduction in irradiation dose leads to a reduction in toxicity. C57BL/6 
recipient mice were irradiated with 4 Gy on day 0 and injected with 1 x 106 EL4-NP luciferase+ 
tumour cells.  On day 1 mice were injected I.V with 1 x 106 F5-TCR + CD3 CD4+ T cells, F5-
TCR CD4+ T cells or mock transduced CD4+ T cells and followed for tumour growth, weight 
loss and clinical severity score.   (A) Tumour Area measured  by calipers.  (B) Mean 
bioluminescent signal in photons/second recorded at site of tumour growth.  (C) Bioluminescent 
signal at site of tumour growth between day 0 and day 25 post tumour challenge.   Results 
shown are from one experiment with n=5 mice/group. 
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contribute to tumour rejection, supported by the efficient tumour rejection in  
mice that received mock-transduced CD4+ T cells. 
 
Weight was well maintained in all mice observed and no increases in severity 
scores were documented (Figure 36A).  There was no significant difference in 
survival between any of the 3 groups (Figure 36B).  Mice were monitored until 
day 40 post tumour injection and then culled for analysis of T cell persistence.  
These results were confirmed in a second independent experiment with a 
further 3 mice per group.   
 
After 4 Gy conditioning, the % of Thy 1.1+ CD4+ T cells detectable in the 
spleen, bone marrow and lymph node was significantly higher in mice that 
had received F5-TCR + CD3 CD4+ T cells.   In mice that received F5-TCR + 
CD3 CD4+ T cells the mean percentage of Thy 1.1+ CD4+ T cells in the bone 
marrow, spleen and lymph node was 3.4%(1-2%-7.1%), 3.5%(0.9%-5.4%) 
and 2.4%(0.9%-4.8%) respectively.  In the mice that received TCR only CD4+ 
T cells the mean percentage of Thy 1.1+ CD4+ T cells within the bone 
marrow, spleen and lymph node was 0.4% (0.1-0.8%) (p=0.004), 1.0% (0.2%-
2%) (p=0.002) and 1.1%(0.2-2.5%) (p=0.01) (Figure 36D). 
 
In mice conditioned with 5.5Gy, there were significantly more adoptively 
transferred cells detectable within all organs i.e. higher percentage of Thy 
1.1+ CD4+ T cells (Figure 36E).  The analysis was performed at a later time 
point in the experiments using 4Gy irradiation (Day 40 post tumour injection 
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as compared to day 10-25 post tumour injection) as the mice had significantly 
longer survival times.  
 
The overall survival of mice that received F5-TCR + CD3 CD4+ T cells 
following 4Gy of irradiation was superior to those that received the same dose 
of F5-TCR + CD3 CD4+ T cells but 5.5 Gray of irradiation (p=0.002) (Figure 
36C).  
 
5.7 TCR + CD3 co-transduced CD4+ T cells confer more toxicity in vivo 
than equivalent numbers of TCR + CD3 co-transduced CD8+ T cells 
 
The following experiments were performed to compare the in vivo toxicity 
following the adoptive transfer of F5-TCR + CD3 CD8+ T cells and F5-TCR + 
CD3 CD4+ T cells.  Experiments previously performed in our laboratory with 
CD8+ T cells co-transduced with F5-TCR and CD3 had not demonstrated 
toxicity in the same EL4-NP tumour model. 
 
C57BL/6 recipients were irradiated with 5.5 Gy irradiation and then 4 hours 
later tumour challenge was administered subcutaneously with 1 x 106 EL4-NP 
cells as previously described.  On day 1, mice were injected intravenously 
with 1 x 106 F5-TCR only CD8+, 1 x 106 F5-TCR + CD3 CD8+ or 1 x 106 F5-
TCR + CD3 CD4+ T cells.  Mice were then monitored for tumour burden and 
for weight loss and development of high clinical severity scores.  The results 
shown are from 2 independent experiments (F5-TCR CD3 CD8+ n=10; F5-
TCR CD3 CD4+ n=10; F5-TCR only CD8+ n=5). 
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Mice that received F5-TCR + CD3 CD4+ T cells died secondary to toxicity 
with a median survival of 13.5 days post tumour injection.  In the F5-TCR + 
CD3 CD8+ T cell group, 8/10 mice died secondary to toxicity with a median 
survival of 15.5 days post tumour challenge.  In the F5-TCR only CD8+ T cell 
group, 1/5 mice died secondary to toxicity.  The remaining 4 mice survived 
with no toxicity (i.e. no cachexia or increased clinical severity scores).  The 
F5-TCR only CD8+ group had a superior survival compared to both F5-TCR + 
CD3 CD8 group (p=0.048, log rank) and to the F5-TCR + CD3 CD4+ group 
(p=0.003, log rank test).  No progressive tumour growth was observed in any 
of the mice (Figure 37A, B and C). 
 
It was observed that mice that receiving F5-TCR + CD3 CD4+ T cells had 
increased numbers of Thy 1.1+ CD4+ T cells within the bone marrow, spleen 
and lymph node compared to the F5-TCR + CD3 CD8+ T cell group and the 
F5-TCR only CD8+ T cell group.  As the mice that received tumour specific 
CD8+ T cells developed minimal tumour growth compared to F5-TCR + CD3 
CD4+ T cell group, it may have been that all the tumour specific CD8+ T cells 
were retained within the tumour microenvironment (site of antigen) and not in 
the periphery.   
 
Within the bone marrow, 51.2% (range 36.9-75.9) of viable lymphocytes were 
Thy 1.1+ CD4+ T cells in the F5-TCR + CD3 CD4+ group compared to 5.1% 
(2.2 -12.2) in the F5-TCR + CD3 CD8+ group (<0.0001).  In the lymph node 
the percentage of Thy 1.1+ CD4+ T cells present was 29% (24.9%-51.7%) in  
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Figure 37  – Toxicity is demonstrated following adoptive transfer of F5-TCR + CD3 
CD8+ T cells but is not as severe as that seen post adoptive transfer of F5-TCR + CD3 
CD4+ T cells. Mice were irradiated with 5.5 Gy on day 0 and 4 hours post irradiation were 
injected subcutaneously with 1 x 106 EL4-NP tumour cells.  On day 1 mice were injected I.V 
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mice that received F5-TCR + CD3 CD4+ T cells compared to 11% (3.1%-
30.8%) in mice that received F5-TCR + CD3 CD8+ T cells (p=0.002).  In the 
spleen, the mean percentage of Thy 1.1+CD4+ T cells was 32.8% (25-37.6%)  
F5-TCR + CD3 CD4+ group compared to 4.4% (0.4%-14%) in the  F5-TCR + 
CD3 CD8+ group (p<0.0001).  Mice that received F5-TCR CD8+ T cells had 
the lowest percentage of Thy 1.1+ CD4+ T cells within all organs (bone 
marrow 2.2%(1.7-3.2); lymph node 2.9%(0.6%-6.7%); spleen 1.8%(0.8-3.1%) 
(Figure 37D). 
 
Previous work in our lab using F5 TCR + CD3 CD8+ T cells has not 
demonstrated increased toxicity following adoptive transfer in the EL4-NP 
tumour challenge model compared to F5-TCR only CD8+ T cells  (5).  
However in these studies a 3 fold lower dose of TCR modified T cells was 
transferred and TCR transduced T cells had been FACS sorted prior to 
adoptive transfer.  CD8+ T cells had also been activated prior to transduction 
using IL-7 and Con-A rather than CD3/CD28 activation beads.  All of these 
factors may have led to a reduction in toxicity from what was seen in the 
experiments reported here. 
 
5.8 Enhanced TCR mispairing in the presence of additional CD3 may 
contribute to toxicity. 
 
Bendle et al demonstrated evidence of TCR mispairing in a model in which 
OT-1 TCR transduced bulk T cells were adoptively transferred into irradiated 
mice.  Post transfer, high dose IL-2 was administered to promote T cell 
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expansion. They found that on day 14 post transfer mice developed marked 
and rapidly progressive cachexia that was not seen in the recipients of 
untransduced T cells and this was shown to be secondary to generation of 
mispaired TCRs.  They also did a small comparison of adoptive transfer of 
OT1 CD4+ T cells with OT-1 CD8+ T cells: both groups of mice developed 
toxicity but toxicity was much higher in the group that received CD4+ T cells 
compared to CD8+T cells  (157).   
 
To explore whether the toxicity that was seen following adoptive transfer of 
F5-TCR + CD3 CD4+ T cells was due in part to TCR mispairing, a vector 
encoding only the β chain of the F5-TCR was generated (pMP71-F5β) 
(Production of the vector is described in Chapter 2, Section 2.7).   
 
CD4+ T cells were transduced with the F5-TCR + CD3 or with F5-TCRβ + 
CD3 as per usual transduction protocols.  Upregulation of the F5-TCRβ chain 
expression was seen in the presence of additional CD3.  However, unlike 
following transduction of the F5-TCR + CD3, no binding to specific pentamer 
was observed (Figure 38).  Interestingly, the percentage of Vβ11+ CD3+ cells 
were higher in the F5β + CD3 transduced CD4+ T cells compared to the F5-
TCR + CD3 CD4+ T cells.  
 
To explore whether CD4+ T cells transduced with only the F5β chain could 
mediate off target effects in vivo, the following experiment was carried out.  
C57BL/6 mice were irradiated with 5.5 Gray on day 0.  No tumour challenge 
was administered.  On day 1, 1 x 106 Mock CD4+, F5-TCRβ CD4+ or F5- 
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Figure 38 – Co-transduction of F5β + CD3 leads to increased surface expression 
of the F5β chain.   CD4+ T cells were mock transduced or transduced with F5-TCR + 
CD3 or F5-TCRβ + CD3 using standard transduction protocol.  Comparison of staining 
of mock transduced, F5-TCR + CD3 and F5-TCRβ + CD3 cells stained for expression of 
(A) Vβ11 and (B) NP-Pentamer.  Cells were initially gated on viable lymphocytes and 
then CD4+ T cells. 
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TCRβ + CD3 CD4+ or CD3 only CD4+ T cells were adoptively transferred to 
the recipient mice.  There were 5 mice per group (except for CD3 only, n=4).  
Mice were monitored for weight loss and by measurement of clinical severity 
score as all previous in vivo experiments.   
 
In the F5-TCRβ + CD3 group there was rapid development of cachexia and 
increased clinical severity scores in all 5 mice.  Median survival in this group 
was only 10 days.  In the F5-TCRβ only group, all 5 mice also died of toxicity 
although the onset of weight loss and increase severity score was delayed 
compared to mice receiving F5-TCRβ + CD3 CD4+ T cells.  The median 
survival in F5-TCRβ only group was 16 days.  In the CD3+ only group, 1/4 
mice developed cachexia and weight loss and was sacrificed 18 days post 
irradiation.  None of the mice in the mock CD4+ T cell group developed any 
evidence of toxicity. Median survival time was not reached in the CD3+ only 
CD4+ T cell group or mock CD4+ T cell treated group and the experiment was 
finished on day 25 post irradiation (Figure 39).   
 
The very rapid onset of toxicity and marked reduction in survival of mice 
receiving CD4+ T cells transduced with the F5-TCRβ chain supports the 
hypothesis that the toxicity is being mediated (in whole or in part) by 
mispairing of the introduced TCR α or β chains with the endogenous α and β 
chains.  In these experiments, the introduced F5-TCRβ chain was able to pair 
with endogenous α TCR chains as the total number of Vβ11+ cells was 
similar between the groups.  These mispaired TCRs are of novel and 
unknown specificity and will not have been screened for auto reactivity by  
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Figure 39 – Adoptive Transfer of CD4+ T cells transduced with F5β chain leads to 
toxicity which is enhanced in the presence of additional CD3.  C57BL/6 mice were 
irradiated with 5.5 Gy on Day 0, no mice received tumour challenge.  On day 1, 1 x 106 
Mock CD4+, F5-TCRβ CD4+, F5-TCRβ + CD3 CD4+ or CD3 only CD4+ T cells were 
adoptively transferred.  (A) Kaplan Meier Plot of overall survival (B) Mean % baseline weight 
(C) Mean severity score (results shown are from 1 experiment, n=5/group (except CD3 only 
n=4). 
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central tolerance processes.  The off target effects of the mispaired F5-TCRβ 
chain is greatly enhanced when CD3 is co-transduced (Figure 39).   A greater 
expansion of the transferred Thy 1.1+ CD4+ T cells was observed in mice that 
received F5-TCRβ + CD3 CD4+ T cells or F5-TCRβ CD4+ T cells compared 
to mice receiving mock transduced or CD4+ T cells transduced with CD3 only 
(Figure 40).  There was greater expansion of the adoptively transferred cells 
in the bone marrow, spleen and lymph nodes in the F5-TCRβ + CD3 group 
and the F5-TCRβ group.  This data supports the hypothesis that the F5-TCRβ 
chain mispairs with endogenous α chains.  Expansion of the adoptively 
transferred cells may be promoted by binding of novel mispaired TCRs to self-
antigen in vivo.   
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Spleen. (results shown are from 1 experiment, n=5/group except for CD3 only n=4).  Analysis 
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5.9 Discussion 
 
Clinical trials utilizing the adoptive transfer of tumour specific gene modified T 
cells to treat malignancies have demonstrable clinical responses but there is 
increasing recognition of the on and off target effects arising in patients 
treated with TCR transduced T cells.   On target refers to toxicity arising 
secondary to the effects of recognition of the target antigen in vivo whilst off 
target toxicities result from targeting of different self antigens which are not 
the cognate peptide for which the TCR is specific for.  Off target toxicity may 
arise due to generation of novel TCR specificities by mispairing of the 
introduced TCR and the endogenous TCR but may also arise secondary to 
cross reactivity of the introduced TCR for self antigens other than the original 
target antigen.  
 
These experiments had initially been designed to improve the function of 
class I restricted CD4+ T cells in tumour protection models although they 
revealed marked and unexpected toxicities following adoptive transfer into 
irradiated syngeneic recipients.  Mice receiving F5-TCR + CD3 CD4+ T cells 
developed very rapid onset of cachexia and high clinical severity scores 
resulting in the premature death of all recipients of F5-TCR + CD3 CD4+ T 
cells.  None of the mice that received F5-TCR CD4+ T cells or mock 
transduced CD4+ T cells developed this same pattern of weight loss with high 
clinical severity scores.  However, potential toxic effects of the F5-TCR CD4+ 
T cells may have been masked in the tumour model as their survival was 
reduced due to progressive tumour growth.  Alternatively, the functional 
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avidity of the F5-TCR CD4+ T cells may have been too low to mediate 
autoreactivity against self antigens.  Thus it would appear that at least in part 
these toxicities were arising as a result of the high expression level of the 
introduced TCR or some other affect of the introduction of an excess of CD3 
molecules.  Further adoptive transfer experiments demonstrated that the 
toxicity was not dependent on T cell dose and still occurred following adoptive 
transfer of only 0.01 x 106 TCR+ CD3 CD4+ T cells.  So whilst reducing the T 
cell dose could delay the onset of toxicity, it did not prevent it.   
 
The most comprehensive study looking at toxicity arising secondary to 
adoptive transfer of TCR transduced T cells in murine models has been 
published by Bendle et al. T cells transduced with the OT-1 TCR were 
adoptively transferred into lethally irradiated C57BL/6 mice followed by the 
administration of high dose IL-2 10-12 days post transfer.  On day 14 post 
transfer, the recipients of the TCR transduced T cells developed marked 
cachexia and the majority died as a result of this toxicity.  Recipients of mock 
transduced T cells did not develop any demonstrable toxicity.  It was 
demonstrated in the recipients of OT-1 TCR transduced T cells that there was 
marked loss of haematopoetic activity within the lymphoid organs and bone 
marrow.  Identical toxicity was demonstrated in OVA transgenic recipients and 
C57BL/6 recipients (which don’t express cognate antigen).  Therefore the 
disease development was not due to an on target toxicity of the TCR 
transduced T cells.  Conversely the adoptive transfer of OT-1 TCR transgenic 
T cells into C57BL/6 mice did not result in any toxicity and 100% of the 
recipients survived.  Thus the GVHD that was seen following transfer of OT-1 
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TCR gene modified T cells was not due to cross reactivity of the OT-1 TCR 
but due to toxicity of the transduced TCR.  The authors termed this pathology 
TCR gene transfer induced GVHD (TI-GVHD).  To confirm that TI-GVHD was 
arising due to mispairing of the introduced OT-1TCR α and β chains, adoptive 
transfer was carried out using T cells transduced with only the α chain or the β 
chain alone.  TI-GVHD occurred following single chain transduction although 
with slightly different incidence and kinetics than what was seen following 
transduction of the complete TCR.  Similar experiments were carried out with 
a further four TCRs (pmel-1, SV40, F5 and Trp-1) and TI-GVHD was seen in 
all mice using all four of these TCRs.  Interestingly the F5-TCR had much 
lower levels of toxicity than the OT-1 TCR resulting in death in only 20% of 
recipients.  Less toxicity was also demonstrated if a lower dose of IL-2 was 
administered (31% of mice died) although the survivors developed a chronic 
GVHD picture.  Transduction of a modified OT1-TCR with an additional 
disulphide bond to reduce mispairing led to a reduced incidence of TI-GVHD 
but didn't completely prevent it.  This paper didn’t specifically explore the 
effects of CD8+ transduced T cells versus CD4+ T cells. In most cases the 
transferred population of T cells contained only a low frequency of CD4+ T 
cells.  However a small experiment comparing OT-1 TCR transduced CD8+ T 
cells versus OT-1 TCR transduced CD4+ T cells demonstrated a higher level 
of toxicity following transfer of CD4+ purified T cells suggesting a dominant 
role for CD4+ T cells in the development of TI-GVHD  (196).  In studies 
utilizing human TCR transduction, 7 different TCRs were transduced into 5 
virus specific human T cell populations (obtained from healthy donors).  
These transduced T cells were stimulated with an LCL panel that expressed 
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the majority of the most common HLA I and II molecules.  Neoreactivity was 
demonstrated in each of the virus specific T cell lines with at least 2 of the 7 
introduced TCRs and occurred following introduction of only the α and β 
chains of the introduced TCRs demonstrating this was occurring as a result of 
TCR mispairing.  Very high frequencies of neoreactive mixed TCR dimers 
were demonstrated and some were alloreactive whilst others were 
autoreactive.  This was not a specific feature of a specific TCR or of a specific 
virus specific T cell as it was seen in all of the virus specific T cell lines and 
with differing introduced alpha and beta chains  (290).  Although mixed TCR 
dimer dependent toxicity has been demonstrated in mice models, it has not 
yet been observed in clinical trials of gene therapy  (7)  (8). 
 
From the above publications it would suggest that following the introduction of 
a novel TCR, the incidence of TCR mispairing and potential toxicity arising 
from this is high. The toxicity seen following adoptive transfer of F5-TCR + 
CD3 CD4+ T cells could be secondary to mispairing of the F5 TCRα and β 
chains with the endogenous TCRα and β chains generating TCRs of unknown 
specificities. This hypothesis was supported by the experiments in which 
CD4+ T cells were transduced only with the F5-TCRβ chain plus or minus 
additional CD3 molecules.  Following adoptive transfer, there was greatly 
reduced survival in recipient mice that received F5-TCRβ only or F5-TCRβ + 
CD3 CD4+ T cells compared to mice receiving mock transduced CD4+ T 
cells.  The onset of weight loss with high clinical severity scores occurred at 
earlier time points in mice receiving F5-TCRβ + CD3 CD4+ T cells.  That 
CD4+ T cells only expressing additional F5-TCRβ chains also mediated 
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toxicity suggesting that this was due to mispairing of the F5-TCRβ chain with 
the endogenous TCR α chain leading to unknown specificities. These novel 
TCRs had not been subject to stringent negative selection processes in the 
thymus and it is possible that TCR with high affinity to auto antigens may be 
generated.  The expression level of the mispaired TCR is increased in the 
presence of additional CD3, greatly potentiating the harmful off target effects.  
The F5-TCR that has been used in these experiments has been engineered 
with an additional disulphide bond, which suggests that whilst this strategy 
can reduce mispairing it does not prevent it completely.   
 
In addition to TCR mispairing there may be additional mechanisms in play 
mediating the toxic effects of the F5-TCR + CD3 CD4+ T cells.  Toxicity was 
not dependent on the presence of cognate NP peptide thus suggesting that 
toxicity was arising due to an off target effect mediated by the adoptively 
transferred T cells.  Off target effects could potentially arise due to cross 
reactivity of the highly expressed F5-TCR in the presence of additional CD3.  
A high level of peptide cross reactivity is an inherent characteristic of antigen 
recognition by T cells.  Mathematical modeling has demonstrated that the T 
cell pool is not of sufficient size to provide immunity against all possible 
foreign peptides if TCR are only specific for one single peptide epitope-MHC 
combination.  In fact it has been estimated that each T cell must be able to 
react to as many as 106 structurally similar peptides in order to provide 
enough immunity against all potential foreign peptides  (291)  (292).  Thus, 
most, if not all TCR will have the ability to recognize a number of different 
peptides, which may not always necessarily share strong sequence 
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homology.  In addition, T cells can be activated using peptides that have 
unrelated sequences to the original peptide on which they were selected on in 
the thymus  (293).   
 
Engineering TCRs to produce high affinity TCR targeting tumour antigens 
carries with it the risk of inducing cross reactive TCRs.  It has been 
demonstrated that T cells that express very high affinity TCR (Kd <1nm) start 
to lose antigen specificity and may become cross or alloreactive  (121)  (253).  
In clinical trials there is evidence that transfer of TCR transduced T cells can 
lead to targeting of normal self antigens eg melan-A specific T cells have 
been shown to target melanocytes in skin, eye and ear and neurons in 
MAGE-A3 specific T cells  (198).  It is possible that the toxicity that is 
demonstrated in these experiments may be as a direct result of increased 
functional avidity of the F5-TCR + CD3 CD4+ T cells leading to cross 
reactivity in a similar manner as that has been described in high affinity TCRs. 
 
Experiments measuring the affinity of TCR-pMHC interaction and generation 
of high affinity TCR has demonstrated that it is likely that there is a minimum 
affinity threshold that is required to result in successful stimulation by cognate-
pMHC.  However above a certain threshold it is likely that no further 
improvement in sensitivity for pMHC is derived.  The range of this maximum 
and minimum affinity thresholds will also be controlled by whether there is a 
functional co-receptor interaction.  Despite that fact that the class I MHC-CD8 
interaction is a low affinity interaction  (114)  (101), the participiation of CD8 to 
the TCR-pMHC binding can increase the sensitivity of binding of T cell to 
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cognate pMHC by up to one million fold.  This results in CD8+ T cells that are 
able to respond to as few as 1-3 agonist ligands if there is a functional CD8 
co-receptor interaction.  It is thought that by increasing the affinity of the 
tumour specific TCR that tolerance to tumour antigens can be broken.  
However there is the risk that when high affinity TCRs are introduced into 
CD8+ T cells, that T cells are generated that are of such high affinity that they 
start to lose specificity for their target antigen and start to bind to self antigens  
non discriminately.  As a result, GVHD may arise as a consequence of 
adoptive transfer of such high affinity TCR. 
 
When generating class I restricted CD4+ T cells there is an advantange to 
introducing a TCR with higher affinity (Kd <10µM) for peptide-class I MHC 
when there is no additional increase in affinity provided by interaction of a co-
receptor.  However even when expressed in CD4+ T cells there does appear 
to be an affinity threshold above which T cells become crossreactive with 
activation occurring in the absence of cognate peptide.  This was 
demonstrated using a HLA-A2 restricted TCR directed against NYES0-1 that 
had a picomolar affinity  (286).  Thus even in CD4+ T cells there is a risk that 
engineering high affinity TCRs to improve anti-tumour activity can lead to 
crossreactivity against structurally related self peptides.  For CD4+ T cells 
transduced with a high affinity TCR for cognate pMHC, it would need to cross 
react with a structurally related self pMHC with an affinity of at least 10µM in 
order to induce autoreactivity whilst for CD8+ T cells, the TCR would have to 
bind to self pMHC with an affinity of only 300µM in order to stimulate 
autoreacvity given the additional interaction of the CD8 co-receptor. 
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Engels et al generated a TCR with nanomolar affinity, m33, which was 
generated from the wild type 2C TCR by yeast phage display technology.  
The 2C TCR recognizes the allogeneic MHC, Ld but also recognizes it’s 
cognate peptide, SIY presented by Kb and self peptides, dEV-8 and p2Ca 
presented by Kb.  The affinity of m33-TCR for SIY- Kb was increased by 1000 
fold compared to the wild type 2C TCR.  In contrast, the affinity for m33-TCR 
for the self peptide, dEV8-Kb demonstrated only a two fold increase in affinity 
compared to wild type.  Murine CD8+ and CD4+ T cells were transduced with 
the m33 TCR.  CD8+ T cells transduced with m33 were able to lyse cancer 
cells overexpressing dEV-8 whilst 2C TCR only lysed SIY overexpressing 
cells. CD4+ T cells transduced with the m33 TCR did not respond to dEV-8- 
Kb but were able to make efficient responses to SIY- Kb leading to IFN-γ 
production and target cell lysis. CD4+ T cells transduced with the wild type 2C 
TCR showed only low reactivity for SIY.  Following adoptive transfer in vivo 
these m33 CD8+ T cells disappeared very rapidly post transfer into a 
syngeneic H2b hosts.  These CD8+ T cells expressed a TCR that had high 
affinity for a ubiquitously expressed self antigen and as a result were deleted 
by peripheral tolerance mechanisms.  There was no evidence of generation of 
GVHD following transfer of CD8+ T cells.  CD8+ T cells transduced with the 
lower affinity 2C TCR were able to survive long term in vivo.  Contrastingly, 
CD4+ T cells transduced with m33 showed anti-tumour effects in vivo in the 
absence of co-transfer of antigen specific CD8+ T cells and were able to 
persist in vivo for greater than 3 months.   CD4+ T cells transduced with m33 
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TCR and additional CD8 molecules underwent rapid deletion in vivo following 
adoptive transfer  (294).   
 
It is not clear why in this model system, the expression of a high affinity TCR 
in CD8+ T cells led to deletion and not GVHD.  It might be related to the wide 
spread expression of the self antigen to which the TCR was specific.  The 
strength of the pMHC binding may have overwhelmed the introduced CD8+ T 
cells leading to fraticide or to antigen induced cell death or may be due to the 
high affinity TCR binding to self antigen with very strong and persistent 
binding.  When a cross reactive T cell is specific for an antigen that has more 
tissue restricted expression the T cells may be able to persist and it may lead 
to localized tissue destruction.   TCR affinity or avidity thus plays an important 
role in recognition of structurally similar peptides to that of the cognate antigen 
and thus is one of the major determinants of TCR cross reactivity.   It is clear 
that an increase in affinity of a TCR can lead to an increase in self reactivity or 
loss of specificity.  Similarly it would be expected that the increase in  surface 
expression of TCR by the provision of additional CD3 leading to enhanced 
functional avidity could potentially lead to increased cross reactivity for self 
peptide and thus targeting of normal tissues and GVHD following adoptive 
transfer.  Ordinarily self reactive T cells will be controlled by peripheral 
tolerance mechanisms such as ignorance due to low level expression of self 
antigen when presented in a non inflammatory environment.  T cells that bind 
to self-antigen in the periphery may also become anergic if self antigen is 
presented by professional APCS that lack co-stimulatory molecules.  In 
addition, potentially auto reactive T cells will be negatively regulated by 
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suppressive CD4+ T regulatory cells.  It may be that when a TCR is 
expressed at a supra physiological level, then the normal tolerance controls 
are broken. The effects of cross reactivity may be even further enhanced in a 
model where a large number of monoclonal T cells are transferred into a 
lymphopaenic environment, which may lead to much higher rates of targeting 
of self antigens than would ordinarily be seen.  At this level, the normal 
checkpoints of peripheral tolerance may be overwhelmed particularly if the 
cross reactive T cell is expressed at a very high level.  In addition, following 
irradiation, the numbers of recipient T regulatory CD4+ T cells that would 
normally be controlling self reactive T cells are markedly depleted. 
 
From clinical trials there is increasing recognition of the potential side effects 
related to recognition of self antigens by the TCR transduced T cells.  The 
DMF4 TCR was the original TCR utilized in the first clinical trial of TCR 
transduced T cells in melanoma patients.  It is specific for a differentiation 
antigen, MART-1 which is upregulated on the surface of melanoma cells.  
DMF-4 TCR is specific for an epitope of MART-1 presented by HLA-A2 and 
has relatively low affinity for it’s cognate pMHC (Kd 170µM).  No evidence of 
autoimmunity was described in the clinical trial using the DMF4 TCR  (7).  A 
second generation TCR was derived from the original DMF4 TCR, called 
DMF5, which was engineered to be of higher avidity and it had demonstrable 
in vitro activity when transduced into CD4+ T cells as well as CD8+ T cells  
(8).  The affinity of the DMF5 TCR (Kd 40µM) was higher than DMF4.  The 
overall objective response rates in clinical trials using the DMF5 TCR were 
higher than those using DMF4 TCR (30% versus 13%) but patients treated 
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with DMF5 TCR experienced a marked spike of IFN-γ production following 
transfer of TCR transduced T cells and they developed serious skin rashes 3-
5 days post transfer.  A high rate of anterior uveitis, hearing loss and 
dizziness were also reported, thought to be secondary to targeting of self 
antigen in the periphery by the high affinity TCR.  
 
Finally, it was hypothesized that addition of an excess of CD3 molecules may 
also lead to upregulation of the endogenous TCR.  The high expression level 
of the endogenous TCR may break peripheral tolerance to self antigens 
leading to auto reactivity and GVHD.  This hypothesis was supported by the 
finding that the adoptive transfer of CD3 only CD4+ T cells (transduced only 
with additional CD3 but no additional TCR) into irradiated recipients led to an 
excess of mortality above what was seen following adoptive transfer of mock 
transduced CD4+ T cells.  50% of mice receiving CD3 only CD4+ T cells 
developed rapid cachexia and high clinical severity scores.  Whilst higher 
levels of toxicity were seen following adoptive transfer of F5-TCR + CD3 
CD4+ T cells, this would support the hypothesis that some adverse effects 
mediated by the adoptively transferred populations arose secondary to 
upregulation of the endogenous TCR.  The higher expression level of the 
endogenous TCR and thus the enhanced functional avidity of these cells may 
lead to breaking of normal peripheral tolerance mechanisms and generation 
of autoreactive T cells targeting normal self tissues.    The peripheral T cell 
repertoire is determined during thymic development during which T cells, 
which recognize self-peptide and MHC with low affinity undergo positive 
selection whilst those that recognize self peptide and MHC with high affinity 
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are deleted during negative selection.  This leaves a T cell repertoire that has 
low affinity for self-antigen but high affinity for foreign antigen.  In normal 
steady state conditions, peripheral tolerance mechanisms prevent self-
reactivity.  It is feasible that when endogenous TCR expression is markedly 
increased to supra physiological levels in the presence of additional CD3 that 
the self-reactive endogenous TCR will bind to self antigen with higher affinity.   
 
The amount of inflammation and the amount of lymphodepletion of host 
haematopoiesis appear to be important drivers of toxic effects mediated by 
adoptively transferred T cell populations. Reduced irradiation doses result in 
markedly reduced inflammation and tissue damage and also reduced 
expansion of the adoptively transferred T cells.  Tissue damage produced at 
high irradiation doses leads to release of danger signals, which leads to 
activation of professional APCs, which express higher levels of MHC and co-
stimulatory molecules.  In addition, the presence of high avidity TCR and the 
presence of strong co-stimulation may be able to overrule CD4+ T regulatory 
suppression  (295).  This would lead to enhancement of any potential 
targeting of self-tissues by the adoptively transferred cells. Auto reactivity may 
be promoted as a result of epitope spreading which may arise in the context 
of acute inflammation induced by irradiation.  The immune response of the 
transduced T cells may originally target the NP peptide but in the context of 
inflammation, the specificity of the immune response may spread to involve 
self-epitopes.  This may then prime and activate other autoreactive T cells, 
recruiting them into the immune response.  It is also possible during acute 
inflammation that cryptic or sequestered epitopes are released from damaged 
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tissues, thus further activating the immune response  (296).  In addition 
molecular mimicry may lead to activation of cross reactive T cells that respond 
to both the NP peptide and self epitopes.   
 
Toxicity was completely prevented if F5-TCR + CD3 CD4+ T cells were 
adoptively transferred into mice that had been irradiated with only 4 Gy, 
leading to 100% survival in this group.  However the toxicity that was seen at 
the higher doses of irradiation was not purely due to direct effects of radiation 
doses as demonstrated by 100% survival seen in mice irradiated with 5.5 Gy 
who received adoptive transfer of mock transduced CD4+ T cells.  At a lower 
dose of irradiation, the tissue damage mediated by the irradiation is less and 
in addition there is significantly lower levels of expansion of the adoptively 
transferred T cells.   Similarly in the publication by Bendle et al, mice that 
received lower doses of IL-2 post adoptive transfer had much lower levels of 
toxicity and superior overall survival than mice given high dose IL-2  (196).  
The higher dose of IL-2 used in these experiments would promote much 
higher levels of expansion of the adoptively transferred cells and thus 
potentiate any adverse effects mediated by the transferred T cell populations.  
 
No publications have yet compared whether adoptive transfer of class I 
restricted CD4+ transduced T cells lead to higher levels of toxicity than CD8+ 
TCR transduced T cells.  Whilst adverse effects were seen in mice receiving 
CD8+ T cells transduced with F5-TCR and CD3 they were not as severe as 
that observed following adoptive transfer of CD4+ T cells transduced with F5-
TCR and CD3.  Median survival in mice receiving F5-TCR+CD3 CD4+ T cells 
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was 13.5 days compared to 15.5 days in mice receiving F5-TCR+ CD3 CD8+ 
T cells (p=ns).  Whilst there was 100% mortality seen in recipients of F5-
TCR+CD3 CD4+ T cells, 20% of the mice receiving F5-TCR+CD3 CD8+ T 
cells survived long term with no adverse events seen.  It is possible that CD4+ 
T cells have inherently higher autoreactive potential than CD8+ T cells and 
this may be a function of class I restricted CD4+ T cells, as class I restricted 
CD4+ T cells may be able to respond to antigen presented by non 
professional APCs. Ordinarily CD4+ T cells recognize antigen presented by 
class II MHC on professional APCs.  Whilst class I restricted TCR can bind 
antigen presented by non-professional APCs on class I MHC, the majority of 
CD8+ T cells require priming via cross presentation of antigen by class I MHC 
on professional APCs following licensing of the APCs via CD4+ T cell help. 
Thus whilst CD8+ T cells require the presence of a CD4+ T cell to prime the 
APC to make antigen specific responses, particularly in the context of a non-
inflammatory antigen, class I restricted CD4+ T cell may not have such 
stringent activation requirements.  In addition, in the context of an introduced 
TCR that is very highly expressed there may be less reliance on the 
expression of co-stimulatory molecules by the APC for activation of the CD4+ 
T cell.  There is no evidence that the CD4 or CD8αβ co-receptor plays an 
inhibitory role in T cell activation and thus it seems unlikely that it is the lack of 
CD4 co-receptor interaction that is leading to increased auto reactivity of the 
CD4+ T cells.    It may be that CD4+ T cells have a higher autoreactive 
potential than CD8+ T cells or that the expression level of the TCR is higer 
within the CD4+ T cell population.   
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Whilst improvements to TCR functional avidity can improve anti tumour 
effects, these experiments have highlighted that this may carry with it an 
increased risk of inducing targeting of normal self tissues by the adoptively 
transferred cells.  How to separate increased tumour protection from potential 
harmful side effects of the transduced T cells will prove challenging.  Further 
work is needed to delineate the exact nature of the toxicity mediated by CD4+ 
T cells co-transduced with additional CD3 and also the role of CD4+ versus 
CD8+ T cels in mediating toxic effects post adoptive transfer.   In addition, this 
was a model system that used a target antigen that is not a self-peptide.  It is 
possible that even higher toxic effects may be noted when adoptively 
transferring T cells that are specific for a tumour peptide that is also 
expressed in normal self tissues.  It highlights the risk that may arise following 
adoptive transfer of TCR transduced T cells, particularly when utilizing high 
avidity TCRs or forcing supra physiological levels of TCR expression.   
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CHAPTER 6 – CONCLUSIONS AND FUTURE WORK  
 
These experiments have explored whether the functional avidity of a CD4+ T 
cell transduced with a class I restricted TCR can be improved by the 
transduction of additional CD3.  Given that one of the main determinants of  
TCR avidity is the density of TCR expression, increasing the transduced TCR 
expression is a very simple way to enhance the avidity of the TCR.  Co-
transduction of CD3 plus TCR provides an excess of CD3 molecules so that 
competition between the introduced and the endogenous TCR for binding to  
CD3 is removed leading to higher levels of surface expression of the 
introduced TCR.  In vitro, CD4+ T cells co-transduced with F5-TCR and CD3 
did have enhanced functional avidity, demonstrating a two fold increase in 
sensitivity to peptide when assessing cytokine production and proliferation 
responses following stimulation with specific peptide.  The co-transduction of 
F5-TCR and CD3 did not improve the functional avidity of a CD4+ T cell to 
that of a CD8+ T cell expressing F5-TCR only and it may be that in order to 
achieve this, additional CD8 co-receptor would need to be co-transduced with 
the F5-TCR.   
 
In vivo, F5-TCR and CD3 CD4+ T cells reduced the volume of tumour burden 
when adoptively transferred into irradiated syngeneic mice challenged with 
EL4-NP tumours.  The CD4+ T cells were transferred in isolation, without 
tumour specific CD8+ T cells and thus tumour reduction that was 
demonstrated was thought to be due entirely to the effects of the CD4+ T 
cells.  The exact mechanism of tumour protection was not explored in this 
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model.  CD4+ T cells transduced with F5-TCR alone were not able to provide 
any degree of tumour protection and this was thought to be a result of the 
impaired functional avidity of the F5-CD4+ T cell when TCR expression was 
at a lower level in the absence of additional CD3.   
 
Following adoptive transfer in vivo, it was demonstrated that the expansion 
and persistence of the F5-TCR + CD3 CD4+ T cells was superior than that of 
F5-TCR CD4+ T cells alone.  In addition, F5-TCR + CD3 CD4+ T cells were 
able to traffic to the tumour bed at faster rates and were present at the tumour 
bed in higher numbers.  This superior in vivo expansion and trafficking led to 
more effective tumour protection post adoptive transfer.   
 
Unexpectedly, mice receiving F5-TCR + CD3 CD4+ T cells developed marked 
toxicity that was not seen in mice receiving F5-TCR CD4+ T cells or mock 
transduced CD4+ T cells.  This toxicity was thought to have arisen as a direct 
result of the F5-TCR + CD3 CD4+ T cells. This toxicity was not dependent on 
the presence of cognate peptide and thus could be due to an off target effect 
of the introduced TCR. It was hypothesized that the toxicity was arising due to 
the very high surface expression of the introduced TCR leading to generation 
of autoreactive T cells that could circumvent normal tolerance mechanisms.  
In addition, toxicity was seen when additional CD3 was introduced into the 
CD4+ T cell even in the absence of an introduced TCR.  It was hypothesized 
that the provision of an excess of CD3 led to upregulation of the endogenous 
TCR.  The endogenous TCR when expressed at a supraphysiological level, 
may be breaking normal tolerance mechanisms and targeting self antigen 
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leading to GVHD.  There may also be a role for TCR mispairing in this model 
as demonstrated by the very fast onset of toxicity that was seen in mice that 
received adoptive transfer of CD4+ T cells transduced with the F5-TCRβ 
chain alone.   
 
This project did not explore fully the mechanism by which CD4+ T cells 
eradicated tumour in vivo and also the mechanism by which toxicity arose in 
this model.  Further experiments should be carried out to explore the exact 
role of CD4+ T cell help in vivo.  Reduction in tumour burden was seen when 
F5-TCR + CD3 CD4+ T cells were transferred in isolation.  It is not clear if 
these effects were due to direct cytotoxicity of the CD4+ T cells or whether the 
CD4+ T cells were recruiting innate recipient immune cells such as NK cells 
or macrophages to eradicate the tumour.  In sub lethally irradiated mice where 
recipient haematopoiesis has been greatly reduced, it would suggest that 
direct cytotoxicity by adoptively transferred CD4+ T cells is the main 
mechanism of tumour eradication in these models.  To explore this in more 
detail, adoptive challenge and tumour challenge could be carried out in RAG -
/- recipient mice which would determine if there was any role for endogenous 
CD4+, CD8+ or B cells. Alternatively anti-CD8 or anti NK1.1 antibodies could 
be administered to deplete endogenous CD8 and NK T cells.  It would also be 
preferable to carry out tumour challenge and adoptive transfer in non 
irradiated controls to ensure that there was no effect of the irradiation itself on  
toxicity or upon tumour protection.  In vivo cytotoxicity assays to demonstrate 
whether CD4+ T cells are cytotoxic have been technically difficult given the 
high and rapid onset of toxicity seen following adoptive transfer of the F5-TCR 
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+ CD3 CD4+ T cells.  Alternatively, In vitro cytotoxicity assays to explore 
whether F5-TCR + CD3 CD4+ T cells are capable of direct toxicity to peptide 
loaded splenocytes or tumour cells in vitro could be performed.   Tumour 
challenge experiments and adoptive transfer could also be carried out using 
CD4+ T cells derived from perforin -/- or granzyme -/- mice.  A reduction in 
tumour killing in the absence of these cytotoxic mechanisms would suggest 
that F5-TCR + CD3 CD4+ T cells do mediate tumour protection at least in part 
by cytotoxic mechanisms.  To determine if there is any role for IFN-γ or TNF-α 
at mediating tumour rejection, neutralizing antibodies directed against these 
cytokines could be administered following adoptive transfer. 
 
A comparison of the adoptive transfer of F5-TCR + CD3 CD4+ T cells and F5-
TCR + CD3 CD8+ T cells demonstrated lower levels of toxicity and superior 
overall survival in mice receiving CD8+ transduced T cells compared to CD4+ 
T cells.  This requires further investigation to try to determine the mechanism 
of toxicity and why CD4+ T cells co-transduced with TCR and CD3 would 
cause more harmful effects than CD8+ T cells transduced with TCR and CD3. 
It may be that CD8+ T cell responses are more tightly regulated than CD4+ T 
cells or that CD4+ T cells, by virtue of their helper functions may lead to 
activation of a broad range of effector cells that are causing non specific 
tissue damage.   
 
Ex vivo experiments to try to rexpand the adoptively transferred T cells or to 
demonstrate cytokine production to demonstrate their function following in 
vivo transfer and to determine whether the F5-TCR CD4+ T cells and F5-TCR 
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+ CD3 CD4+ T cells demonstrate any autoreactivity in vitro may add more 
information regarding the differing functions of the F5-TCR only or F5-TCR + 
CD3 CD4+ T cells.  Cytokine production ex vivo could be measured by 
luminex assays following stimulation with NP-peptide, to determine if the 
adoptively transferred populations maintain the same cytokine production 
profile that had been demonstrated in vitro prior to adoptive transfer.  
Potentially, the adoptively transferred T cells may have altered function 
following transfer in vivo.   In vitro functional assays using a syngeneic MLR to 
stimulate the ex vivo T cells using syngeneic APCs may demonstrate 
reactivity against syngeneic cells that do not express the cognate peptide and 
may demonstrate autoreactivity of the adoptively transferred cells.   
 
A comparison of CD4+ T cells transduced with F5-TCR and CD3 with CD4+ T 
cells transduced with F5-TCR and CD8 would provide information about the 
the degree to which both techniques improves functional avidity.  From these 
experiments it suggests that the provison of additional CD3 did not improve 
the functional avidity of the F5-TCR CD4+ T cell to that of a F5-TCR CD8+ T 
cell.  Potentially, the transduction of CD8 plus the F5-TCR could generate 
CD4+ T cells that have the same functional avidity of F5-TCR CD8+ T cell so 
an experiment comparing the in vitro function of F5-TCR + CD3 CD4+, F5-
TCR + CD8 CD4+ T cells and F5-TCR CD8+ T cell populations could be 
carried out.  Adoptive transfer of F5-TCR CD8 CD4+ T cells could be carried 
out to determine if the F5-TCR CD8 CD4+ T cells mediate the same level of 
toxicity as that of a F5-TCR CD3 CD4+ T cell.   
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Tissue sections could be assessed to demonstrate definitively whether there 
was evidence of graft versus host disease in mice that died of toxicity 
following adoptive transfer.  The GVHD that has been described post adoptive 
transfer has been shown to have a predilection for targeting of haematopoetic 
tissues such as spleen bone marrow resulting in marked reduction of normal 
haematopoesis.  Serum samples could be obtained from the recipients of 
adoptively transferred T cells and analyzed for production of differing 
cytokines to try to determine if there were any differences in cytokines 
produced in vivo and potentially whether they had an causative effect in the 
toxicity mediated by the transduced CD4+ T cells.  Bendle et al demonstrated 
that GVHD secondary to adoptively transferred TCR transduced T cells was 
prevented if T cells from IFN-γ knockout mice were transduced and used for 
adoptive transfer. This suggested that the production of IFN-γ by the 
adoptively transferred T cells was an important mediator toxic effects of the 
transduced T cells  (196).  T cells derived from IFN-γ -/- knockout mice or 
from granzyme or perforin -/- knockout mice could be used for transduction 
with the F5-TCR and CD3 to determine if reduced toxicity is seen when these 
effector mechanisms are absent from the transduced T cells. 
 
F5-TCR + CD3 CD4+ T cells were predominantly of a Th1 phenotype and 
thus it would be interesting to explore whether toxicity was seen with the 
same cells if they were skewed to a Th2 phenotype prior to adoptive transfer.  
Transduced T cells could be cultured in the presence of IL-4 to polarize these 
cells to a Th2 phenotype prior to adoptive transfer to determine whether this 
has any effect on the level of toxicity that is seen and also on the degree of 
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tumour protection that is seen.  Th1 and Th17 CD4+ T cells appear to be the 
predominant cell type at mediating autoimmunity in vivo whilst Th2 CD4+ T 
cells do not appear to induce autoimmunity in most model systems.  Given the 
plasticity of CD4+ T cell subsets, it is possible that the Th2 polarized CD4+ T 
cells may not maintain a stable phenotype and that following transfer into an 
inflammatory environment may switch back to a Th1 phenotype. 
 
To confirm the results of this series of experiments, tumour challenge should 
be carried out with CD4+ T cells transduced with a differing range of TCRs to 
ensure that these results are not as a result of a peculiarity of the F5-TCR 
only.   The WT1-TCR is a fully CD8 dependent class I restricted TCR which is 
not functional when expressed in CD4+ T cells in isolation.  WT1 is a 
transcription factor involved in growth and differentiation and is expressed 
within the kidneys, gonads, uterus and mesothelium.  WT1 is overexpressed 
in Acute Myeloid Leukaemia, myelodysplasia, Acute Lymphoblastic 
Leukaemia and Chronic Myeloid Leukaemia and also in a number of solid 
organ malignancies.  To fully explore this, an in vivo system using a murine 
leukaemia model where the leukaemia cells expressed WT1 could be utilized.  
Adoptive transfer of WT1-TCR + CD3 CD4+ T cells targeting WT1 would 
allow exploration of toxicity using a different TCR and also would represent a 
more physiological system where the tumour antigen is also expressed by 
normal tissues.   
 
Given that increased toxicity is seen when CD3 is transduced into polyclonal 
CD4+ T cells in isolation it was hypothesized that the endogenous TCR was 
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being upregulated.  In order to properly assess the level of expression of the 
endogenous TCR following transduction of CD3 only, cells could be stained 
for a number of common Vβ or Vα regions to look for upregulation of TCRs 
that express that particular variable region.  This could be compared to 
untransduced T cells to see if there is any upregulation of the endogenous 
TCR.  Alternatively, T cells could be sorted to produce a pure population of T 
cells that express a particular Vβ subtype prior to transduction of CD3 and this 
may show quite clearly if there is an increase in surface expression following 
transduction of additional CD3 molecules.   
 
In addition to transducing CD4+ T cells with F5-TCRβ chain, a vector could be 
generated that expressed only the F5-TCRα chain.  CD4+ T cells could be 
transduced with the F5-TCRα chain plus or minus additional CD3.  Given the 
effect of transducing F5-TCRβ chain plus or minus additional CD3, it would be 
expected that the F5-TCRα would mispair with the endogenous TCRβ chains 
leading to neoreactive T cells.  
 
To further explore the effects of TCR mispairing, a monoclonal population of 
CD4+ T cells, e.g OT-II T cells, could be transduced with the F5-TCR.  In this 
situation, only 2 novel TCR specificities can be generated and thus the degree 
of autoimmunity seen in this situation if solely dependent on the mispairing of 
the F5-TCR.  Thus the potential for generating autoreactive T cells should be 
much lower than that which would be seen when transducing a polyclonal 
CD4+ T cell population.   
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These experiments have demonstrated severe toxicity that has arisen as a 
direct consequence of the adoptively transferred CD4+ T cells.  TCR 
engineering to enhance anti-tumour potential of transduced T cells has to be 
carefully balanced with the potential risk of generating lethal autoimmunity.  
There needs to be clearer understainding of the mechanism by which the 
CD4+ T cells mediate toxicity and to what extent TCR mispairing and 
upregulation of the endogenous TCR played a role in the toxic effects of the 
adoptively transferred CD4+ T cells.  Whether CD4+ T cells are shown to be 
inherently more autoreactive than CD8+ T cells will also have important 
implications if CD4+ T cells expressing high affinity TCRs are to be utilized in 
clinical trials. The strategy of increasing TCR surface expression by co-
transduction of CD3 may be limited if a byproduct of this technique is to 
increase the surface expression of the endogenous TCR and thus generate 
autoreactive T cells.   In addition, if TCR mispairing plays a major role in 
toxicity then this would suggest that techniques to prevent TCR mispairing 
such as introduction of an additional disulphide bond can’t completely prevent 
TCR mispairing.  Strategies that downregulate the expression of the 
endogenous TCR such as zinc finger nucleases may be a safer technique to 
utilize.  This also highlights the need to have a suicide gene mechanism in 
place in transduced T cells that will be used for adoptive transfer so that any 
autoreactive T cells can be efficiently and quickly deleted should GVHD arise 
in vivo.   
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APPENDIX 1 – LIST OF ABBREVIATIONS 
 
TCR – T cell Receptor 
PBMC – Peripheral Blood Mononuclear Cell 
APC – Antigen Presenting Cell 
LTR – Long Terminal Repeat 
DC – Dendritic Cell 
HSC – Haematopoetic Stem Cell 
Ii – Invariant Chain 
CDR – Complementarity Determining Region 
HSV-TK – Herpes Simplex Virus Thymidine Kinase 
DLI – Donor Lymphocyte Infusion 
GVHD – Graft Versus Host Disease 
CID – Chemical Inducer of Dimerization 
IL-2R-γ – Interleukin 2 receptor gamma chain 
Tregs – CD4+ T regulatory cells 
Tfh -  T follicular helper CD4+ T cell 
CTL – Cytotoxic T Lymphocyte 
PTLD – Post transplant lymphoproliferative disorder 
Ph-Eco – Phoenix Ecotrophic cell 
BMDC – Bone Marrow derived Dendritic Cell 
ER – Endoplasmic Reticulum 
TAP – Transporter associated with antigen processing 
MIIC – MHC class II compartment 
CLIP – Class II associated peptide 
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HEV – High endothelial venule 
CAR – Chimeric Antigen receptors 
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APPENDIX 2 
 
 
Sequence of pMP71-F5α-2A-F5β 	  
  1 AGCATCGTTC TGTGTTGTCT CTGTCTGACT GTGTTTCTGT ATTTGTCTGA 
    51 AAATTAGCTC GACAAAGTTA AGTAATAGTC CCTCTCTCCA AGCTCACTTA 
   101 CAGGCGGCCG CGCCACCATG AACTATTCTC CAGCTTTAGT GACTGTGATG 
   151 CTGTTTGTGT TTGGGAGGAC CCATGGAGAC TCAGTAACCC AGATGCAAGG 
   201 TCAAGTGACC CTCTCAGAAG ACGACTTCCT ATTTATAAAC TGTACTTATT 
   251 CAACCACATG GTACCCGACT CTTTTCTGGT ATGTCCAATA TCCTGGAGAA 
   301 GGTCCACAGC TCCTTTTGAA AGTCACAACA GCCAACAACA AGGGAATCAG 
   351 CAGAGGTTTT GAAGCTACAT ATGATAAAGG AACAACGTCC TTCCACTTGC 
   401 AGAAAGCCTC AGTGCAGGAG TCAGACTCTG CTGTGTACTA CTGTGTTCTG 
   451 GGTGATCGAC AGGGAGGCAG AGCTCTGATA TTTGGAACAG GAACCACGGT 
   501 ATCAGTCAGC CCCAACATCC AGAACCCAGA ACCCGCGGTG TACCAGCTGA 
   551 AGGACCCCAG AAGCCAGGAC AGCACCCTGT GCCTGTTCAC CGACTTCGAC 
   601 AGCCAGATCA ACGTGCCCAA GACAATGGAA AGCGGCACCT TCATCACCGA 
   651 CAAGTGCGTG CTGGACATGA AGGCTATGGA CAGCAAGAGC AACGGCGCCA 
   701 TCGCCTGGTC CAACCAGACC TCCTTCACAT GCCAAGACAT CTTCAAAGAG 
   751 ACCAACGCCA CCTACCCCAG CAGCGACGTG CCCTGCGATG CCACTCTCAC 
   801 CGAGAAGAGC TTCGAGACCG ACATGAACCT GAACTTCCAG AACCTGAGCG 
   851 TGATGGGCCT GAGAATCCTG CTCCTGAAAG TGGCCGGCTT CAACCTGCTG 
   901 ATGACCCTGC GGCTCTGGAG TTCTGGCAGC GGCGCTACCA ACTTCAGCCT 
   951 GCTGAAGCAG GCCGGCGACG TGGAGGAAAA CCCTGGGCCC ATGGCCCCCC 
  1001 GGCTCCTTTT CTGTCTGGTT CTTTGCTTCT TGAGAGCAGA ACCAACAAAT 
  1051 GCTGGTGTCA TCCAAACACC TAGGCACAAG GTGACAGGGA AGGGACAAGA 
  1101 AGCAACTCTG TGGTGTGAGC CAATTTCAGG ACATAGTGCT GTTTTCTGGT 
  1151 ACAGACAGAC CATTGTGCAG GGCCTGGAGT TCCTGACTTA CTTTCGAAAT 
  1201 CAAGCTCCTA TAGATGATTC AGGGATGCCC AAGGAACGAT TCTCAGCTCA 
  1251 GATGCCCAAT CAGTCGCACT CAACTCTGAA GATCCAGAGC ACGCAACCCC 
  1301 AGGACTCAGC GGTGTATCTT TGTGCAAGCA GCTCCCGGAC TGGGGGGCAT 
  1351 GCTGAGCAGT TCTTCGGACC AGGGACACGA CTCACCGTCC TCGAGGACCT 
  1401 GCGGAACGTG ACCCCCCCCA AGGTGTCCCT GTTCGAGCCC AGCAAGGCCG 
  1451 AGATCGCCAA CAAGCAGAAA GCCACACTGG TCTGTCTGGC TAGGGGCTTC 
  1501 TTCCCCGACC ACGTGGAGCT GTCTTGGTGG GTCAACGGCA AAGAAGTCCA 
  1551 TAGCGGCGTC TGCACCGACC CTCAGGCTTA CAAAGAGAGC AACTACTCCT 
  1601 ACTGCCTGAG CAGCCGGCTG AGAGTGAGCG CCACCTTCTG GCACAACCCC 
  1651 CGGAACCACT TCCGGTGCCA GGTGCAGTTC CACGGCCTGA GCGAAGAGGA 
  1701 CAAGTGGCCT GAGGGCTCCC CCAAGCCCGT GACCCAGAAC ATCAGCGCCG 
  1751 AGGCCTGGGG CAGAGCCGAC TGCGGCATCA CCAGCGCCAG CTACCACCAG 
  1801 GGCGTGCTGT CCGCCACCAT CCTGTACGAG ATCCTGCTGG GCAAGGCCAC 
  1851 ACTGTACGCC GTGCTGGTGT CCGGCCTGGT CCTGATGGCT ATGGTGAAGA 
  1901 AGAAGAACAG CTGATGAGTC GACTGTACAA GTAAGAATTC GGATCCAAGC 
  1951 TTAGGCCTGC TCGCTTTCTT GCTGTCCCAT TTCTATTAAA GGTTCCTTTG 
  2001 TTCCCTAAGT CCAACTACTA AACTGGGGGA TATTATGAAG GGCCTTGAGC 
  2051 ATCTGGATTC TGCCTAGCGC TAAGCTTCCT AACACGAGCC ATAGATAGAA 
  2101 TAAAAGATTT TATTTAGTCT CCAGAAAAAG GGGGGAATGA AAGACCCCAC 
  2151 CTGTAGGTTT GGCAAGCTAG CTTAAGTAAG CCATTTTGCA AGGCATGGAA 
  2201 AAATACATAA CTGAGAATAG AGAAGTTCAG ATCAAGGTTA GGAACAGAGA 
  2251 GACAGGAGAA TATGGGCCAA ACAGGATATC TGTGGTAAGC AGTTCCTGCC 
  2301 CCGGCTCAGG GCCAAGAACA GTTGGAACAG CAGAATATGG GCCAAACAGG 
  2351 ATATCTGTGG TAAGCAGTTC CTGCCCCGGC TCAGGGCCAA GAACAGATGG 
  2401 TCCCCAGATG CGGTCCCGCC CTCAGCAGTT TCTAGAGAAC CATCAGATGT 
  2451 TTCCAGGGTG CCCCAAGGAC CTGAAATGAC CCTGTGCCTT ATTTGAACTA 
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  2501 ACCAATCAGT TCGCTTCTCG CTTCTGTTCG CGCGCTTCTG CTCCCCGAGC 
  2551 TCAATAAAAG AGCCCACAAC CCCTCACTCG GCGCGCCAGT CCTCCGATAG 
  2601 ACTGCGTCGC CCGGGGTACC CGTATTCCCA ATAAAGCCTC TTGCTGTTTG 
  2651 CATCCGAATC GTGGACTCGC TGATCCTTGG GAGGGTCTCC TCAGATTGAT 
  2701 TGACTGCCCA CCTCGGGGGT CTTTCATTCT CGAGAGCTTT GGCGTAATCA 
  2751 TGGTCATAGC TGTTTCCTGT GTGAAATTGT TATCCGCTCA CAATTCCACA 
  2801 CAACATACGA GCCGGAAGCA TAAAGTGTAA AGCCTGGGGT GCCTAATGAG 
  2851 TGAGCTAACT CACATTAATT GCGTTGCGCT CACTGCCCGC TTTCCAGTCG 
  2901 GGAAACCTGT CGTGCCAGCT GCATTAATGA ATCGGCCAAC GCGCGGGGAG 
  2951 AGGCGGTTTG CGTATTGGGC GCTCTTCCGC TTCCTCGCTC ACTGACTCGC 
  3001 TGCGCTCGGT CGTTCGGCTG CGGCGAGCGG TATCAGCTCA CTCAAAGGCG 
  3051 GTAATACGGT TATCCACAGA ATCAGGGGAT AACGCAGGAA AGAACATGTG 
  3101 AGCAAAAGGC CAGCAAAAGG CCAGGAACCG TAAAAAGGCC GCGTTGCTGG 
  3151 CGTTTTTCCA TAGGCTCCGC CCCCCTGACG AGCATCACAA AAATCGACGC 
  3201 TCAAGTCAGA GGTGGCGAAA CCCGACAGGA CTATAAAGAT ACCAGGCGTT 
  3251 TCCCCCTGGA AGCTCCCTCG TGCGCTCTCC TGTTCCGACC CTGCCGCTTA 
  3301 CCGGATACCT GTCCGCCTTT CTCCCTTCGG GAAGCGTGGC GCTTTCTCAA 
  3351 TGCTCACGCT GTAGGTATCT CAGTTCGGTG TAGGTCGTTC GCTCCAAGCT 
  3401 GGGCTGTGTG CACGAACCCC CCGTTCAGCC CGACCGCTGC GCCTTATCCG 
  3451 GTAACTATCG TCTTGAGTCC AACCCGGTAA GACACGACTT ATCGCCACTG 
  3501 GCAGCAGCCA CTGGTAACAG GATTAGCAGA GCGAGGTATG TAGGCGGTGC 
  3551 TACAGAGTTC TTGAAGTGGT GGCCTAACTA CGGCTACACT AGAAGGACAG 
  3601 TATTTGGTAT CTGCGCTCTG CTGAAGCCAG TTACCTTCGG AAAAAGAGTT 
  3651 GGTAGCTCTT GATCCGGCAA ACAAACCACC GCTGGTAGCG GTGGTTTTTT 
  3701 TGTTTGCAAG CAGCAGATTA CGCGCAGAAA AAAAGGATCT CAAGAAGATC 
  3751 CTTTGATCTT TTCTACGGGG TCTGACGCTC AGTGGAACGA AAACTCACGT 
  3801 TAAGGGATTT TGGTCATGAG ATTATCAAAA AGGATCTTCA CCTAGATCCT 
  3851 TTTAAATTAA AAATGAAGTT TTAAATCAAT CTAAAGTATA TATGAGTAAA 
  3901 CTTGGTCTGA CAGTTACCAA TGCTTAATCA GTGAGGCACC TATCTCAGCG 
  3951 ATCTGTCTAT TTCGTTCATC CATAGTTGCC TGACTCCCCG TCGTGTAGAT 
  4001 AACTACGATA CGGGAGGGCT TACCATCTGG CCCCAGTGCT GCAATGATAC 
  4051 CGCGAGACCC ACGCTCACCG GCTCCAGATT TATCAGCAAT AAACCAGCCA 
  4101 GCCGGAAGGG CCGAGCGCAG AAGTGGTCCT GCAACTTTAT CCGCCTCCAT 
  4151 CCAGTCTATT AATTGTTGCC GGGAAGCTAG AGTAAGTAGT TCGCCAGTTA 
  4201 ATAGTTTGCG CAACGTTGTT GCCATTGCTG CTGGCATCGT GGTGTCACGC 
  4251 TCGTCGTTTG GTATGGCTTC ATTCAGCTCC GGTTCCCAAC GATCAAGGCG 
  4301 AGTTACATGA TCCCCCATGT TGTGCAAAAA AGCGGTTAGC TCCTTCGGTC 
  4351 CTCCGATCGT TGTCAGAAGT AAGTTGGCCG CAGTGTTATC ACTCATGGTT 
  4401 ATGGCAGCAC TGCATAATTC TCTTACTGTC ATGCCATCCG TAAGATGCTT 
  4451 TTCTGTGACT GGTGAGTACT CAACCAAGTC ATTCTGAGAA TAGTGTATGC 
  4501 GGCGACCGAG TTGCTCTTGC CCGGCGTCAA TACGGGATAA TACCGCGCCA 
  4551 CATAGCAGAA CTTTAAAAGT GCTCATCATT GGAAAACGTT CTTCGGGGCG 
  4601 AAAACTCTCA AGGATCTTAC CGCTGTTGAG ATCCAGTTCG ATGTAACCCA 
  4651 CTCGTGCACC CAACTGATCT TCAGCATCTT TTACTTTCAC CAGCGTTTCT 
  4701 GGGTGAGCAA AAACAGGAAG GCAAAATGCC GCAAAAAAGG GAATAAGGGC 
  4751 GACACGGAAA TGTTGAATAC TCATACTCTT CCTTTTTCAA TATTATTGAA 
  4801 GCATTTATCA GGGTTATTGT CTCATGAGCG GATACATATT TGAATGTATT 
  4851 TAGAAAAATA AACAAATAGG GGTTCCGCGC ACATTTCCCC GAAAAGTGCC 
  4901 ACCTGACGTC TAAGAAACCA TTATTATCAT GACATTAACC TATAAAAATA 
  4951 GGCGTATCAC GAGGCCCTTT CGTCTTCAAG CTGCCTCGCG CGTTTCGGTG 
  5001 ATGACGGTGA AAACCTCTGA CACATGCAGC TCCCGGAGAC GGTCACAGCT 
  5051 TGTCTGTAAG CGGATGCCGG GAGCAGACAA GCCCGTCAGG GCGCGTCAGC 
  5101 GGGTGTTGGC GGGTGTCGGG GCGCAGCCAT GACCCAGTCA CGTAGCGATA 
  5151 GTTACTATGC GGCATCAGAG CAGATTGTAC TGAGAGTGCA CCATATGCGG 
  5201 TGTGAAATAC CGCACAGATG CGTAAGGAGA AAATACCGCA TCAGGCGCCA 
  5251 TTCGCCATTC AGGCTGCGCA ACTGTTGGGA AGGGCGATCG GTGCGGGCCT 
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  5301 CTTCGCTATT ACGCCAGCTG GCGAAAGGGG GATGTGCTGC AAGGCGATTA 
  5351 AGTTGGGTAA CGCCAGGGTT TTCCCAGTCA CGACGTTGTA AAACGACGGC 
  5401 CAGTGAATTA GTACTCTAGC TTAAGTAAGC CATTTTGCAA GGCATGGAAA 
  5451 AATACATAAC TGAGAATAGA GAAGTTCAGA TCAAGGTTAG GAACAGAGAG 
  5501 ACAGGAGAAT ATGGGCCAAA CAGGATATCT GTGGTAAGCA GTTCCTGCCC 
  5551 CGGCTCAGGG CCAAGAACAG TTGGAACAGC AGAATATGGG CCAAACAGGA 
  5601 TATCTGTGGT AAGCAGTTCC TGCCCCGGCT CAGGGCCAAG AACAGATGGT 
  5651 CCCCAGATGC GGTCCCGCCC TCAGCAGTTT CTAGAGAACC ATCAGATGTT 
  5701 TCCAGGGTGC CCCAAGGACC TGAAATGACC CTGTGCCTTA TTTGAACTAA 
  5751 CCAATCAGTT CGCTTCTCGC TTCTGTTCGC GCGCTTCTGC TCCCCGAGCT 
  5801 CAATAAAAGA GCCCACAACC CCTCACTCGG CGCGCCAGTC CTCCGATTGA 
  5851 CTGCGTCGCC CGGGTACCCG TATTCCCAAT AAAGCCTCTT GCTGTTTGCA 
  5901 TCCGAATCGT GGACTCGCTG ATCCTTGGGA GGGTCTCCTC AGATTGATTG 
  5951 ACTGCCCACC TCGGGGGTCT TTCATTTGGA GGTTCCACCG AGATTTGGAG 
  6001 ACCCCTGCCC AGGGACCACC GACCCCCCCG CCGGGAGGTA AGCTGGCCAG 
  6051 CGGTCGTTTC GTGTCTGTCT CTGTCTTTGG GCGTGTTTGT GCCGGCATCT 
  6101 AATGTTTGCG CCTGCGTCTG TACTAGTTGG CTAACTAGAT CTGTATCTGG 
  6151 CGGTCCCGCG GAAGAACTGA CGAGTTCGTA TTCCCGGCCG CAGCCCCTGG 
  6201 GAGACGTCCC AGCGGCCTCG GGGGCCCGTT TTGTGGCCCA TTCTGTATCA 
  6251 GTTAACCTAC CCGAGTCGGA CTTTTTGGAG CTCCGCCACT GTCCGAGGGG 
  6301 TACGTGGCTT TGTTGGGGGA CGAGAGACAG AGACACTTCC CGCCCCCGTC 
  6351 TGAATTTTTG CTTTCGGTTT TACGCCGAAA CCGCGCCGCG CGTCTTGTCT 
  6401 GCTGC 
 
 	  	  	  	  
pMP71-CD3ζ-2A-CD3ε-2A-CD3δ-2A-CD3γ-IRES-GFP 	  
TCAAGGTTAG GAACAGAGAG ACAGGAGAAT ATGGGCCAAA CAGGATATCT 
GTGGTAAGCA GTTCCTGCCC CGGCTCAGGG CCAAGAACAG TTGGAACAGC 
AGAATATGGG CCAAACAGGA TATCTGTGGT AAGCAGTTCC TGCCCCGGCT 
CAGGGCCAAG AACAGATGGT CCCCAGATGC GGTCCCGCCC TCAGCAGTTT 
CTAGAGAACC ATCAGATGTT TCCAGGGTGC CCCAAGGACC TGAAATGACC 
CTGTGCCTTA TTTGAACTAA CCAATCAGTT CGCTTCTCGC TTCTGTTCGC 
GCGCTTCTGC TCCCCGAGCT CAATAAAAGA GCCCACAACC CCTCACTCGG 
CGCGCCAGTC CTCCGATTGA CTGCGTCGCC CGGGTACCCG TATTCCCAAT 
AAAGCCTCTT GCTGTTTGCA TCCGAATCGT GGACTCGCTG ATCCTTGGGA 
GGGTCTCCTC AGATTGATTG ACTGCCCACC TCGGGGGTCT TTCATTTGGA 
GGTTCCACCG AGATTTGGAG ACCCCTGCCC AGGGACCACC GACCCCCCCG 
CCGGGAGGTA AGCTGGCCAG CGGTCGTTTC GTGTCTGTCT CTGTCTTTGG 
GCGTGTTTGT GCCGGCATCT AATGTTTGCG CCTGCGTCTG TACTAGTTGG 
CTAACTAGAT CTGTATCTGG CGGTCCCGCG GAAGAACTGA CGAGTTCGTA 
TTCCCGGCCG CAGCCCCTGG GAGACGTCCC AGCGGCCTCG GGGGCCCGTT 
TTGTGGCCCA TTCTGTATCA GTTAACCTAC CCGAGTCGGA CTTTTTGGAG 
CTCCGCCACT GTCCGAGGGG TACGTGGCTT TGTTGGGGGA CGAGAGACAG 
AGACACTTCC CGCCCCCGTC TGAATTTTTG CTTTCGGTTT TACGCCGAAA 
CCGCGCCGCG CGTCTTGTCT GCTGCAGCAT CGTTCTGTGT TGTCTCTGTC 
TGACTGTGTT TCTGTATTTG TCTGAAAATT AGCTCGACAA AGTTAAGTAA 
TAGTCCCTCT CTCCAAGCTC ACTTACAGGC GGCCGCATGA AGTGGAAAGT 
GTCTGTTCTC GCCTGCATCC TCCACGTGCG GTTCCCAGGA GCAGAGGCAC 
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AGAGCTTTGG TCTGCTGGAT CCCAAACTCT GCTACTTGCT AGATGGAATC 
CTCTTCATCT ACGGAGTCAT CATCACAGCC CTGTACCTGA GAGCAAAATT 
CAGCAGGAGT GCAGAGACTG CTGCCAACCT GCAGGACCCC AACCAGCTCT 
ACAATGAGCT CAATCTAGGG CGAAGAGAGG AATATGACGT CTTGGAGAAG 
AAGCGGGCTC GGGATCCAGA GATGGGAGGC AAACAGCAGA GGAGGAGGAA 
CCCCCAGGAA GGCGTATACA ATGCACTGCA GAAAGACAAG ATGGCAGAAG 
CCTACAGTGA GATCGGCACA AAAGGCGAGA GGCGGAGAGG CAAGGGGCAC 
GATGGCCTTT ACCAGGGTCT CAGCACTGCC ACCAAGGACA CCTGTGATGC 
CCTGCATATG CAGACCCTGG CCCCTCGCGT GAAGCAGACT TTGAATTTTG 
ACCTTCTCAA GTTGGCGGGA GACGTGGAGT CCAACCCAGG GCCCATGCGG 
TGGAACACTT TCTGGGGCAT CCTGTGCCTC AGCCTCCTAG CTGTTGGCAC 
TTGCCAGGAC GATGCCGAGA ACATTGAATA CAAAGTCTCC ATCTCAGGAA 
CCAGTGTAGA GTTGACGTGC CCTCTAGACA GTGACGAGAA CTTAAAATGG 
GAAAAAAATG GCCAAGAGCT GCCTCAGAAG CATGATAAGC ACCTGGTGCT 
CCAGGATTTC TCGGAAGTCG AGGACAGTGG CTACTACGTC TGCTACACAC 
CAGCCTCAAA TAAAAACACG TACTTGTACC TGAAAGCTCG AGTGTGTGAG 
TACTGTGTGG AGGTGGACCT GACAGCAGTA GCCATAATCA TCATTGTTGA 
CATCTGTATC ACTCTGGGCT TGCTGATGGT CATTTATTAC TGGAGCAAGA 
ATAGGAAGGC CAAGGCCAAG CCTGTGACCC GAGGAACCGG TGCTGGTAGC 
AGGCCCAGAG GGCAAAACAA GGAGCGGCCA CCACCTGTTC CCAACCCAGA 
CTATGAGCCC ATCCGCAAAG GCCAGCGGGA CCTGTATTCT GGCCTGAATC 
AGAGAGCAGT CGAGGGCAGA GGAAGTCTGC TAACATGCGG TGACGTCGAG 
GAGAATCCTG GCCCAATGGA ACACAGCGGG ATTCTGGCTA GTCTGATACT 
GATTGCTGTT CTCCCCCAAG GGAGCCCCTT CAAGGTACAA GTGACCGAAT 
ATGAGGACAA AGTATTTGTG ACCTGCAATA CCAGCGTCAT GCATCTAGAT 
GGAACGGTGG AAGGATGGTT TGCAAAGAAT AAAACACTCA ACTTGGGCAA 
AGGCGTTCTG GACCCACGAG GGATATATCT GTGTAATGGG ACAGAGCAGC 
TGGCAAAGGT GGTGTCTTCT GTGCAAGTCC ATTACCGAAT GTGCCAGAAC 
TGTGTGGAGC TAGACTCGGG CACCATGGCT GGTGTCATCT TCATTGACCT 
CATCGCAACT CTGCTCCTGG CTTTGGGCGT CTACTGCTTT GCAGGACATG 
AGACCGGAAG GCCTTCTGGG GCTGCTGAGG TTCAAGCACT GCTGAAGAAT 
GAGCAGCTGT ATCAGCCTCT TCGAGATCGT GAAGATACCC AGTACAGCCG 
TCTTGGAGGG AACTGGCCCC GGAACAAGAA ATCTCAATGT ACTAACTACG 
CTTTGTTGAA ACTCGCTGGC GATGTTGAAA GTAACCCCGG TCCTATGGAG 
CAGAGGAAGG GTCTGGCTGG CCTCTTCCTG GTGATCTCTC TTCTTCAAGG 
CACTGTAGCC CAGACAAATA AAGCAAAGAA TTTGGTACAA GTGGATGGCA 
GCCGAGGAGA CGGTTCTGTA CTTCTGACTT GTGGCTTGAC TGACAAGACT 
ATCAAGTGGC TTAAAGACGG GAGCATAATA AGTCCTCTAA ATGCAACTAA 
AAACACATGG AATCTGGGCA ACAATGCCAA AGACCCTCGA GGCACGTATC 
AGTGTCAAGG AGCAAAGGAG ACATCAAACC CCCTGCAAGT GTATTACAGA 
ATGTGTGAAA ACTGCATTGA GCTAAACATA GGCACCATAT CCGGCTTTAT 
CTTCGCTGAG GTCATCAGCA TCTTCTTCCT TGCTCTTGGT GTATATCTCA 
TTGCGGGACA GGATGGAGTT CGCCAGTCAA GAGCTTCAGA CAAGCAGACT 
CTGTTGCAAA ATGAACAGCT GTACCAGCCC CTCAAGGACC GGGAATATGA 
CCAGTACAGC CATCTCCAAG GAAACCAACT GAGGAAGAAG GTCGACCTCG 
AGATCCGCCC CTCTCCCTCC CCCCCCCCTA ACGTTACTGG CCGAAGCCGC 
TTGGAATAAG GCCGGTGTGC GTTTGTCTAT ATGTTATTTT CCACCATATT 
GCCGTCTTTT GGCAATGTGA GGGCCCGGAA ACCTGGCCCT GTCTTCTTGA 
CGAGCATTCC TAGGGGTCTT TCCCCTCTCG CCAAAGGAAT GCAAGGTCTG 
TTGAATGTCG TGAAGGAAGC AGTTCCTCTG GAAGCTTCTT GAAGACAAAC 
AACGTCTGTA GCGACCCTTT GCAGGCAGCG GAACCCCCCA CCTGGCGACA 
GGTGCCTCTG CGGCCAAAAG CCACGTGTAT AAGATACACC TGCAAAGGCG 
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GCACAACCCC AGTGCCACGT TGTGAGTTGG ATAGTTGTGG AAAGAGTCAA 
ATGGCTCTCC TCAAGCGTAT TCAACAAGGG GCTGAAGGAT GCCCAGAAGG 
TACCCCATTG TATGGGATCT GATCTGGGGC CTCGGTGCAC ATGCTTTACA 
TGTGTTTAGT CGAGGTTAAA AAAACGTCTA GGCCCCCCGA ACCACGGGGA 
CGTGGTTTTC CTTTGAAAAA CACGATGATA ATATGGCCAC AACCATGGTG 
AGCAAGGGCG AGGAGCTGTT CACCGGGGTG GTGCCCATCC TGGTCGAGCT 
GGACGGCGAC GTAAACGGCC ACAAGTTCAG CGTGTCCGGC GAGGGCGAGG 
GCGATGCCAC CTACGGCAAG CTGACCCTGA AGTTCATCTG CACCACCGGC 
AAGCTGCCCG TGCCCTGGCC CACCCTCGTG ACCACCCTGA CCTACGGCGT 
GCAGTGCTTC AGCCGCTACC CCGACCACAT GAAGCAGCAC GACTTCTTCA 
AGTCCGCCAT GCCCGAAGGC TACGTCCAGG AGCGCACCAT CTTCTTCAAG 
GACGACGGCA ACTACAAGAC CCGCGCCGAG GTGAAGTTCG AGGGCGACAC 
CCTGGTGAAC CGCATCGAGC TGAAGGGCAT CGACTTCAAG GAGGACGGCA 
ACATCCTGGG GCACAAGCTG GAGTACAACT ACAACAGCCA CAACGTCTAT 
ATCATGGCCG ACAAGCAGAA GAACGGCATC AAGGTGAACT TCAAGATCCG 
CCACAACATC GAGGACGGCA GCGTGCAGCT CGCCGACCAC TACCAGCAGA 
ACACCCCCAT CGGCGACGGC CCCGTGCTGC TGCCCGACAA CCACTACCTG 
AGCACCCAGT CCGCCCTGAG CAAAGACCCC AACGAGAAGC GCGATCACAT 
GGTCCTGCTG GAGTTCGTGA CCGCCGCCGG GATCACTCTC GGCATGGACG 
AGCTGTACAG AATTCGAGCA TCTTACCGCC ATTTATTCCC ATATTTGTTC 
TGTTTTTCTT GATTTGGGTA TACATTTAAA TGTTAATAAA ACAAAATGGT 
GGGGCAATCA TTTACATTTT ATGGGATATG TAATTACTAG TTCAGGTGTA 
TTGCCACAAG ACAAACATGT TAAGAAACTT TCCCGTTATT TACGCTCTGT 
TCCTGTTAAT CAACCTCTGG ATTACAAAAT TTGTGAAAGA TTGACTGATA 
TTCTTAACTA TGTTGCTCCT TTTACGCTGT GTGGATATGC TGCTTTAATG 
CCTCTGTATC ATGCTATTGC TTCCCGTACG GCTTTCGTTT TCTCCTCCTT 
GTATAAATCC TGGTTGCTGT CTCTTTATGA GGAGTTGTGG CCCGTTGTCC 
GTCAACGTGG CGTGGTGTGC TCTGTGTTTG CTGACGCAAC CCCCACTGGC 
TGGGGCATTG CCACCACCTG TCAACTCCTT TCTGGGACTT TCGCTTTCCC 
CCTCCCGATC GCCACGGCAG AACTCATCGC CGCCTGCCTT GCCCGCTGCT 
GGACAGGGGC TAGGTTGCTG GGCACTGATA ATTCCGTGGT GTTGTCGGGG 
AAGCTGACGT CCTTTCCATG GCTGCTCGCC TGTGTTGCCA ACTGGATCCT 
GCGCGGGACG TCCTTCTGCT ACGTCCCTTC GGCTCTCAAT CCAGCGGACC 
TCCCTTCCCG AGGCCTTCTG CCGGTTCTGC GGCCTCTCCC GCGTCTTCGC 
TTTCGGCCTC CGACGAGTCG GATCTCCCTT TGGGCCGCCT CCCCGCCTGT 
TTCGCCTCGG CGTCCGGTCC GTGTTGCTTG GTCGTCACCT GTGCAGAATT 
GCGAACCATG GATTCCACCG TGAACTTTGT CTCCTGGCAT GCAAATCGTC 
AACTTGGCAT GCCAAGAATT CGGATCCAAG CTTAGGCCTG CTCGCTTTCT 
TGCTGTCCCA TTTCTATTAA AGGTTCCTTT GTTCCCTAAG TCCAACTACT 
AAACTGGGGG ATATTATGAA GGGCCTTGAG CATCTGGATT CTGCCTAGCG 
CTAAGCTTCC TAACACGAGC CATAGATAGA ATAAAAGATT TTATTTAGTC 
TCCAGAAAAA GGGGGGAATG AAAGACCCCA CCTGTAGGTT TGGCAAGCTA 
GCTTAAGTAA GCCATTTTGC AAGGCATGGA AAAATACATA ACTGAGAATA 
GAGAAGTTCA GATCAAGGTT AGGAACAGAG AGACAGGAGA ATATGGGCCA 
AACAGGATAT CTGTGGTAAG CAGTTCCTGC CCCGGCTCAG GGCCAAGAAC 
AGTTGGAACA GCAGAATATG GGCCAAACAG GATATCTGTG GTAAGCAGTT 
CCTGCCCCGG CTCAGGGCCA AGAACAGATG GTCCCCAGAT GCGGTCCCGC 
CCTCAGCAGT TTCTAGAGAA CCATCAGATG TTTCCAGGGT GCCCCAAGGA 
CCTGAAATGA CCCTGTGCCT TATTTGAACT AACCAATCAG TTCGCTTCTC 
GCTTCTGTTC GCGCGCTTCT GCTCCCCGAG CTCAATAAAA GAGCCCACAA 
CCCCTCACTC GGCGCGCCAG TCCTCCGATA GACTGCGTCG CCCGGGGTAC 
CCGTATTCCC AATAAAGCCT CTTGCTGTTT GCATCCGAAT CGTGGACTCG 
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CTGATCCTTG GGAGGGTCTC CTCAGATTGA TTGACTGCCC ACCTCGGGGG 
TCTTTCATTC TCGAGAGCTT TGGCGTAATC ATGGTCATAG CTGTTTCCTG 
TGTGAAATTG TTATCCGCTC ACAATTCCAC ACAACATACG AGCCGGAAGC 
ATAAAGTGTA AAGCCTGGGG TGCCTAATGA GTGAGCTAAC TCACATTAAT 
TGCGTTGCGC TCACTGCCCG CTTTCCAGTC GGGAAACCTG TCGTGCCAGC 
TGCATTAATG AATCGGCCAA CGCGCGGGGA GAGGCGGTTT GCGTATTGGG 
CGCTCTTCCG CTTCCTCGCT CACTGACTCG CTGCGCTCGG TCGTTCGGCT 
GCGGCGAGCG GTATCAGCTC ACTCAAAGGC GGTAATACGG TTATCCACAG 
AATCAGGGGA TAACGCAGGA AAGAACATGT GAGCAAAAGG CCAGCAAAAG 
GCCAGGAACC GTAAAAAGGC CGCGTTGCTG GCGTTTTTCC ATAGGCTCCG 
CCCCCCTGAC GAGCATCACA AAAATCGACG CTCAAGTCAG AGGTGGCGAA 
ACCCGACAGG ACTATAAAGA TACCAGGCGT TTCCCCCTGG AAGCTCCCTC 
GTGCGCTCTC CTGTTCCGAC CCTGCCGCTT ACCGGATACC TGTCCGCCTT 
TCTCCCTTCG GGAAGCGTGG CGCTTTCTCA ATGCTCACGC TGTAGGTATC 
TCAGTTCGGT GTAGGTCGTT CGCTCCAAGC TGGGCTGTGT GCACGAACCC 
CCCGTTCAGC CCGACCGCTG CGCCTTATCC GGTAACTATC GTCTTGAGTC 
CAACCCGGTA AGACACGACT TATCGCCACT GGCAGCAGCC ACTGGTAACA 
GGATTAGCAG AGCGAGGTAT GTAGGCGGTG CTACAGAGTT CTTGAAGTGG 
TGGCCTAACT ACGGCTACAC TAGAAGGACA GTATTTGGTA TCTGCGCTCT 
GCTGAAGCCA GTTACCTTCG GAAAAAGAGT TGGTAGCTCT TGATCCGGCA 
AACAAACCAC CGCTGGTAGC GGTGGTTTTT TTGTTTGCAA GCAGCAGATT 
ACGCGCAGAA AAAAAGGATC TCAAGAAGAT CCTTTGATCT TTTCTACGGG 
GTCTGACGCT CAGTGGAACG AAAACTCACG TTAAGGGATT TTGGTCATGA 
GATTATCAAA AAGGATCTTC ACCTAGATCC TTTTAAATTA AAAATGAAGT 
TTTAAATCAA TCTAAAGTAT ATATGAGTAA ACTTGGTCTG ACAGTTACCA 
ATGCTTAATC AGTGAGGCAC CTATCTCAGC GATCTGTCTA TTTCGTTCAT 
CCATAGTTGC CTGACTCCCC GTCGTGTAGA TAACTACGAT ACGGGAGGGC 
TTACCATCTG GCCCCAGTGC TGCAATGATA CCGCGAGACC CACGCTCACC 
GGCTCCAGAT TTATCAGCAA TAAACCAGCC AGCCGGAAGG GCCGAGCGCA 
GAAGTGGTCC TGCAACTTTA TCCGCCTCCA TCCAGTCTAT TAATTGTTGC 
CGGGAAGCTA GAGTAAGTAG TTCGCCAGTT AATAGTTTGC GCAACGTTGT 
TGCCATTGCT GCTGGCATCG TGGTGTCACG CTCGTCGTTT GGTATGGCTT 
CATTCAGCTC CGGTTCCCAA CGATCAAGGC GAGTTACATG ATCCCCCATG 
TTGTGCAAAA AAGCGGTTAG CTCCTTCGGT CCTCCGATCG TTGTCAGAAG 
TAAGTTGGCC GCAGTGTTAT CACTCATGGT TATGGCAGCA CTGCATAATT 
CTCTTACTGT CATGCCATCC GTAAGATGCT TTTCTGTGAC TGGTGAGTAC 
TCAACCAAGT CATTCTGAGA ATAGTGTATG CGGCGACCGA GTTGCTCTTG 
CCCGGCGTCA ATACGGGATA ATACCGCGCC ACATAGCAGA ACTTTAAAAG 
TGCTCATCAT TGGAAAACGT TCTTCGGGGC GAAAACTCTC AAGGATCTTA 
CCGCTGTTGA GATCCAGTTC GATGTAACCC ACTCGTGCAC CCAACTGATC 
TTCAGCATCT TTTACTTTCA CCAGCGTTTC TGGGTGAGCA AAAACAGGAA 
GGCAAAATGC CGCAAAAAAG GGAATAAGGG CGACACGGAA ATGTTGAATA 
CTCATACTCT TCCTTTTTCA ATATTATTGA AGCATTTATC AGGGTTATTG 
TCTCATGAGC GGATACATAT TTGAATGTAT TTAGAAAAAT AAACAAATAG 
GGGTTCCGCG CACATTTCCC CGAAAAGTGC CACCTGACGT CTAAGAAACC 
ATTATTATCA TGACATTAAC CTATAAAAAT AGGCGTATCA CGAGGCCCTT 
TCGTCTTCAA GCTGCCTCGC GCGTTTCGGT GATGACGGTG AAAACCTCTG 
ACACATGCAG CTCCCGGAGA CGGTCACAGC TTGTCTGTAA GCGGATGCCG 
GGAGCAGACA AGCCCGTCAG GGCGCGTCAG CGGGTGTTGG CGGGTGTCGG 
GGCGCAGCCA TGACCCAGTC ACGTAGCGAT AGTTACTATG CGGCATCAGA 
GCAGATTGTA CTGAGAGTGC ACCATATGCG GTGTGAAATA CCGCACAGAT 
GCGTAAGGAG AAAATACCGC ATCAGGCGCC ATTCGCCATT CAGGCTGCGC 
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AACTGTTGGG AAGGGCGATC GGTGCGGGCC TCTTCGCTAT TACGCCAGCT 
GGCGAAAGGG GGATGTGCTG CAAGGCGATT AAGTTGGGTA ACGCCAGGGT 
TTTCCCAGTC ACGACGTTGT AAAACGACGG CCAGTGAATT AGTACTCTAG 
CTTAAGTAAG CCATTTTGCA AGGCATGGAA AAATACATAA CTGAGAATAG 
AGAAGTTCAG A 	  	  
Sequence of F5-TCRβ chain insert 
 
GCGAGCAGGCCTAAGCTTGGATCCGAATTCTTACTTGTACAGTCGACTCATCAGCTG
TTCTTCTTCTTCACCATAGCCATCAGGACCAGGCCGGACACCAGCACGGCGTACAGT
GTGGCCTTGCCCAGCAGGATCTCGTACAGGATGGTGGCGGACAGCACGCCCTGGTGG
TAGCTGGCGCTGGTGATGCCGCAGTCGGCTCTGCCCCAGGCCTCGGCGCTGATGTTC
TGGGTCACGGGCTTGGGGGAGCCCTCAGGCCACTTGTCCTCTTCGCTCAGGCCGTGG
AACTGCACCTGGCACCGGAAGTGGTTCCGGGGGTTGTGCCAGAAGGTGGCGCTCACT
CTCAGCCGGCTGCTCAGGCAGTAGGAGTAGTTGCTCTCTTTGTAAGCCTGAGGGTCG
GTGCAACGCCGCTATGGACTTCTTTGCCGTTGACCCACCAAGACAGCTCCACGTGGT
CGGGGAAGAAGCCCCTAGCCAGACAGACCAGTGTGGCTTTCTGCTTGTTGGCGATCT
CGGCCTTGCTGGGCTCGAACAGGGACACCTTGGGGGGGGTCACGTTCCGCAGGTCCT
CGAGGACGGTGAGTCGTGTCCCTGGTCCGAAGAACTGCTCAGCATGCCCCCCAGTCC
GGGAGCTGCTTGCACAAAGATACACCGCTGAGTCCTGGGGTTGCGTGCTCTGGATCT
TCAGAGTTGAGTGCGACTGATTGGGCATCTGAGCTGAGAATCGTTCCTTGGGCATCC
CTGAATCATCTATAGGAGCTTGATTTCGAAAGTAAGTCAGGAACTCCAGGCCCTGCA
CAATGGTCTGTCTGTACCAGAAAACAGCACTATGTCCTGAAATTGGCTCACACCACA
GAGTTGCTTCTTGTCCCTTCCCTGTCACCTTGTGCCTAGGTGTTTGGATGACACCAG
CATTTGTTGGTTCTGCTCTCAAGAAGCAAAGAACCAGACAGAAAAGGAGCCGGGGGG
CCATAGCGG 
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